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Abstract 
Cholinergic neurons play a key role in cognitive processes through the action of the 
neurotransmitter acetylcholine (ACh). Dysfunction of these neurons occurs in several 
neurodegenerative disorders, including Alzheimer’s disease (AD). The high-affinity 
choline transporter CHT recycles choline back into synaptic terminals, which is the rate-
limiting step to ACh production. CHT proteins traffic between the cell surface and 
subcellular organelles in a constitutive manner, which maintains plasma membrane 
transporter levels, thereby regulating CHT activity and maintaining cholinergic 
transmission. Pathological conditions associated with AD may alter CHT function in a 
manner that reduces choline uptake activity and impairs cholinergic neurotransmission. 
Thus, my experiments focused on understanding the mechanisms regulating the 
subcellular distribution and activity of CHT in neural cells stably expressing the 
transporter exposed to AD-related pathological conditions. Important AD risk factors that 
can lead to pathological changes in the cholinergic nerve terminal microenvironment 
include increased generation of the reactive oxygen species (ROS) peroxynitrite   
(ONOO
-
), high serum cholesterol level at midlife and mutations in genes encoding the 
amyloid precursor protein (APP). My investigation revealed that ONOO
-
 alters CHT 
function through changes to CHT subcellular trafficking, as opposed to nitrosative or 
oxidative modification to CHT itself.  Moreover, CHT movement through subcellular 
endosomes and lysosomes was not altered by ONOO
-
, but blocking proteasome function 
attenuated ONOO
-
 mediated inhibition of CHT function. Second, I evaluated how CHT 
activity and trafficking is regulated by plasma membrane cholesterol and its association 
with cholesterol-rich lipid rafts. The results of these experiments showed that membrane 
cholesterol and lipid rafts play an important role in regulating CHT trafficking and 
activity by retaining functional CHT at the cell surface. Finally, my studies revealed that 
CHT function is inhibited by both wild-type and Swedish mutant APP but the underlying 
mechanisms differ. Wild-type APP facilitates CHT endocytosis, whereas Swedish mutant 
APP mediated inhibition of CHT function is caused by the susceptibility of CHT to Aβ 
released into the extracellular environment. My studies help define the molecular 
regulation of CHT proteins under pathological conditions. Information from studies such 
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as these will aid the design of therapeutic strategies to treat pathologies involving 
cholinergic dysfunction. 
Keywords: Alzheimer’s disease, cholinergic neurons, high-affinity choline transporter, 
oxidative stress, cholesterol, amyloid precursor protein  
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Chapter 1  
1  General Introduction  
 
  
 2 
 
1.1 Significance of this PhD thesis 
Cholinergic neurons play an important role in the central nervous system and are 
responsible for a wide array of activities, including memory and cognition, through the 
action of the neurotransmitter acetylcholine (ACh). Dysfunction of these neurons occurs 
in many neurologic and psychiatric disorders, with the best studied being Alzheimer’s 
disease (AD). Many reports have suggested that the cognitive deficits seen in AD are 
related to the loss and dysfunction of cholinergic signalling. However, the specific 
changes that occur in the aging brain that result in cholinergic dysfunction, and the extent 
to which they can be prevented or reversed, is still unclear. While the cause of AD is 
unknown, several risk factors have been identified. These risk factors include increasing 
age, brain injury, high serum cholesterol level at midlife, mutations in genes encoding the 
amyloid precursor protein (APP) and increased generation of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) in the brain. Greater understanding of the 
molecular events occurring in the cholinergic presynaptic nerve terminal under these 
pathological situations is essential for developing new treatment methods, and is the 
focus of current research today. 
1.2 The cholinergic system  
1.2.1 Cholinergic projections 
In the periphery, ACh is the main neurotransmitter used at pre- and post-ganglionic 
parasympathetic synapses, at pre-ganglionic sympathetic synapses and at the 
neuromuscular junction. In the central nervous system (CNS), ACh signalling is widely 
distributed through several major cell groups and pathways. Cholinergic neurons project 
to most regions of the brain as interneurons or by projection neurons. The cholinergic 
neurons that undergo neurodegeneration during aging associated with memory 
impairments are primarily found within the basal forebrain (1-3). This cholinergic 
complex is comprised of the medial septum, horizontal and vertical diagonal band of 
Broca, and nucleus basalis of Meynert, and provides the major cholinergic projections to 
the cerebral cortex, hippocampus, amygdala and olfactory bulb (4, 5). The medial septum 
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provides the main source of cholinergic projections to the hippocampus (6) and directly 
synapses with both neurons and interneurons (7, 8). Several cholinergic projections do 
not directly synapse with post-synaptic sites, indicating a role for cholinergic bulk 
transmission (9). 
1.2.2 Acetylcholine signalling and metabolism 
At the pre-synaptic cholinergic nerve terminal, ACh is produced in the cytoplasm by the 
combination of acetyl-CoA and choline by choline acetyltransferase (ChAT) and 
packaged into synaptic vesicles (SV) by the vesicular acetylcholine transporter (VAChT). 
It is stored intracellularly until depolarization of the neuron causes movement of SV to 
the plasma membrane and release of ACh into the extracellular environment. Once in the 
synaptic cleft, ACh can bind to pre-synaptic or post-synaptic G protein-coupled 
muscarinic ACh receptors (mAChR) or cation-permerable, cys-loop ligand-gated 
nicotinic ACh receptors (nAChR) (10-12). The binding of ACh to nAChR can cause 
depolarization or alterations in intracellular calcium levels of the post-synaptic cell, 
which lead to changes in neurotransmitter release, signal transduction cascades, cell 
survival, and gene transcription (13-15). The mAChR are subdivided into five major 
groups according to their G-protein coupling with M1, M3 and M5 receptors selectively 
coupling to the Gq/G11 family and the M2 and M4 receptors couple to the Gi/Go G-
proteins (16, 17). ACh stimulation of these receptors leads to several biochemical and 
electrophysiological responses, which depend on the location and identity of the receptor 
that is activated (18).  
Alternatively, the ACh that does not bind to post-synaptic receptors is hydrolyzed rapidly 
into choline and acetate by the enzyme acetylcholinesterase (AChE). For the re-synthesis 
of ACh, the high-affinity choline transporter CHT is responsible for recycling choline 
back into the pre-synaptic nerve terminal, which is thought to be the rate-limiting step to 
ACh production (19, 20). The synthesis, storage, degradation and release of ACh are 
shown schematically in Figure 1-1. The significance of CHT in cholinergic 
neurotransmission is highlighted by the fact that the CHT specific antagonist  
 4 
 
 
 
Figure 1-1 Acetylcholine metabolism.  
At the pre-synaptic cholinergic nerve terminal, ACh is produced in the cytoplasm 
by the combination of acetyl-CoA with choline catalyzed by choline 
acetyltransferase (ChAT) and packaged into synaptic vesicles (SV) by the 
vesicular acetylcholine transporter (VAChT). Depolarization of the neuron causes 
movement of SV to the plasma membrane and release of ACh into the 
extracellular environment. Once in the synaptic cleft, ACh can bind to pre-
synaptic or post-synaptic G protein-coupled muscarinic ACh receptors (mAChR) 
or ligand-gated nicotinic ACh receptors (nAChR). ACh that does not bind to post-
synaptic receptors is hydrolyzed rapidly into choline and acetate by the enzyme 
acetylcholinesterase (AChE). For the re-synthesis of ACh, the high-affinity 
choline transporter CHT is responsible for recycling choline back into the pre-
synaptic nerve terminal, which is thought to be the rate-limiting step to ACh 
production (19, 20). 
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hemicholinium-3 (HC-3) administration to animals causes lethal respiratory failure and 
that CHT knockout mice die at birth from hypoxia also due to respiratory failure (21).  
1.2.3 Molecular features of CHT 
For many years, the high-affinity choline uptake system has been well established in 
brain synaptosomes (22, 23, 20) and thought to be unique to cholinergic neurons (24). 
However, the gene for the transporter responsible, CHT, was only recently cloned in the 
year 2000 from Caenorhabditis elegans (25). The subsequent cloning of several 
mammalian cDNAs encoding CHT, including rat (25), mouse (26) and human (27, 28), 
have allowed various studies characterizing CHT distribution and regulation. 
Human CHT shares 93% sequence identity with rat CHT, contains 580 amino acids and 
has a predicted molecular weight of approximately 63kDa. CHT provides cells with high-
affinity, sodium and chloride- dependent, HC-3 - sensitive choline uptake and is a 
member of the solute carrier 5 (SLC5) family of solute transporters (assigned as 
SLC5A7) (29), sharing approximately 20-25% amino acid sequence identity with 
members of this family (25). CHT contains 13 predicted transmembrane domains (TMD), 
an extracellular amino-terminus (30) and an intracellular carboxy-terminus (Figure 1-2) 
(31). Cysteine scanning analysis has provided recent experimental evidence to confirm 
this predicted transmembrane topology of CHT (32). Primary amino acid sequence 
analysis predicts that human CHT has two extracellular asparagine (N) residues that may 
serve as putative glycosylation sites, and experimental evidence indicates that CHT is 
indeed glycosylated (31). CHT has several consensus phosphorylation sites for various 
kinases (27), a strong putative dimerization motif (GxxxGxxxG) in TMD 12 and a second 
GxxxG motif in TMD 2, similar to those identified recently in other neurotransmitter 
transporters (33). Several candidate sequences for putative cholesterol binding motifs 
have been identified in CHT (34). Finally, it has been identified that CHT contains a 
dileucine-like internalization motif [Leu-531, Val-532] in its carboxyl-terminal tail that is 
required for its clathrin-mediated endocytosis (30).  
CHT is predominantly found within cholinergic neurons (35, 36), although there have 
been studies where CHT expression has been observed in non-neuronal tissues (37- 
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Figure 1-2 Schematic representation of transmembrane topology of rat high-affinity 
choline transporters.  
CHT is a 13 trans-membrane domain (TMD) protein with an extracellular amino-
terminus, an intracellular carboxyl-terminus that contains at least 15 putative 
phosphorylation sites (shown in pink) as predicted by NetPhos 2.0 software, and an 
extracellular aspargine residue, which serves as a consensus site for glycosylation. The 
dileucine-like trafficking motif is located at residues leucine-531 and valine-532 and is 
shown in orange. The positions of putative CRAC-like and CARC cholesterol binding 
sequence motifs are shown in TMDs 4, 11, 12, and 13. The positioning of transmembrane 
domains shown is based on data for human CHT [Q9GZV3] submitted recently to 
UniProtKB/Swiss-Prot at http://www.uniprot.org/uniprot/Q9GZV3 [Last modified July 
24, 2013]; rat and human CHT share 93% sequence identity. 
 
 7 
 
41). The human CHT gene is approximately 25kb in length and contains 9 coding exons 
(25). CHT activity is regulated both post-translationally and at the transcriptional level.  
At the transcriptional level, CHT expression is regulated by several factors, including 
intraneuronal cyclic adenosine monophosphate (cAMP) concentration (42), nerve growth 
factor (NGF)-TrkA signalling (35, 43), post-synaptic activity dependent retrograde 
signalling (47). Also, mouse neurons that express the p75 neurotrophin receptor express a 
much higher level of CHT mRNA than do those that lack this receptor (45, 46). At the 
post-translational level, CHT trafficking is a critical regulatory mechanism of CHT and 
can be influenced by protein modifications to, or protein-protein interactions with, CHT.    
1.2.4 Regulation of high-affinity choline uptake by CHT trafficking 
CHT is active while present at the plasma membrane, but experimental evidence 
indicates that the majority of the transporter is found intracelluarly within endocytic and 
synaptic vesicles (30, 31, 36, 47). Several observations show that an increase in neuronal 
activity leads to an increase in choline uptake (48-51), which is likely related to enhanced 
trafficking of CHT to the cell surface, as has been observed in HC-3 bindings assays and 
subcellular fractionation experiments (52). Because CHT is located mainly within SV, 
and depolarization of neurons increases the exocytosis of SV, release of ACh into the 
synaptic cleft enhances CHT trafficking to the cell surface, it is hypothesized that 
increased high-affinity choline uptake during depolarization is responsible for 
maintaining high levels of ACh release during neuronal stimulation (53).  
Several reports support the idea that CHT trafficking is critical in regulating high-affinity 
choline uptake. For example, it has been observed in attentional task-performing rats that 
CHT plasma membrane levels and choline uptake activity are increased (54). Other 
studies show that despite reduced total CHT proteins in mice that are heterozygous for 
CHT compared to wild-type mice, HC-3 binding and high-affinity choline uptake are 
unchanged, suggesting a compensatory mechanism in the CHT heterozygous mice 
involving the recruitment of CHT to the cell surface (21). Aberrant CHT trafficking is 
observed in mice lacking adaptor protein-3, which is thought to be involved in the 
formation of synaptic vesicles from endosomes (55). These experiments showed that 
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while cell surface levels of CHT were reduced by 30%, choline uptake activity was 
unaffected and likely due to the recruitment of intracellular CHT reserve stores (56). 
Studies using an endosomal ablation protocol to block CHT movement into early 
endosomes revealed that CHT surface expression and uptake activity is reduced in a 
time-dependent manner (57). Taken together, the results of these studies highlight the 
importance of understanding the mechanisms involved in CHT trafficking since this 
maintains a steady-state level of transporter at the plasma membrane, thereby regulating 
CHT activity and ACh synthesis.  
1.2.5 CHT subcellular trafficking   
There is only a small amount of transporter at the plasma membrane, which constitutively 
traffics between the cell surface and intracellular organelles (Figure 1-3). This was shown 
by experiments utilizing an amino-terminal FLAG-tagged CHT and cell surface 
biotinylation experiments where it was observed that only 15% of CHT is located at the 
cell surface in HEK293 cells (30), similar to the amount found in nerve endings from rat 
brain (31, 36). Experiments employing the carboxyl-terminal fragment of AP180 
(AP180C) and a dominant negative (DN) mutant of dynamin (Dyn K44A), which block 
clathrin-dependent endocytosis (58) and some forms of clathrin-independent endocytosis 
(59, 60), revealed that CHT is internalized through a clathrin-dependent mechanism (30). 
Once internalized, CHT colocalizes with GFP-tagged Rab-5 proteins (30, 47) and is 
recycled back to the cell surface rapidly through Rab-4 positive endosomes or through 
slow Rab-11 positive recycling endosomes (61). It has also been proposed that CHT 
recycles back to the cell surface through synaptic vesicles during depolarization-mediated 
exocytotic release of ACh (30, 47, 61). Alternatively, CHT can be transported through 
Rab-7 and Rab-9 positive late endosomes to lysosomes for degradation (62).   
The mechanisms involved in the recruitment of CHT from intracellular stores to the cell 
surface, the internalization of CHT into early endosomes, or the recycling of CHT back to  
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Figure 1-3 Pathways of CHT subcellular trafficking.  
CHT is internalized from the plasma membrane through a clathrin-dependent mechanism. 
Once internalized, CHT colocalizes with GFP-tagged Rab-5 proteins and is recycled back 
to the cell surface rapidly through Rab-4 positive endosomes or through slow recycling 
endosomes. It has also been proposed that CHT recycles back to the cell surface through 
synaptic vesicles during depolarization-mediated exocytotic release of ACh. 
Alternatively, CHT can be transported through Rab-7 and Rab-9 positive late endosomes 
to lysosomes for degradation.  
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the cell surface, are not well understood. It is well known that post-translational 
modifications of transmembrane proteins, such as phosphorylation and ubiquitination, 
can alter protein trafficking and activity. Early studies showed that HC-3 binding and 
choline uptake in brain preparations is altered by phosphorylation (63-66), and more 
recently it was demonstrated that this is related to changes in CHT trafficking, as CHT 
internalization and choline uptake activity is reduced by protein kinase C (PKC) 
activators and protein phosphatase PP1/PP2A inhibitors (67,68). Other early studies 
identified ubiquitin as a post-translational modification that inhibits high-affinity choline 
uptake activity and ACh synthesis (69,70). A recent study found that CHT is 
ubiquitinated in HEK293 cells by the ubiquitin ligase Nedd-42 and that this negatively 
regulates its cell surface expression (71).  
The interaction of CHT with other cellular proteins is another mechanism by which the 
subcellular trafficking of the transporter is regulated, but only a few proteins have been 
identified to date. Prostate apoptosis response-4 (Par-4), which is up-regulated during 
neurodegeneration and AD, has been shown to interact with CHT and inhibit high-
affinity choline uptake by reducing the incorporation of CHT on the cell surface (72). 
The SEC-14 like protein 1 (SEC14L1), which may act as a phospholipid transfer protein, 
interacts with CHT and inhibits choline uptake activity, likely through alterations in CHT 
trafficking (73). Interestingly, wild-type APP (APPwt) has been shown to interact with 
CHT through the carboxyl-terminal of APP. The interaction is thought to mediate CHT 
presynaptic localization in both the mouse neuromuscular junction and central 
cholinergic neurons, while over-expression of CHT and APP in HEK293 cells increases 
its rate of internalization from the cell surface into early endosomes (74). Finally, it has 
been shown that CHT co-immunoprecipitates with β-amyloid (Aβ) peptides in rat brain 
hippocampal synaptosomes, which could alter either high-affinity choline uptake activity 
or CHT trafficking (75).  
1.3 Cholinergic dysfunction in AD  
AD is characterized by specific neuronal and synaptic loss, the deposition of amyloid 
plaques and neurofibrillary tangles, and the loss of neurotransmitter systems. While 
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several neurotransmitter pathways are known to be involved in AD, the loss of 
cholinergic neurons is thought to be particularly important (76, 77). Basal forebrain 
cholinergic neurons, which play a key role in attention, learning, memory, perception, 
and consciousness (78, 79), are thought to undergo selective degeneration during the 
course of AD. This is supported by several early studies that examined post-mortem brain 
tissue from individuals with AD and found substantial deficits of ChAT expression (80-
82), reduced ACh release and loss of cholinergic perikarya from the nucleus basalis (83, 
84). In the following years, the observations that clinical dementia ratings associated with 
the loss of presynaptic cholinergic proteins including ChAT, mAChR, nAChR, and 
reduced ACh levels (85-87), led to the hypothesis that cholinergic dysfunction is related 
to the cognitive decline and memory loss seen in AD (77).  
Support for this hypothesis was based on post-mortem analysis of brains from patients in 
the advanced stages of late-onset AD; however, whether loss and dysfunction of 
cholinergic neurons occurs in the early stages of the disease is controversial (88, 89). 
Positron emission tomography (PET) studies using specific AChE tracers revealed a 
slight loss of AChE activity in the hippocampus of patients with mild cognitive 
impairment (MCI) or in the early stages of AD (90, 91), while other studies observed no 
differences in ChAT activity measured in several brain regions between individuals with 
MCI or in the early stages of AD, compared to non-impaired controls (92, 93). In contrast 
to this, a separate study found that ChAT activity was significantly increased above 
controls in the hippocampus and superior frontal cortex of individuals with MCI (94). 
While the numbers of ChAT or VAChT-positive basal forebrain cholinergic neurons in 
patients with MCI are unchanged compared to non-impaired control individuals, a 
decrease in the levels of high-affinity NGF receptor TrkA and the p75 low-affinity 
neurotrophin receptor, which are required for trophic support of basal forebrain 
cholinergic neurons, has been reported in individuals with early AD or MCI (95, 96). 
Furthermore, there is evidence from experimental lesions in animals and from post-
mortem human studies to suggest that many cholinergic neurons shrink in size during AD 
pathology rather than die. (97-99). Taken together, these observations suggest that 
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cholinergic neurons may undergo dysfunction rather than die in individuals with mild AD 
or MCI. 
While studies examining cortical and hippocampal ChAT activity have been used 
extensively to assay cholinergic function, there have only been a few reports on CHT in 
neurodegeneration and in AD patients. These studies have been contradictory, with some 
studies showing a significant enhancement of [
3
H]HC-3 binding to the transporter in 
cortical regions in post-mortem AD brain (100) while others show significantly lower 
densities of [
3
H]HC-3 binding sites in both the frontal cortex and hippocampus of AD 
brains compared to controls (101, 102). In terms of high-affinity choline uptake, one 
study showed a decrease in necropsy brain of AD subjects (103), and others indicate that 
while there is a general loss of cholinergic projections as measured by a decrease in 
ChAT activity, high-affinity choline uptake is increased significantly in the remaining 
nerve terminals (104).  
1.4 Evidence of oxidative stress in AD 
A common feature of several neurodegenerative disorders is the evidence of extensive 
oxidative stress, which appears to occur particularly early on in AD and contributes to the 
pathology of the disease by mediating the loss and dysfunction on neuronal cells (105, 
106). Oxidative stress occurs when the production of ROS such as hydrogen peroxide 
(H2O2), nitric monoxide (NO), superoxide anion (O2
-
), peroxynitrite (ONOO
-
) and 
reactive hydroxyl radical (OH·), is unregulated and is greater than antioxidant capacity. 
The brain is particularly susceptible to ROS because it is low in antioxidant defense 
systems, has a high oxygen consumption and it is rich in polyunsaturated fatty acids, 
which are easily attacked by free radicals (107). Increased production of ROS in the brain 
can result in the oxidation of lipids, proteins, RNA and DNA, which leads to 
inflammation, tissue damage and subsequent cellular apoptosis of neurons or glial cells 
(108). The oxidative stress hypothesis of AD is formulated based on the observations that 
a primary risk factor for the disease is age, and during aging antioxidant capacity is 
reduced and ROS accumulates in the brain. 
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This hypothesis is supported by several lines of evidence that show that the signature 
markers of oxidative stress are up-regulated in AD pathology. The concentration of (E)-
4-hydroxy-2-nonenal (HNE), an electrophilic breakdown product of lipid peroxidation 
formed by the attack of ROS on the double bond arachidonic acid (109), is significantly 
increased in brain tissue (110) and cerebrospinal fluid (CSF) of individuals with AD 
(111). Lipid peroxidation products acrolein, malondialdehyde and F2-isoprostanes are all 
increased in AD brains compared to controls (112), with F2-isoprostanes being elevated 
in the cortex and hippocampus, but not in the cerebellum, an area not typically affected 
by AD lesions, and in the post-mortem ventricular and lumbar CSF from patients with 
AD (113, 114). Increased oxidative damage occurs to all four bases of DNA in the brains 
of AD patients compared to cognitively intact control subjects (115) and extensive 
protein carbonylation (116) and nitration is observed in brains of individuals with MCI or 
AD (117, 118). Finally, the endogenous antioxidant defence enzymes catalase, 
superoxide dismutase, glutathione peroxidase and glutathione reductase are up-regulated 
in the hippocampus and amygdala in AD brains (119, 120).  
1.5 Sources of ROS in the AD brain 
1.5.1 Overview  
ROS are produced in the brain by direct interactions between redox-active metals and 
oxygen species, or through indirect pathways involving the activation of phospholipases, 
nitric oxide synthases and xanthine oxidase, which occurs as a result of dysregulation of 
calcium homeostasis (121). It is not clear whether disruption of calcium homeostasis is a 
cause or result of ROS production as some studies have shown that increases in 
intracellular calcium induce the production of ROS, while others show low 
concentrations of ROS cause an increase in cytosolic calcium levels (122, 123). The most 
investigated potential sources of ROS within the AD brain are altered mitochondrial 
activity, the presence of unbound metal ions and Aβ peptides themselves. There is an 
extensive literature that supports mitochondrial dysfunction and subsequent oxidative 
damage during AD. Mitochondria generate O2
-
 and NO as physiologically important by-
products of cellular respiration and contain many redox enzymes and respiratory 
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complexes capable of transferring single electrons to oxygen, generating O2
-
. While 
mitochondria contain several antioxidant defence systems, insults to the mitochondria, 
including ROS itself, can cause an imbalance between ROS production and removal 
leading to an overall net production of ROS (124).  
1.5.2 Metal ions as a source of ROS  
An important source of oxidative stress in the brain comes from the presence of metal 
ions. Metal ions are believed to play a role in the pathogenesis of AD (125). The 
concentrations of iron and zinc in various brain regions affected by AD are elevated in 
patients with AD compared to cognitively intact controls while copper levels are reduced 
(126, 127). Copper and iron are active redox metals that are toxic when present in excess 
due to their involvement in many processes related to ROS generation. The reactivity of 
copper and iron with molecular oxygen promotes the formation of H2O2, O2
-
 and the 
highly reactive OH· through the well-known Haber-Weiss and Fenton reactions (128, 
129). It is thought that metal ions contribute to AD pathogenesis and increase cellular 
ROS production by binding to Aβ. APP has a copper binding site in its amino-terminal 
domain, which reduces Cu
2+
 to Cu
1+
 (130) and a zinc binding site, which is thought to 
play a structural role (131), and Aβ itself also contains specific high and low affinity 
Cu
2+
 and Zn
2+ 
binding sites. The reduction of Cu
2+
 and Fe
3+
 by interacting with Aβ results 
in a redox-active peptide-metal ion complex which catalyzes the production of H2O2, 
using O2
-
 and biological reducing agents, such as cholesterol, vitamin E and 
catecholamines as substrates (132-135). The redox-active Aβ-metal ion complex itself 
can subsequently reduce H2O2 to OH·. The aggregation of Aβ is fundamental to Aβ-
mediated toxicity; however, emphasis has shifted away from amyloid fibrils as the 
predominant toxic species to the soluble oligomeric forms of Aβ. Interestingly, the 
interaction with copper, zinc, or iron with Aβ mediates the aggregation of the peptide 
(136, 137) while chelation of the metal ions can reverse the aggregation of synthetic Aβ 
and dissolve amyloid in post-mortem human brain samples (138, 139). Studies examining 
the time course of H2O2 generation during Aβ aggregation showed that H2O2 generation 
reaches a maximum during the early stages when oligomers are the main species present 
and declines as fibrils are formed (140, 141). A very recent study revealed that the latter 
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observation is due to conversion of H2O2 into OH· through redox activity of mature 
fibrils in the presence of redox-active ions, challenging the idea that the end stage fibrils 
are non-toxic structures (142).  
1.5.3 Aβ as a source of oxidative stress 
In addition to its ability to induce ROS formation through metal ion binding, internalized 
Aβ can generate oxidative stress by exerting direct effects on the mitochondrial 
membrane resulting in damage to the electron transport chain compromising neuron 
viability through energy depletion (143). This has been observed in PC12 cells, where Aβ 
causes mitochondrial dysfunction by impairing glycolysis, which results in depletion of 
cellular ATP levels (144). The iron-sulfur center containing enzyme complexes of the 
electron transport chain, α-ketoglutarate dehydrogenases and aconitase, have been shown 
to be vulnerable to damage by Aβ in various model systems (145, 146) and Aβ has been 
shown to potentiate induction of the mitochondrial permeability pore (147, 148), which 
causes depolarization of the mitochondrial membrane, calcium efflux and reduced 
glutathione and NADPH levels (149,150). Damage to the mitochondrial membrane and 
the electron transport chain increases mitochondrial ROS production (151), which can 
then further impair mitochondrial function. Finally, Aβ activates microglia in several 
experimental models (153-155) which are capable of releasing of NO (155) and O2
- 
(156). NO and O2
- 
combine together to produce significant amounts of a much more 
reactive molecule, ONOO
-
, which has been implicated in AD because of the levels of 
nitrotyrosine, a product of the reaction of ONOO
-
 with tyrosine, are elevated in AD 
(157). Consistent with this is the observation that ONOO
- 
can be generated by microglia 
activated by Aβ (158). 
1.6 ROS cellular targets  
ROS are highly reactive molecules that can react with a number of different targets in the 
brain to initiate neuronal death and neurodegeneration through various different 
pathways. ROS impair cellular function and cause cell death through the oxidation of 
lipids, proteins and DNA, and through the formation of toxic molecules such as alcohols, 
aldehydes, peroxides, ketones and cholesterol oxide. The products of membrane lipid 
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peroxidation by ROS, such as HNE and acrolein, cause toxicity to cells by covalently 
modifying proteins on cysteine, lysine and histidine residues by a process called Michael 
addition. This can impair the function of membrane ion-motive ATPases, such as the 
Na
+
/K
+
- and Ca
2+
- ATPases, as well as glucose and glutamate transporters, which can 
cause membrane depolarization and a reduction in cellular ATP levels (159, 160). HNE 
stimulates the apoptotic cascade through disruption of cellular calcium homeostasis (161) 
by activating of c-Jun amino terminal kinases and mitogen-activated protein kinase-1 
(MAPK) (162). The interaction of ROS with DNA can cause mutations and strand 
breaks, and ROS modifications to proteins can alter protein function through reversible 
post-translational modifications or impair protein activity. The perturbed calcium 
homeostasis as a result of ROS overproduction can also lead to an excitotoxic response, 
where excessive calcium influx results in the activation of glutamate receptors and 
initiates events resulting in apoptosis (163, 164).   
1.7 APP features and trafficking  
A major pathological hallmark feature of AD is the accumulation of insoluble aggregates 
of Aβ which is produced by the sequential proteolytic processing of its precursor, APP 
(165, 166). APP is a large, 695-770 amino acid, type-1 transmembrane protein with an 
extracellular amino terminus and an intracellular carboxyl terminus (167, 168). APP is 
produced in large amounts in neurons and quickly metabolized (169) through multiple 
different pathways of proteolysis by α, β and γ-secretase enzymes (170) at various 
subcellular locations (171). Initially, APP is sorted in the endoplasmic reticulum (ER) 
and the Golgi apparatus, where it is subject to post-translational modification such as N- 
and O-linked glycosylation, tyrosine sulfation and ectodomain and cytoplasmic 
phosphorylation (172-175). APP is transported to the axon and dendrites in post-Golgi 
transport vesicles (176) where it undergoes fast axonal transport to synaptic terminals 
(177) and is either trafficked directly to the cell surface or to endosomal compartments 
through clathrin-associated vesicles. At the cell surface, APP is internalized into clathrin-
coated pits mediated by the interaction of the intracellular YENPTY domain of APP 
(178) with multiple binding partners. This requires the presence of a phosphotyrosine 
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binding domain on the interacting protein, with the two best studied proteins being X11 
and Fe65. Mutation of the YENPTY domain alters APP endocytosis (179) and 
diminishes Aβ production (180). Following internalization, APP is transported to 
endosomal compartments, where a small portion of endocytosed APP is recycled back to 
the cell surface, while a considerable amount of APP is degraded in lysosomes (165). 
Finally, APP retrograde trafficking occurs between endosomes and the trans-Golgi 
network (TGN), which is mediated by retromer complexes. Sorting protein-related 
receptor (sorLA) is an adaptor protein that affixes cargo to the retromer complex and 
binds APP (181).  
1.8 APP metabolism  
APP undergoes proteolytic processing through one of two pathways: non-amyloidogenic 
processing of APP, which leads to the generation of non-pathogenic peptide fragments 
and prevents Aβ production, or amyloidogenic processing leading to the generation of Aβ 
(Figure 1-4). The amyloidogenic processing of APP occurs when the β-secretase, β-site 
APP cleaving enzyme-1 (BACE1), mediates the initial and rate-limiting step in the 
processing of APP (182). BACE1 cleaves APP at a position located 99 amino acids from 
the carboxyl terminus, resulting in release of the soluble amino-terminal ectodomain of 
APP (sAPPβ) and a 99 amino acid membrane-bound intracellular carboxyl-terminal 
fragment (C99 or βCTF). The carboxyl-terminal fragment is then processed within the 
membrane by the γ-secretase multi-protein complex, which is composed of presenilin 1 
(PS-1), presenilin 2 (PS-2), nicastrin, Aph-1 and Pen-2 (183). The γ-secretase complex 
cleaves the βCTF at one of several sites between amino acids 38 and 34 to generate Aβ 
and the APP intracellular domain (AICD). AICD is released into the cytosol and Aβ is 
thought to accumulate intra-neuronally (184) or to be released into extracellular fluids, 
such as plasma or cerebrospinal fluid through the recycling of endosomal compartments 
to the cell surface. The γ-secretase cleavage produces Aβ that is 40 amino acids in length  
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Figure 1-4 APP metabolism through the amyloidogenic and non-amyloidogenic 
pathway.   
Cleavage of APP in the amyloidogenic pathway involves processing by both β-secretase 
(BACE1) and the γ-secretase complex that releases the soluble amino-terminal 
ectodomain of APP (sAPPβ), the APP intracellular domain (AICD) and an Aβ peptide 
that can be of varying length, with the 40 and 42 amino acid Aβ peptides being the most 
abundant. Alternatively, APP processing can occur through the non-amyloidogenic 
pathway where it is first cleaved by the α-secretase (ADAM10) then by the γ-secretase 
complex, thereby preventing the generation of toxic Aβ peptides and leading to the 
production of the soluble amino-terminal ectodomain of APP (sAPPα), the AICD and p3, 
a truncated peptide that is pathologically irrelevant. 
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(Aβ1-40), and the more toxic Aβ that is 42 amino acids in length (Aβ1-42) at a ratio of 
10:1. The Aβ1-42 isoform is more hydrophobic, more prone to form fibrils, more 
resistant to degradation and is the isoform most commonly found within cerebral amyloid 
plaques (185). The non-amyloidogenic processing of APP is the more prevalent pathway, 
and occurs when APP is cleaved within the Aβ domain at a position 83 amino acids away 
from the carboxyl terminal domain. APP is cleaved by 3 enzymes with α-secretase 
activity belonging to the ADAM family of proteases: ADAM9, ADAM10 and ADAM17 
(186). This generates a truncated membrane-bound intracellular carboxyl-terminal 
fragment (C83 or αCTF), lacking the amino-terminal portion of the Aβ domain. The 
αCTF is then cleaved within the membrane by the γ-secretase protein complex to 
generate AICD and p3, a truncated Aβ peptide, which is pathologically irrelevant (187). 
Autosomal dominant forms of AD, which typically manifest with early-onset 
pathogenesis (188), are often caused by mutations in the genes encoding APP, PS-1 and 
PS-2, and cause changes in the stability and processing of Aβ. While most mutations in 
APP are found close to the γ-secretase cleavage site, the Swedish mutation, which is the 
most well-studied APP mutation, causes a double amino acid change next to the BACE1 
cleavage site. This enhances cleavage of the mutant APP by BACE1 leading to increased 
production of both Aβ1-40 and Aβ1-42 in the plasma of individuals carrying this 
mutation (189). Mutations in PS-1 and PS-2 alter the amino acids within their nine TMD 
and typically increase the production of the more toxic Aβ1-42 (190). Other mutations, 
such as the Arctic mutation, increase the aggregation of Aβ (191). Increased number of 
the APP gene locus (192) is also known to cause AD, an example of which is seen in 
Down syndrome, in which trisomy of chromosome 21 occurs and causes early 
accumulation of Aβ (193). In total there are 32 APP, 179 PSEN1 and 14 PSEN2 gene 
mutations, most of which result in an increase in the production of the more toxic Aβ1-42 
as compared to Aβ1-40 (194).  
1.9 Intracellular sites of Aβ production 
The precise subcellular location of APP processing and subsequent Aβ generation is 
controversial. Aβ generation can occur wherever β and γ- secretase enzymes are located, 
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and thus it is possible that this can occur in various subcellular compartments. 
Accumulation of Aβ has been observed in the ER, the TGN, post-TGN secretory vesicles, 
mitochondria, endosomes, lysosomes, multivesicular bodies, autophagic vacuoles and the 
cytosol (195-204). While a consensus has not yet been reached, the identities of 
organelles involved in APP processing and Aβ generation have been researched 
extensively. Based on the results of biochemical and genetic studies, the importance of 
APP endocytic trafficking in Aβ production is generally agreed upon. In vivo experiments 
demonstrate that endocytosis is required for synaptic activity-dependent release of 
approximately 70% of Aβ in neurons (205). According to the most accepted model, APP 
that reaches the cell surface is predominantly processed by α-secretases (206); however, 
some unprocessed APP is internalized into early endosomes, where the initial cleavage of 
APP by BACE1 to form the βCTF occurs. This is supported by the observations that 
early endosomes have the optimal pH for BACE1 activity, and fluorescence energy 
resonance transfer analysis showing APP and BACE1 interact predominantly in these 
compartments (207). The βCTF that is produced in this reaction is then processed further 
within early endosomes by the γ-secretase complex resulting in the generation of Aβ, 
which is subsequently released into the extracellular environment by the recycling of 
endosomes to the cell surface. Alternatively, the βCTF could potentially be trafficked to 
other downstream post-endocytic locations such as late endosomes, the multivesicular 
body or the lysosome for processing. APP that is not cleaved by BACE1 in early 
endosomes can be recycled back to the cell surface or back to the TGN by the 
SorLA/retromer protein complex, which is thought to retain APP within the Golgi and 
prevent its processing to Aβ. While the standard model indicates that very little Aβ is 
generated outside of the endosomal pathways, several groups have identified the ER and 
TGN as a major site for Aβ production (208-210), which is consistent with the 
localization of β- and γ- secretases to this pathway (211, 212). Furthermore, some α-
secretase activity has also been observed in the TGN (212).  
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1.10 Assembly state of Aβ 
Aβ is produced as a monomer, but can exist in several different assembly states including 
monomers, dimers, trimers, tetramers, dodecamers, higher-order oligomers, protofibrils 
and insoluble mature fibrils, which form microscopically visible amyloid plaques that 
define AD pathology (213). Fibril formation of Aβ is a complex, nucleation dependent, 
process of protein aggregation involving the misfolding of Aβ peptides into soluble and 
insoluble fibrillar assemblies (214). Kinetic studies have shown that the misfolding of Aβ 
monomers precedes the formation of oligomers, which then act as seeds for the formation 
and elongation of Aβ fibrils (215). The mechanisms driving this process in the AD brain 
are not fully understood. For many years, the insoluble fibrillar form of Aβ was thought 
to be responsible for the neurodegeneration and cognitive decline associated with AD 
(216). However, studies showed that accumulation of insoluble fibrillar forms of Aβ in 
transgenic mice overexpressing APP was accompanied by minimal neuron loss (217), 
and that the correlation between fibrillar forms of Aβ and cognitive impairment was weak 
(218). Similarly, in humans, a weak correlation between fibrillar Aβ plaque level in the 
brain and dementia was found, and cognitively intact individuals have been found to have 
high levels of fibrillar Aβ in their brains (219, 220). These observations indicate that a 
species other than the fibrillar Aβ could be responsible for the cognitive deficits in the 
early stages of AD. The toxicity of the various molecular species of Aβ has been 
confirmed by different experimental approaches, including using synthetic or endogenous 
Aβ peptides, cell culture systems overexpressing APP and APP transgenic mice. Aβ 
monomers may play a neuroprotective role by promoting neuronal survival through the 
activation of the phosphoinosotide-3-kinase (PI3K) pathway (221, 222) and in vitro and 
in vivo studies have established that oligomeric and protofibril forms of Aβ are potent 
neurotoxins (223-225). Oligomeric species of Aβ are more potent than fibrils and plaques 
in eliciting synaptic dysfunction and inhibiting long-term potentiation, a form of synaptic 
plasticity (226, 227). Most importantly, synapse loss and cognitive impairment correlate 
more with brain levels of soluble oligomeric Aβ levels than with the density of fibrillar 
Aβ plaques (228-230) suggesting that oligomers are the primary toxic species in AD.   
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1.11 Physiological roles of APP 
While the mechanisms involving the production of Aβ have been well studied, the 
physiological function of APP, and whether a loss of these functions plays a role in AD, 
remains unknown. The analysis of APP function in vivo is complicated by two major 
factors. First, APP belongs to an evolutionarily conserved protein family that includes the 
amyloid precursor-like proteins (APLP1 and APLP2) in mammals, and functional 
redundancy between these proteins may compensate for APP loss of function in animal 
models of targeted gene inactvation. Second, the proteolytic processing of APP leads to 
various extracellular and intracellular APP fragments with different functions.  
The combined deletion of APP together with its homologs leads to early postnatal death 
(231,232), while APP, APLP1 and APLP2 single knockout mice are viable and fertile. 
However, many studies have shown that animal models of targetted APP inactivation 
have several defects and abnormalities (233,234). In transfected cell lines and cultured 
neurons, APP has been shown to modulate cell growth, neurite outgrowth (235), neuronal 
survival (236), cell adhesion (237) and cell motility (238). These functions of can be 
reproduced by the soluble ectodomain of APP, which has also been implicated in cellular 
processes including neuroprotection, memory enhancing functions, regulation of gene 
expression and regulation of neuronal excitability and synaptic plasticity (239,240). The 
AICD is also known to have a functional role by acting as a transcription factor 
controlling a wide variety of cell functions (241), including apoptosis (242), cell 
signaling, calcium homeostasis (243) controlling neuronal networks (244), cellular 
trafficking and cytoskeletal dynamics (245). During neuronal differentiation and 
maturation APP expression is up-regulated (246), and its expression is also induced 
during traumatic brain injury (247). APP is targeted to synaptic sites through rapid 
anterograde transport and the level of APP is correlated to synaptogenesis (248). Taken 
together, the results from studies using different in vivo transgene overexpression or 
targetted allele animal models and cultured cells indicate that APP plays a key 
neurotrophic role in early developmental events, including neuronal migration, 
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synaptogenesis and cell adhesion, with the processing of APP leading to various peptide 
fragments with several cellular functions.   
1.12  Cholesterol as a risk factor for AD 
A number of cardiovascular risk factors, such as hypertension, hypercholesterolemia and 
diabetes mellitus, have been shown in observational and epidemiologic studies to be 
associated with AD and dementia (249, 250). Studies show that cardiovascular disease 
(CVD) and AD occur together more often than would be expected by chance (251) and 
neuritic plaques have been observed in patients with myocardial infarctions without 
having previously diagnosed dementia (252). Furthermore, vascular injury may lower the 
threshold for cognitive manifestations of clinical dementia (253). These observations 
have led to the hypothesis that AD and CVD may share a common risk factor. Data from 
human epidemiological studies show that hypercholesterolemia, in particular elevated 
low-density lipoprotein cholesterol (LDL-C), is one of the major risk factors for both AD 
and CVD (254).  
Mean cholesterol levels in individuals with AD are not higher than in those without; 
however, the results of large epidemiologic studies and prospective population studies 
suggest that an elevation in plasma cholesterol level in midlife increases the risk of 
developing AD in older age (255). One study found that individuals with familial 
hypercholesterolemia were more likely to develop MCI than those without (256), and 
similarly, another found that a high cholesterol level at midlife was associated with an 
increased risk of developing dementia later in life (257). In patients with AD, high levels 
of total cholesterol or LDL-C contributes to faster cognitive decline (258), and in patients 
without AD or dementia, a separate study reported that high levels of total cholesterol, or 
LDL-C, were related to lower scores on the Modified Mini-Mental State Exam (259). 
1.13 The role of cholesterol in the brain  
The brain is the most cholesterol-rich organ in the body, containing approximately 20% 
of the total body cholesterol, but accounting for only approximately 2% of the body mass 
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(260). Cholesterol is tightly regulated between the major brain cells, neurons and glia, 
and is required for normal brain development. Cholesterol forms an essential component 
of cell membranes and plays a crucial role in development and maintenance of neuronal 
plasticity and function (261), with depletion of cholesterol resulting in synaptic and 
dendritic spine degeneration, failed neurotransmission, and decreased synaptic plasticity 
(262). Cholesterol is synthesized through the isoprenoid biosynthetic pathway from 
acetyl coenzyme-A by a complex series of reactions catalysed by over 20 enzymes; 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase catalyses the rate-limiting 
step of this process and is the target of statin pharmacotherapy (263). Enzymes involved 
in cholesterol production, such as HMG-CoA, are expressed at high levels in cortical, 
hippocampal and cholinergic neurons (264) and the expression of enzymes, cholesterol 
transport proteins and lipoprotein receptors varies between brain regions (265), as does 
cholesterol content (266). Cholesterol synthesis in the developing central nervous system 
(CNS) is much higher than that in the adult state. In the mature CNS, most of the 
cholesterol is found concentrated within the specialized membranes of myelin (267) 
where it is immobilized due to its slow rate of turnover, with the rest of brain cholesterol 
being found in the plasma membranes of neurons and glial cells, as well as extracellular 
lipoproteins. The turnover rate of cholesterol in individual neurons and astrocytes is 
likely higher than that of myelin bound cholesterol, and is thought to reach an estimated 
20% turnover per day depending on the brain area and neuronal cell type (268).  
1.14 Cholesterol metabolism in the brain 
The majority of cholesterol in the brain is free, unesterified cholesterol and its 
homoeostasis is tightly regulated through a series of processes that include synthesis, 
storage, transport, and removal. In the periphery, cholesterol homeostasis is mediated by 
a lipoprotein transport system between the liver, intestine and other organs through blood 
circulation.  Cholesterol levels in the brain do not respond to the homeostastic control 
mechanisms regulating peripheral plasma cholesterol levels, indicating that there is a 
distinct metabolism of cholesterol in the CNS. While some studies have demonstrated 
that a small amount of cholesterol from the periphery can be transported into the CNS in 
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humans and in mice (269, 270), the majority of experimental evidence indicates that the 
CNS is isolated from the complex peripheral cholesterol transport system by the blood-
brain barrier (271). The endothelial cells that comprise the blood-brain barrier express 
mRNA for the low-density lipoprotein receptor (LDLR), scavenger receptor class B type 
I (SR-BI) and members of the ATP binding cassette (ABC) family of transporters and, 
under in vitro conditions, are able to transport cholesterol across the endothelial cells, 
indicating that these transporters may be involved in mediating cholesterol influx across 
the blood brain barrier (272). However, in vivo studies show that only small amounts of 
apolipoprotein B, the main apolipoprotein associated with LDL particles in the peripheral 
cholesterol transport system, are found in the human brain, suggesting that full size 
particles do not pass by the blood-brain barrier and very little clearance of 
125
I-labeled 
homologous LDL into the CNS was observed in mice, rabbit and sheep (273-275). 
Furthermore, in mice fed a high-cholesterol diet, plasma total cholesterol levels were 
increased 7-fold, while no changes in cholesterol concentration or rate of synthesis were 
demonstrated in any region of the CNS (276). Thus, it is commonly assumed that the 
majority of CNS cholesterol (>95%) originates from de novo synthesis.  
Neurons and glial cells, including astrocytes, microglia and oligodendrocytes, can 
synthesize cholesterol. In vitro cell culture experiments show that the pathway of 
cholesterol synthesis differs in the sequence of enzymatic steps and resulting precursors 
between neurons and astrocytes (277). Astrocytes synthesize cholesterol at a higher rate 
than do neurons, and oligodendrocytes, the cells that are responsible for myelinization, 
have a higher capacity for cholesterol production than do astrocytes (278). In addition to 
de novo synthesis, cholesterol can also be taken up from extracellular sources, and a 
significant amount of cholesterol is transported between neurons and glial cells by 
cholesterol-containing lipoproteins, which are mainly secreted by astrocytes (279, 280, 
281). A subset of the apolipoproteins found in the plasma are present in the CNS, 
including apolipoprotein E (APOE), apolipoprotein J/clusterin (APOJ/CLU), and 
apolipoprotein D (APOD), and have been shown to be up-regulated in various different 
types of injury and disease (282-284). One of the 3 isoforms of APOE, APOE4, is a well-
known risk factor for late-onset AD. Lipoproteins secreted by astrocytes differ in 
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their chemical and physical properties from those present in plasma (285, 286) having 
densities similar to those of high-density lipoproteins and containing only either APOE 
and APOJ/CLU. The mechanisms involved in lipoprotein assembly and secretion by 
astrocytes are not well understood. After secretion, the nascent lipoproteins may acquire 
cholesterol in a process similar to high-density lipoproteins, or they could be taken up 
directly by neurons (287, 288). A specific subtype of the ABC family of transporters, 
ABCA1, mediates the lipidation of nascent particles and in adult rodents is mainly 
expressed by neurons and expressed at low levels by glial cells (289). The uptake of 
lipoproteins in the brain is thought to be mediated by the binding of APO proteins to two 
specific receptors, the prototypic LDLR, which is expressed by neurons and glial cells 
(290, 291), and the LDL-related protein 1 (LRP1), which is predominantly expressed by 
neurons (292). It has been suggested that in the mature state, neurons rely on the delivery 
of cholesterol-containing, astrocyte-derived lipoproteins and few studies have addressed 
lipoprotein uptake by astrocytes as they are thought to export rather than import lipids 
(268). Cholesterol acquired from lipoproteins transits through the endosomal and 
lysosomal pathway and is mainly stored within subcellular recycling compartments and 
internal vesicles of multi-vesicular bodies in the endocytic pathway (293). Excess 
cholesterol is stored intracellularly in lipid droplets after esterification by the enzyme 
acyl-coenzyme A: cholesterol acyltransferase 1 (ACAT) (294), which has been shown to 
be present in neurons, but not glial cells (295). Finally, some cholesterol must be 
exported into the circulation to maintain homeostasis in the brain. There are two methods 
by which this is accomplished. The first is the excretion of small amounts of APOE-
bound cholesterol into the CSF, where 1-2 mg of cholesterol is eliminated daily (296). 
The second, and the more quantitative method, is the elimination of cholesterol is by its 
conversion to 24S-hydroxycholesterol (24OHC) (297). The hydroxylation of cholesterol 
at carbon 24 is mediated by the cytochrome P-450 species CYP46A1, and allows its 
translocation between lipophilic compartments and facilitates its movement through the 
blood brain barrier (298). Interestingly, CYP46A1 is found localized to neurons, 
indicating that cholesterol elimination in the brain begins in neurons and not in glial cells 
(296). 
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1.15 Statins in AD  
There is an established link between elevated plasma cholesterol levels and the risk of 
developing AD. Statins inhibit cholesterol synthesis, thereby reducing plasma cholesterol 
levels, and are the first line pharmacological therapy for the treatment of 
hypercholesterolemia (299). Taken together, these observations have led to the idea that 
statins could be useful in treating or preventing AD. There are many ways that high 
cholesterol could affect the progression of AD pathology. Cell culture studies show that 
cholesterol can increase the activity of the β- and γ-secretases (300-302) and reduce the 
movement of APP through the non-amyloidogenic pathway (303-306). Following the 
generation of Aβ, cholesterol has been shown to influence its aggregation state, with high 
cholesterol promoting its accumulation following secretion whereas low cholesterol 
levels allow more internalization and degradation of Aβ (307, 308). Finally, cholesterol 
may also affect different non-amyloid factors, such as inflammation, oxidative stress or 
tau metabolism (309). Preclinical and human studies regarding the relevance of statins as 
a potential treatment or preventative for AD have shown conflicting results, with 
preclinical studies suggesting beneficial effects of statins, while human trials have 
provided more inconsistent results.  
The results of various preclinical cell culture experiments have shown that statins can 
reduce the generation of Aβ (310, 311) and several in vivo studies in animal models of 
AD have confirmed this finding (312, 313). Statins can also inhibit the production of O2
- 
by endothelial cells (314) and increase the expression of eNOS either through the 
inhibition of Rho isoprenylation (315), or directly through activation of the PI3K/Akt 
pathway (316). Furthermore, statins are protective against Aβ-induced oxidative stress in 
mouse models of AD (317, 318). These preclinical observations indicate that statins 
could provide beneﬁts as a potential treatment or preventative for AD, but it is unclear 
whether this is due to lower cholesterol levels or to statin pleiotropy (319). Barone et al. 
(320) found that atorvastatin reduced lipid peroxidation, protein nitration and protein 
oxidation in the parietal cortex of elderly dogs in an Aβ and cholesterol-independent 
manner. The neuroprotective effect observed in this study was suggested to be mediated 
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through the activation of the cell stress response, as expression of effectors of the 
adaptive cell response increased and correlated with the reduction of oxidative and 
nitrosative stress biomarkers in the parietal cortex of these animals (321, 322).  
While the consensus from preclinical evidence regarding the neuroprotective effects of 
statins is encouraging, human clinical trials have shown much more inconsistent results. 
Several observational studies in humans support the hypothesis that statins may be a 
potential treatment for dementia or AD or may act to decrease the risk of developing of it 
(323-330). However, these findings have been challenged by other observational studies. 
In one study, statins did not improve cognitive performance in non-demented elderly 
individuals (331) and similar results were observed in a separate large cohort study that 
assessed more than 2 million individuals, with approximately 11 percent taking statins 
(332). Furthermore, Zandi et al. (333) found no correlation between statin use and 
dementia or AD in elderly individuals assessed from 1995 to 1997, and again in 1998-
2000. A separate study found that statin treatment did not alter the risk of developing 
dementia or AD in individuals 65 years and older, which was not affected by the 
lipophilicity of the statin used (334). The results of randomized control trials (RCT) have 
yielded similar contradictory results. One large double blind RCT study demonstrated 
that pravastatin treatment had no protective effect on cognitive function over a follow-up 
period of 3 years (335), and another showed that atorvastatin treatment for 72 weeks had 
no significant effect in delaying cognitive decline in patients with mild to moderate AD 
(336). Similarly, Sano et al. (2011) found simvastatin treatment had no effect in 
individuals with mild to moderate AD. In contrast to this, administering lovastatin to non-
demented individuals reduced serum Aβ levels in a dose-dependent manner (338). In 
another study, atorvastatin treatment for 1 year had a positive effect on cognitive 
performance after 6 month of treatment, but this was restricted to individuals who met 
specific criteria (339). Other groups have also assessed the effect of statin use in patients 
diagnosed with AD. Li et al. (2007) examined neuropathological changes of AD and 
found that statin users had lower Braak stages (a measure of neurofibrillary tangle 
involvement), but not lower scores on a quantitative scale of amyloid plaque pathology, 
than non-users. A meta-analysis of all statin RCT results suggests that there is insufficient 
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evidence to recommend statins as a treatment or preventative for AD (341). This is likely 
due to major differences in study design and data analysis, as well as the different 
lipophilicity and chemical structure of different statins which influences their ability to 
cross the BBB.   
1.16 Hypotheses for my thesis research  
1.16.1 Working hypothesis  
My working hypothesis was that pathological conditions associated with 
Alzheimer’s disease alter CHT function by changing the subcellular trafficking of 
the transporter in a manner that reduces choline uptake activity and cholinergic 
neurotransmission.  Specifically, my research investigated the effect of peroxynitrite 
(Chapter 2) and cholesterol manipulation (Chapter 3) on CHT activity and trafficking, 
and whether CHT is differentially regulated by its interaction with either wild-type APP 
or APP containing the Swedish mutation (Chapter 4).  
1.16.2 Hypothesis for Chapter 2 
Experiments in Chapter 2 were designed to determine the effect of the peroxynitrite 
donor SIN-1 on CHT activity and trafficking. The hypothesis of this study was that 
inhibition of CHT by SIN-1 is mediated via alterations in transporter trafficking, as 
opposed to oxidative or nitrosative modification of CHT protein.  
1.16.3 Hypothesis for Chapter 3 
The experiments presented in Chapter 3 were carried out to assess how CHT activity and 
trafficking is regulated by plasma membrane cholesterol and its association with 
cholesterol-rich lipid rafts.  For this study, my hypothesis was that CHT is localized to 
lipid rafts and disruption of rafts alters CHT activity and trafficking, and causes a 
decrease in choline uptake activity and cholinergic neurotransmission.  
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1.16.4 Hypothesis for Chapter 4 
The experiments presented in Chapter 4 were designed to assess whether CHT is 
differentially regulated by its interaction with either the wild-type or Swedish mutant 
APP. My hypothesis for this study was that the interaction of CHT with either wild-
type APP or APP containing the Swedish mutation alters CHT function through 
different mechanisms that alter CHT trafficking and choline uptake activity.  
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Chapter 2  
2 Peroxynitrite donor SIN-1 modifies high-affinity choline 
transporter activity by altering its intracellular trafficking1 
  
                                                 
1
 A version of this work has been published in the following manuscript: 
 Cuddy LK, Gordon AC, Black SA, Jaworski E, Ferguson SSG, Rylett RJ. Peroxynitrite donor 
SIN-1 modifies high-affinity choline transporter activity by modifying its intracellular trafficking. 
J Neurosci 18 April 2012 32 (16):5573-5584 
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2.1 Introduction 
CHT is an integral component of cholinergic neurons that moves choline from the 
synaptic cleft into cholinergic nerve endings where it is used as substrate for ACh 
synthesis. This choline uptake is HC-3 sensitive and can be the rate-limiting step for ACh 
synthesis (1, 2). Importantly, CHT is sensitive to oxidative stress (3,4), and a critical 
target for disruption of neuronal communication.  
Increasing evidence suggests a role for reactive oxygen and nitrogen moieties in 
progression of neurodegenerative disorders such as Alzheimer’s disease (5). ONOO- 
forms by combination of O2
-
 and NO, with these reactive species occurring in response to 
tissue injury (6-9). ONOO
-
 has multiple fates within cells, including contributing to 
membrane lipid peroxidation and protein oxidation and nitration. ONOO
-
 inhibits the 
function of some neurotransmitter transporters, including the dopamine (10) and 5-
hydroxytryptamine transporters (11). Also, ONOO
-
 decreases CHT activity in 
synaptosomes from T. marmorata (3). Our laboratory found that SIN-1, which generates 
ONOO
-
 and other reactive oxidants, causes rapid, dose-dependent inhibition of CHT and 
this is attenuated by ONOO
-
 scavengers (4). Importantly, oxidants such as H2O2 did not 
alter CHT activity (3, 4). 
CHT proteins internalize constitutively by clathrin-mediated endocytosis, residing 
predominantly in intracellular organelles including synaptic vesicles rather than at the 
cell surface (12-17). Recruitment of CHT to the plasma membrane is a critical 
mechanism regulating solute transport (12, 15, 17, 18). CHT interaction with the 
endocytic machinery is mediated by a dileucine-like motif located in its intracellular 
carboxyl-terminus, and we showed that mutation of a single leucine in this motif 
(L531A) substantially reduces constitutive trafficking of CHT with L531A-CHT proteins 
retained at the cell surface (14).  
Here, I found that inhibition of choline uptake in SIN-1 treated cells is due to decreased 
cell surface CHT levels rather than altered solute binding affinity, and that SIN-1 
modulates CHT activity by increasing its internalization and this correlates with 
 61 
 
decreased plasma membrane CHT (4). However, the mechanisms by which SIN-1 
modulates CHT trafficking between plasma membrane and subcellular organelles are 
unknown. Thus, the aim of this study was to characterize mechanisms by which SIN-1 
modulates CHT function. The endocytosis-defective mutant L531A-CHT was used to 
test my prediction that it would be resistant to SIN-1 inhibition if the mechanism by 
which SIN-1 decreases CHT activity involves enhancing CHT internalization. I tracked 
CHT movement in endosomal-lysosomal compartments and found that acute SIN-1 
treatment does not alter these events, but importantly, blocking proteasome, but not 
lysosome, function attenuated SIN-1-mediated inhibition of CHT. 
2.2 Materials and methods 
2.2.1 Materials  
SIN-1 [3-morpholinosydnonimine] was from Biomol Research Labs (Plymouth Meeting, 
PA), lactacystin and MG-132 were from Calbiochem, chloroquine was from Sigma-
Aldrich (St. Louis, MO), bafilomycin A1 was from Santa Cruz Biotechnology (Santa 
Cruz, CA), and [methyl-
3
H]choline chloride (128 Ci/mmol) and [methyl-
3
H]hemicholinium-3 diacetate ([
3
H]HC-3) (144.5 Ci/mmol) were from Perkin-Elmer Life 
Sciences (Boston, MA). Other chemicals were purchased from Sigma-Aldrich at the 
highest purity available. SH-SY5Y human neuroblastoma cells were from the American 
Type Culture Collection (Manassus, VA), and Invitrogen (Burlington, ON, Canada) 
supplied HEK 293 Flp-In cells, fetal bovine serum (FBS), and culture media and 
reagents. Zenon-Alexa Fluor 488 and 555 mouse IgG labelling kits were from Molecular 
Probes (Eugene, OR). Enhanced ChemiLuminescence immunoblot reagent (ECL) was 
from GE Healthcare Life Sciences (Baie d’Urfé, QC, Canada) and Biodegradable 
Scintillant was from Amersham Canada Ltd. (Oakville, ON, Canada). Polyclonal CHT 
antibody was raised in rabbits to the antigenic peptide DVDSSPEGSGTEDNLQ that is 
conserved at the carboxyl-terminus of human and rat CHT (Genemed Synthesis, San 
Antonio, TX); this peptide was conjugated to KLH carrier protein by an amino-terminal 
cysteine residue. CHT-specific IgG was affinity-purified in our laboratory from the crude 
anti-serum on NHS-Sepharose (Amersham) to which antigenic peptide had been coupled 
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as the binding element. The specificity of this antibody for detection of CHT was 
described previously (4). Peroxidase-conjugated goat anti-rabbit IgG was from Jackson 
ImmunoResearch Laboratories (West Grove PA). 
2.2.2 Stable transfection and selection of cell lines  
Full-length rat CHT cDNA ligated to pSPORT was a gift from Dr. T. Okuda (19); a 
FLAG epitope tag (DYKDDDDK) was added to the amino-terminus by PCR and the 
resulting cDNA ligated to pcDNA3.1 or pcDNA5 (4). Mutant L531A-CHT was produced 
by site-directed mutagenesis using a QuikChange kit (Stratagene). SH-SY5Y cells were 
transfected with plasmids [FLAG-CHT or FLAG-L531A-CHT cDNA ligated to 
pcDNA3.1] by Lipofectamine 2000. Stable transformants (SY5Y-CHT and SY5Y-
L531A-CHT, respectively) were selected using 500 μg/ml geneticin (G418) for 4 weeks, 
then grown in Dulbecco’s modified Eagle medium (DMEM), 10% fetal bovine serum 
(FBS), 100 U/ml penicillin, 100 μg/ml each of streptomycin and G418. SH-SY5Y cell 
differentiation was induced by addition of 10 μM all-trans-retinoic acid (RA) for 3 days. 
HEK 293 cell lines stably-expressing either FLAG-CHT were created by introducing 
plasmids in pcDNA5 into the Flp Recombinase Target site in HEK-Flp-In cells by 
Lipofectamine 2000 transfection (HEK-CHT cells). Stable transformants were selected 
and expanded in DMEM containing 10% FBS, 10 μg/ml gentamicin and 50 μg/ml 
hygromycin-B.  
To inhibit clathrin-mediated constitutive trafficking of CHT proteins, we used AP180C, a 
DN protein of the carboxyl-terminal portion of adaptin AP180, which can bind to and 
sequester clathrin to effectively interfere with clathrin-mediated endocytosis (20). 
Interruption of dynamin-mediated protein trafficking was achieved using Dyn-K44A as a 
DN dynamin protein which has a point mutation that ablates dynamin GTPase activity 
that is required for membrane scission (21).  
2.2.3 SIN-1 treatment  
The use of ONOO
-
 donors such as SIN-1 allows continuous production of a low level of 
ONOO
-
 by a substance that is relatively stable over a longer period of time (22). As the 
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half-life of ONOO
-
 radical is less than 1 sec, bolus administration of this agent does not 
produce either consistent or sustained concentrations of ONOO
-
 under experimental 
conditions. The donor efficiency of SIN-1 may be altered by changes in pH and buffer 
composition; previous studies that used a Krebs buffer similar to that employed in the 
present study estimated that 1 μmol ONOO- is formed per min in a solution of 1 mM 
SIN-1. This suggests that the SIN-1 treatments used here could generate ONOO
-
 levels 
representative of those seen in brain under some conditions (23). The estimated half-life 
for SIN-1 in these buffer conditions is 14-26 min, suggesting that donor activity would be 
sustained throughout the treatment periods used in our study. Total ONOO
-
 production 
capacity under these buffer conditions has been estimated to be 30 μM, although the 
ONOO
-
 concentration in solution at a given time will be lower than this due to its much 
shorter half-life. 
2.2.4 Confocal cell imaging 
Digital images of live and fixed cells were acquired with a Zeiss LSM510-Meta laser 
scanning confocal microscope using a 63X magnification oil-immersion objective. 
Fluorescent labelling of FLAG-tagged CHT proteins in live cells was accomplished using 
rabbit anti-FLAG antibody complexed to either Zenon-555 dye (for Rab5a-GFP, Rab7-
GFP and Rab9-YFP) or Zenon-488 dye (for Lamp-1 staining or when no co-stain was 
used). This fluorescently-tagged antibody was added to the medium bathing cells where it 
could bind to the FLAG-epitope on the extracellularly-oriented amino-terminus of CHT 
proteins inserted at the plasma membrane. Imaging of live cells allowed real-time 
tracking of internalization of CHT into cells and movement of these proteins between 
subcellular organelles. In some experiments, cells were transfected with fluorescently-
labelled subcellular compartment markers including Rab5a-GFP (early endosomes), 
Rab7-GFP (early to late endosomes) or Rab9-YFP (late endosomes). Also in some 
experiments, cells were formaldehyde-fixed after allowing the internalization of Zenon-
labelled CHT proteins as this facilitated imaging and was required for counter-staining 
cells to visualize lysosomes using an anti-human antibody directed to LAMP-1. 
Formalin-fixation of GFP or YFP-fusion protein expressing cells did not alter the image 
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quality of these fluorophores compared to images that were captured from live cells 
expressing these fusion proteins.  
Colocalization analysis was performed on confocal images using Imaris 7.0 with the 
Imaris Colocalization module (bit-plane) to examine the colocalization of the brightest 
2% of pixels in each channel. Graphing and statistical analysis was performed using 
Prism GraphPad using one-way ANOVA with Tukey’s post-hoc test. 
2.2.5 [3H]Choline uptake assay  
Monolayers of cells were washed, then incubated at 37
o
C in Krebs-Ringer HEPES 
solution (KRH) [mM: NaCl, 124; KCl, 5; MgSO4, 1.3; CaCl2, 1.5; glucose, 10; HEPES-
NaOH, 20, pH 7.4]. Either vehicle or SIN-1 was added to cells for specified times, 
followed by incubation for 5 min with 0.5 μM [3H]-choline (0.5 μCi/ml) in the absence or 
presence of 1 μM HC-3. Cells were placed on ice and washed with cold KRH, then lysed 
in 0.1 M NaOH. After 30 min incubation, aliquots of samples were analyzed for tritium 
by liquid scintillation spectrometry and protein concentration using Biorad protein dye. 
Each independent experiment consisted of triplicate plates of cells per treatment group, 
with results normalized to sample protein content and averaged. Specific choline uptake 
was calculated as the difference between total choline uptake and non-specific uptake in 
the presence of HC-3, with the resulting [
3
H]choline uptake data expressed as pmol / mg 
protein per 5 min ± SEM. 
2.2.6 [3H]HC-3 binding assay  
Monolayers of cells were washed and incubated in KRH at 37
o
C with the addition of 
either vehicle or 1 mM SIN-1 for specified times, then washed with ice-cold KRH and 
kept on ice for 10 min to stop protein trafficking activity. Cells were then incubated with 
[
3
H]HC-3 (10 nM; 0.23 Ci/mmol) in the presence or absence of 1 μM unlabelled HC-3 
for 1 h on ice. For kinetic analysis, HC-3 binding was measured over the range of 0.5 - 10 
nM HC-3 with the specific activity of [
3
H]HC-3 held constant at 0.23 Ci/mmol. 
Following incubation, cells were washed rapidly with cold KRH to remove unbound HC-
3 and then lysed using 0.1 M NaOH for 30 min. Aliquots of cell lysates were used for 
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quantification of tritium and protein content. Each independent experiment had triplicate 
determinations with HC-3 binding normalized to sample protein content and then 
averaged. Specific HC-3 binding was calculated as the difference between total and non-
specific HC-3 binding, and values were expressed as fmol / mg protein ± SEM. 
2.2.7 Cell surface protein biotinylation assay  
Cells plated on 60 mm dishes were washed with HEPES-buffered saline solution 
(HBSS), then treated at 37
o
C with either vehicle (HBSS) or HBSS containing 1 mM SIN-
1 for the times indicated. After treatment, cells were placed on ice under cold HBSS to 
stop protein trafficking. Plasma membrane proteins were biotinylated on ice by 
incubating with 1 mg/ml sulfo-NHS-SS-biotin in HBSS for 1 h (4, 24). Unbound biotin 
was quenched by washing and incubating cells in cold 100 mM glycine in HBSS. After 
two further washes with HBSS, cells were lysed on ice for 30 min in Triton X-100 lysis 
buffer [1% w/v Triton-X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM AEBSF, 
10 μg/ml each of leupeptin and aprotinin, and 25 μg/ml pepstatin A, 700 U/ml DNase]. 
Neutravidin beads were incubated with cell lysates for 1 h at 4
o
C with gentle mixing to 
bind biotin-labelled proteins to allow separation from the non-biotinylated proteins. 
Beads were then washed with lysis buffer three times, PBS twice, and bound proteins 
were eluted by incubation for 10 min at 55˚C with Laemmli sample buffer [2% SDS, 
10% glycerol, 62.5 mM Tris-HCl pH 6.8, 2.5% β-mercaptoethanol and 0.001% bromo-
phenol blue]. Aliquots of biotinylated proteins and total cell lysates were separated on a 
7.5% SDS-PAGE gel and transferred to polyvinylidene difluoride (PVDF) membrane. 
Membranes were blocked in 8% non-fat dry milk in wash buffer (PBS, 0.1% Tween-20) 
for 1 h, then incubated for 2 h with rabbit anti-CHT antibody (1:1,000) in wash buffer 
with 8% milk. After washing, membranes were incubated for 1 h with peroxidase-
conjugated goat anti-rabbit IgG secondary antibody (1:10,000) in wash buffer containing 
8% milk, and again washed. Immunoreactive proteins on membranes were detected by 
chemiluminescence using the enhanced chemiluminescence (ECL) kit (GE Healthcare). 
Immunopositive bands (at approximately 50-kDa for CHT protein) were quantified by 
densitometry using Scion Image software (NIH). Bands for cell surface CHT were 
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normalized by comparison to vehicle-treated control cells in each experiment which 
represented basal cell surface CHT levels.  
2.2.8 Data analysis 
Data are presented as the mean ± SEM with n values representing the number of 
independent experiments performed on separate populations of cells; each n value was 
obtained from the average of multiple sample replicates in each experiment. GraphPad 
Prism 5 and InStat software were used for data analysis. Sigmoid and Michaelis-Menten 
equations were used to calculate kinetic parameters (Bmax and KD) of HC-3 binding. 
Statistical significance was assessed by paired Student’s t-test, or between groups using 
one-way ANOVA with either Dunnett’s or Tukey’s post-hoc multiple comparison test, as 
appropriate (asterisks denote p < 0.05). 
Replicate experiments were performed on cells cultured in successive passages as much 
as possible to minimize inter-experiment variability; intra-experiment variability between 
replicate samples was minimal thus facilitating comparisons of treatment effects.  
2.3 Results 
2.3.1 SIN-1 decreases activity of wild-type CHT, but not mutant 
L531A-CHT  
Initial experiments in this chapter characterized SIN-1 effects on choline uptake in SH-
SY5Y cells stably expressing wild-type CHT or the endocytosis-deficient mutant L531A-
CHT. My lab showed previously that SIN-1 treatment of cells decreases choline uptake 
activity and reduces cell surface CHT levels due to accelerated endocytosis (4). Also, 
CHT undergoes clathrin-mediated endocytosis and L531A-CHT, which lacks the 
dileucine trafficking motif, is defective in this internalization (14). Thus, I predicted that 
if SIN-1 reduces cell surface levels of CHT by increasing its clathrin-mediated 
endocytosis, then L531A-CHT activity would be resistant to this SIN-1 mediated effect. 
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Laser scanning confocal images of live cells confirmed that a large proportion of CHT is 
located in subcellular organelles, whereas L531A-CHT resides at the cell surface (data 
not shown) (14). Also, consistent with the increased levels of plasma membrane CHT, 
choline uptake activity in SY5Y-L531A-CHT cells is significantly greater than in SY5Y-
CHT cells (1673±151 and 816±106 pmol/mg protein/5 min, respectively). A critical 
observation made in the this study in support of my prediction is that acute SIN-1 
exposure caused a dose-dependent decrease in choline uptake by wild-type CHT, but did 
not alter activity of SY5Y-L531A-CHT. Consistent with our previous findings (4), 
choline uptake was 49±14% of control in SY5Y-CHT cells treated with 1 mM SIN-1, but 
L531A-CHT was resistant to inhibition by 1 mM SIN-1, retaining 95±11% of control 
uptake activity. Figure 2-1 illustrates dose-response relationships for choline uptake in 
SIN-1-treated retinoic acid-differentiated SY5Y-CHT and SY5Y-L531A-CHT cells. A 
statistically significant difference was seen between SY5Y-CHT and SY5Y-L531A-CHT 
dose-response curves at 1 mM SIN-1. It is important to note that as 1 mM SIN-1 did not 
alter activity of L531A-CHT, it is unlikely that inhibition of CHT is due to oxidative or 
nitrosative modification of CHT proteins.  
At higher doses of SIN-1 (5 mM), inhibition of the two transporters did not differ 
significantly (49% and 33% of control uptake for L531A-CHT and CHT) (data not 
shown), but this is likely due to non-specific effects of SIN-1 such as the collapse of ionic 
gradients required for active uptake of choline or compromised membrane integrity, 
rather than to an effect of the drug on CHT. We showed previously that the decrease in 
CHT activity mediated by acute exposure of cells to 1 mM SIN-1 is not due to damage to 
cell integrity or toxicity monitored by LDH release and the MTT assay (4). Also, the 
SIN-1-mediated inhibition of choline uptake occurs rapidly; choline uptake activity 
assayed at 5 min of SIN-1 exposure reveals a significant decrease in CHT activity (data 
not shown).  
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Figure 2-1 SIN-1 inhibits choline uptake activity of wild-type CHT but not L531A-
CHT in SH-SY5Y cells.  
Retinoic acid-differentiated SH-SY5Y cells stably expressing either wild-type CHT or 
L531A-CHT were treated for 30 min with either vehicle or varying concentrations of 
SIN-1, and then HC-3-sensitive choline uptake activity was measured. Baseline uptake 
was found to be 816 ± 106 and 1673 ± 151 pmol of choline per milligram of protein over 
5 min for CHT and L531A-CHT, respectively. Data (percentage of control uptake in the 
absence of SIN-1) are expressed as mean ± SEM of four or five independent experiments, 
each with triplicate measurements. Statistical analysis was performed on the data before 
it being normalized to vehicle-treated control uptake for each group; asterisks denote 
statistically significant differences at p ≤ 0.05. 
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2.3.2 SIN-1 decreases cell surface levels of wild-type CHT, but not 
L531A-CHT 
Two approaches, equilibrium binding of the CHT antagonist [
3
H]HC-3 and plasma 
membrane protein biotinylation, were used to measure the SIN-1 effects on the amount of 
CHT protein at the cell surface. Plasma membrane levels of wild-type and L531A-CHT 
were assayed in SH-SY5Y cells after 15 min incubation with either vehicle or 1 
mM SIN-1. Consistent with the data shown in Figure 2-1 on the effects of SIN-1 on 
choline uptake activity, CHT and L531A-CHT responded differentially to exposure to 
this ONOO
−
 donor. In the first approach, specific binding of [
3
H]HC-3 was significantly 
decreased in SIN-1-treated SY5Y-CHT cells to 69.0 ± 3.7% of vehicle-treated cells (n = 
3 independent experiments; p = 0.004). By comparison, there were no differences in 
specific binding of [
3
H]HC-3 between vehicle- and SIN-1-treated SY5Y-L531A-CHT 
cells (111.4 ± 15.6% of vehicle-treated cells; n = 4 independent experiments; p= 0.64). 
With the second approach, immunoblots of biotinylated cell surface proteins were used to 
assess the plasma membrane levels of CHT in vehicle- and SIN-1-treated SY5Y-CHT 
and SY5Y-L531A-CHT cells. Cell surface levels of wild-type CHT are significantly 
reduced in SIN-1-treated SY5Y-CHT cells to 61.5 ± 13.7% when compared with vehicle-
treated cells (n = 4 independent experiments; p = 0.005). By comparison, cell surface 
levels of mutant L531A-CHT do not differ between control and SIN-1 treatment groups 
in SY5Y-L531A-CHT cells (108.5 ± 14.9% of vehicle-treated cells; n = 4 independent 
experiments; p = 0.42). Statistical analysis was by paired Student's t test. Thus, based on 
both [
3
H]HC-3 binding and protein biotinylation data, cell surface levels of CHT were 
significantly decreased by SIN-1. Neither method revealed a significant change in the 
plasma membrane levels of L531A-CHT protein in SIN-1-treated SH-SY5Y cells when 
compared with controls. 
For kinetic analysis of the effects of SIN-1 on [
3
H]HC-3 binding to wild-type CHT 
protein, HEK-CHT cells were used as they express higher levels of CHT, thereby 
facilitating quantification of ligand binding. Analysis of [
3
H]HC-3 (0.5–10 nM) binding 
to CHT was performed following treatment with or without 1 mM SIN-1 (Figure 2-2) to  
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Figure 2-2 SIN-1 decreases CHT activity by changing the number of transporter 
proteins at the cell surface, but not altering binding of solute to transporters.  
Kinetic parameters for cell surface [
3
H]HC-3 binding in HEK-CHT cells were estimated 
using between 0.5 and 10 nM HC-3. Data were calculated as fentomoles of HC-3 bound 
per milligram of protein, and expressed as mean ± SEM (n = 4). Data were fit by 
Michaelis-Menten nonlinear regression analysis of individual experiments, and 
differences between vehicle and SIN-1 treatments were examined by comparison of the 
apparent binding affinity for ligand (KD) and the number of CHT sites (Bmax) values of 
the two curves. While the apparent KD for HC-3 binding to CHT did not differ between 
vehicle- and SIN-1-treated cells, the Bmax for [
3
H]HC-3 binding decreased to ~50% of the 
control value in cells treated with 1mM SIN-1 (p<0.05, Student’s t test).  
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establish whether the observed decrease in cell surface binding of HC-3 was due to a 
change in binding affinity (KD) of HC-3 for its target on CHT or only to a change in the 
plasma membrane level of CHT (Bmax). The apparent KD for HC-3 binding to CHT did 
not differ between vehicle- and SIN-1-treated cells (4 ± 0.9 and 4 ± 0.7 nM, 
respectively). However, SIN-1 did reduce the cell surface CHT levels with the Bmax for 
[
3
H]HC-3 binding decreased by ∼50% from 473 ± 82 in control cells to 226 ± 71 fmol of 
[
3
H]HC-3 bound/mg protein by SIN-1 (p < 0.05; Student's t test). 
2.3.3 Blockade of clathrin-mediated endocytosis attenuates 
inhibition of CHT by SIN-1 
Major endocytic pathways for cell surface proteins can be selectively down-regulated by 
expression in the cells of DN proteins that block the function of critical proteins. In these 
experiments, I inhibited clathrin-mediated endocytosis with AP180C (20) and used Dyn-
K44A as a blocker of both dynamin- and clathrin-dependent endocytosis (21) to examine 
routes by which CHT internalizes from the plasma membrane during acute SIN-1 
exposure. SY5Y-CHT cells were transiently-transfected with plasmids encoding either 
GFP as a negative control protein or DN proteins, then choline uptake activity was 
assayed in the absence and presence of SIN-1.  
Figure 2-3A reveals that the expression of AP180C blocked the SIN-1 effect indicating 
that clathrin-mediated endocytosis is involved in the response of CHT to SIN-1
 
in these 
cells. Dyn-K44A also attenuated ONOO
-
-mediated inhibition of CHT. To verify that 
these DN proteins functioned to block CHT internalization, we imaged cells co-
expressing CHT and either AP180C or Dyn-K44A; control cells were transfected with 
empty vector pcDNA3.1. Figure 2-4B illustrates that cells that were transfected to 
express either of these DN proteins displayed increased CHT localization at the plasma 
membrane and had substantially reduced subcellular levels of the transporter protein 
when compared to cells not expressing either of the DN proteins (denoted by arrows) or 
that were transfected with empty vector. 
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Figure 2-3 
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Figure 2-3 Inhibition of CHT activity by SIN-1 is attenuated by AP180C and Dyn-
K44A.  
Selected endocytic pathways were inhibited in SY5Y-CHT cells using DN proteins. A, 
SY5Y-CHT cells were transiently transfected to express either empty vector pcDNA3.1 
as a control, AP180C to block the clathrin-dependent pathway, or Dyn-K44A to block 
dynamin-dependent pathways. HC-3-sensitive choline uptake was assayed in transfected 
cells after 20 min of either vehicle or 1 mm SIN-1 treatment; HC-3-sensitive choline 
uptake was determined as the difference between uptake in the absence and presence of 1 
μm HC-3, and expressed as picomoles/milligrams of protein per 5 min. Data were 
analyzed using a repeated-measures one-way ANOVA with Tukey's post hoc multiple-
comparisons test. Data are expressed as the mean ± SEM of five independent 
experiments. A single asterisk (*) denotes when SIN-1 treatment is significantly different 
from vehicle treatment (p ≤ 0.05), and a double asterisk (**) indicates when SIN-1-
treated groups are significantly different from each other (p ≤ 0.05). B, Live cells 
transfected with plasmids encoding either AP180C or Dyn-K44A had visible 
accumulation of Zenon 488-labeled CHT at the cell surface, whereas cells that were 
either transfected with the empty vector pcDNA3.1 as the control or that did not become 
transfected in the DN-transfected plates had substantial internalization of fluorescently 
labeled CHT into subcellular compartments (these latter cells are identified by white 
arrows in the AP180C and Dyn-K44A samples). Scale bars: Vector and Dyn-K44A, 5 
μm; AP180C, 10 μm. 
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2.3.4 CHT internalizes into Rab5a-positive organelles in control 
and SIN-1 treated cells  
We found previously that acute exposure of cells to the ONOO
-
-donor SIN-1 alters 
choline uptake activity by increasing the rate at which CHT proteins undergo 
endocytosis, potentially accounting for the reduction of CHT at the plasma membrane 
(4). The mechanism by which this occurs is not known, but it could be due to modified 
interaction of CHT with other proteins and/or internalization machinery such as 
endocytic and trafficking adaptor or Rab proteins. To address this, I assessed the 
distribution of CHT internalized from the cell surface to subcellular organelles in live 
vehicle- and SIN-1-treated SY5Y-CHT and SY5Y-L531A-CHT cells that coexpress 
GFP-tagged Rab5a as a marker of early endosomes. As shown in Figure 2-4 Panels A-C, 
wild-type CHT entered Rab5a-positive vesicles in  vehicle-treated cells, showing a high 
level of colocalization with this marker in punctate structures. Acute exposure of SY5Y-
CHT cells to SIN-1 did not appear to substantially change the level of internalized CHT 
colocalizing with Rab5a (Panels D-F). It is interesting to note that the Rab5a-positive 
vesicles appeared to be larger in SIN-1-treated cells. By comparison, there was negligible 
internalization of mutant CHT to Rab5a-positive endosomes in either vehicle- or SIN-1-
treated SY5Y-L531A-CHT cells during the experimental observation period (Panels G-
L). 
2.3.5 CHT is present in the late endosome/lysosome system under 
both vehicle and SIN-1 treatment  
Confocal imaging of live cells in which CHT trafficking was followed  was used to 
further address the movement of CHT into late endosomes and lysosomes and to assess if 
this was altered by SIN-1 treatment. Co-localization was seen between CHT and Rab7-
GFP (Figure 2-5), Rab9-YFP (Figure 2-6) and endogenous Lamp-1 (Figure 2-7) in both 
vehicle-treated control cells and cells that were acutely exposed to 1 mM SIN-1. 
As illustrated in Figure 2-5, CHT co-localizes with the late endosomal marker Rab7, but 
the amount of this co-localization was not substantially altered by SIN-1 treatment. To 
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Figure 2-4 Wild-type CHT but not L531A-CHT traffics to Rab5a-positive 
subcellular compartments in live cells.  
Confocal images showing Zenon 555-labeled CHT (red) and GFP-tagged Rab5a (green) 
distribution in vehicle-treated cells and cells treated with 1 mm SIN-1 for 15 min. 
Colocalized CHT and Rab5a appear as yellow. Zenon 555 dye conjugated with rabbit 
anti-FLAG antibody was added to the medium bathing the cells for 10 min at 37°C where 
it could bind to the extracellular FLAG epitope on CHT, and then the movement of 
fluorescently labeled proteins into cells was tracked at 10 min after the addition of 
treatment. Similar levels of colocalization of CHT with Rab5a-GFP were observed in 
both vehicle (Panels A–C)- and SIN-1 (Panels D–F)-treated cells expressing wild-type 
CHT. Interestingly, the subcellular organelles containing CHT-Rab5a in SIN-1-treated 
cells were larger than those observed in the vehicle-treated cells. In support of my 
hypothesis, L531A-CHT does not appear to internalize in either vehicle (Panels G–I)- or 
SIN-1 (Panels J–L)-treated cells, and the accumulation of Zenon-labeled L531A-CHT 
can be observed at the cell surface. Scale bars, 5 μm. 
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Figure 2-5 CHT colocalization with Rab7-GFP is seen in vehicle-treated (A) and 
SIN-1-treated (B) SY5Y-CHT cells.  
Confocal images show Zenon 555-labeled CHT (red) and GFP-tagged Rab7 (green) 
distribution in vehicle- and 1 mm SIN-1-treated SY5Y-CHT cells. Colocalized CHT and 
Rab7 appear as yellow. Zenon 555 dye conjugated to rabbit anti-FLAG antibody was 
added to the medium bathing the cells for 10 min at 37°C where it could bind to the 
FLAG epitope on the N terminus of CHT located at the cell surface. This facilitated 
tracking of the internalization and distribution of CHT proteins in cells after 15 min of 
either vehicle or SIN-1 treatment. Scale bar, 3 μm. 
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Figure 2-6 
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Figure 2-6 CHT colocalization with Rab9-YFP in SY5Y-CHT cells is not changed by 
SIN-1 treatment.  
Confocal images show Zenon 555-labeled CHT (red) and YFP-tagged Rab9 (green) 
distribution in vehicle- and 1 mm SIN-1-treated SY5Y-CHT cells. Zenon 555 dye 
conjugated to rabbit anti-FLAG antibody was added to the medium bathing the cells for 
15 min where it could bind to the FLAG epitope of the extracellular N terminus of CHT 
proteins that were located at the cell surface. This facilitated tracking of the 
internalization and distribution of CHT proteins in cells at 0, 30, and 60 min under either 
vehicle (Panels A–C) or SIN-1 (Panels D–F) treatment. Colocalized CHT and Rab9-
YFP appear as yellow in the Overlay images, and the histograms resulting from analysis 
of these images are shown (G). CHT and Rab9-YFP pixels that were determined to be 
colocalized in the colocalization channel are shown as white in the Colocalized Pixels 
images. To quantify colocalization, the brightest 2% of the red pixels (to the right of the 
vertical yellow line on the histograms) and green pixels (above the horizontal yellow line 
on the histograms) were selected. Imaris software was used to quantify the colocalization 
of CHT with Rab9-YFP. Data were analyzed by one-way ANOVA followed by Tukey's 
posttest and are expressed as mean ± SEM for a minimum of 40 cells per treatment group 
from four independent experiments (a single asterisk denotes p ≤ 0.01). Scale bar, 3 μm. 
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Figure 2-7 
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Figure 2-7 CHT colocalization with Lamp-1 is seen in vehicle- and SIN-1-treated 
SY5Y-CHT cells.  
Confocal images show Zenon 488-labeled CHT (green) and Alexa Fluor 555-labeled 
Lamp-1 (red) distribution in vehicle-treated and 1 mm SIN-1-treated SY5Y-CHT cells. 
Zenon 488 dye conjugated to rabbit anti-FLAG antibody was added to the medium 
bathing the cells for 15 min where it could bind to the FLAG epitope of the N terminus of 
CHT located at the cell surface. This facilitated tracking of the internalization and 
distribution of CHT proteins in cells at 0, 30, and 60 min of either vehicle (Panels A–C) 
or SIN-1 (Panels D–F) treatment. The colocalization of CHT and LAMP-1 can be seen 
as yellow in the Overlay panels. Images were analyzed as described in Figure 2-6 and in 
Materials and Methods. CHT and Lamp-1 that were determined to be colocalized in the 
colocalization channel are shown as white in the Colocalized Pixels images. 
Quantification of colocalized CHT and LAMP-1 is shown (G). Data were analyzed with a 
one-way ANOVA followed by Tukey's posttest and are expressed as the mean ± SEM for 
a minimum of 40 cells per treatment from four independent experiments. Scale bar, 3 μm. 
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assess the amount of CHT in late endosomes and lysosomes further under SIN-1 and 
vehicle treatment, I used a quantitative approach to determine the relative amount of CHT 
co-localization with Rab9-YFP or endogenous Lamp-1 using a method described 
previously by Lorenzen et al (2010). An example of this analysis is shown in Figure 2-6 
for CHT and Rab7-YFP. The brightest 2% of pixels of CHT (red), indicated to the right 
of the vertical yellow line on the histogram, that fall within the brightest 2% of pixels of 
Rab9-YFP (green), indicated above the horizontal line on the histogram, was selected as 
the threshold intensity. The percentage of pixels that were both red and green were then 
determined as the percent of the two proteins that are colocalized. In these experiments, I 
found that CHT is extensively colocalized with both the late endosomal marker Rab9 and 
the lysosomal marker Lamp-1 under both vehicle and SIN-1 treatments. Further analysis 
to quantify these images revealed that in vehicle treated cells at 0, 30 and 60 min 
colocalization of CHT with Lamp-1 was 39.9 2.3, 30.9 1.6 and 37.6 1.3, respectively, 
and under SIN-1 conditions at 0, 30, 60 min was 35.7 1.9, 30.7 1.7 and 35.5 1.6, 
respectively. The high levels of colocalization of CHT with both Rab9-YFP and Lamp-1 
suggests that CHT transits through the late endosomal/lysosomal pathway. Moreover, this 
data also suggests that SIN-1 does not alter the trafficking of CHT in this protein 
degradative pathway. 
2.3.6 Inhibition of the proteasome, but not the lysosome, blocks 
the SIN-1 effect on choline uptake  
To further determine if SIN-1 alters CHT trafficking through the late endosome/lysosome 
pathway and to investigate if SIN-1 targets CHT into an alternate route for degradation 
by the proteasome, the proteolytic activities of the lysosome and proteasome were 
blocked using a pharmacological approach. In this experiment, separate sets of cells were 
treated with either the lysosome inhibitors chloroquine or bafilomycin A1 or the 
proteasome inhibitors lactacystin or MG132, then choline uptake activity was assayed in 
the absence and presence of 1 mM SIN-1. Figure 2-8 (A and B) showed that neither 
chloroquine nor bafilomycin A1 modified the inhibition of CHT activity by SIN-1. This 
is a further indication that the movement of CHT to the lysosome for degradation is not 
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altered by SIN-1 treatment. An interesting observation in this experiment is that that 
chloroquine caused a significant increase in choline uptake activity compared to control 
in vehicle-treated cells (Figure 2-8A). This is consistent with the idea that CHT is 
normally trafficked to and degraded by the lysosome, and suggests that inhibition of this 
degradative process allows more CHT to be available for recycling back to the cell 
surface. Importantly, both of the proteasome inhibitors lactacystin and MG132 attenuated 
the SIN-1 mediated inhibition of CHT (Figure 2-8C and 2-8D) indicating that the 
proteasome may play a role in the inhibition of choline uptake activity observed in SIN-1 
treated cells.  
2.3.7 Ubiquitination of CHT is enhanced in SIN-1 treated cells  
Finally, I investigated whether CHT is ubiquitinated and whether this is modified by 
acute SIN-1 treatment of SH-SY5Y-CHT cells. Ubiquitination is a reversible 
posttranslational modification of cellular proteins that can alter their subcellular 
trafficking or may target them to either lysosomes or proteasomes for degradation. In 
these experiments, I used either SH-SY5Y cells stably expressing the empty vector 
pcDNA3.1 and not CHT to serve as a negative control or SY5Y-CHT stably expressing 
FLAG-tagged CHT protein. Cells were treated with vehicle or 1 mM SIN-1 for 20 min, 
and FLAG-CHT was recovered from lysates using anti-FLAG affinity resin. Figure 2-
9 (bottom two panels) shows a representative immunoblot that was probed for ubiquitin 
using anti-ubiquitin antibody, stripped, and reprobed for FLAG-CHT using anti-CHT 
antibody. The anti-ubiquitin immunoblot reveals faint protein bands positive for ubiquitin 
in both the vehicle- and SIN-1-treated cells. The most robust ubiquitin-positive band 
appears in the SIN-1-treated cells at an apparent molecular mass of ∼80 kDa; a 
corresponding band is evident in the anti-CHT blot (denoted by the arrows). No 
ubiquitinated or CHT-positive bands were detected in negative control “vector” cells. 
Despite CHT having a molecular weight of ∼62 kDa, this protein generally appears on 
SDS-PAGE as a diffuse band with an apparent molecular mass of ∼50 kDa. Based on a 
shift in the mass of FLAG-CHT of ∼30 kDa, this suggests that SIN-1 treatment may lead  
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Figure 2-8 
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Figure 2-8 Inhibition of CHT activity by SIN-1 is attenuated by proteasome 
inhibitors lactacystin and MG-132, but not by lysosome inhibitors chloroquine and 
Baf-A.  
Proteolytic activity of the lysosome and proteasome were blocked using a 
pharmacological approach. A, Cells were treated with either DMSO or 20 nm Baf-A 
dissolved in complete medium for 24 h at 37°C. HC-3-sensitive choline uptake was 
assayed in cells after 20 min of either vehicle or 1 mm SIN-1 treatment. HC-3-sensitive 
choline uptake was determined as the difference between uptake in the absence and 
presence of 1 μm HC-3, and expressed as picomoles/milligram of protein per 5 min. Data 
are expressed as mean ± SEM of five independent experiments. B, Cells were treated 
with either double-distilled H2O or 50 μm chloroquine dissolved in complete medium for 
2 h at 37°C. HC-3-sensitive choline uptake was assayed in cells after 20 min of either 
vehicle or 1 mm SIN-1 treatment. Data are expressed as mean ± SEM of five independent 
experiments. C, Cells were treated with either double-distilled H2O or 0.5 μm lactacystin 
dissolved in complete medium for 1 h at 37°C. HC-3-sensitive choline uptake was 
assayed in cells after 20 min of either vehicle or 1 mm SIN-1 treatment. Data are 
expressed as mean ± SEM of five independent experiments. D, Cells were treated with 
either DMSO or 5 μm MG-132 in complete medium for 30 min at 37°C. Data were 
analyzed using a repeated-measures one-way ANOVA with Tukey's post hoc multiple-
comparisons test. Data are expressed as mean ± SEM of four independent experiments. 
*SIN-1 treatment is significantly different from vehicle treatment (p < 0.05). **Drug 
treatment is significantly different from vehicle treatment (p < 0.05). ***SIN-1-treated 
groups are significantly different from each other (p < 0.05). 
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Figure 2-9 SIN-1 treatment causes CHT ubiquitination in SY5Y-CHT cells.  
FLAG-CHT was recovered from lysates prepared from SY5Y-CHT cells that were 
treated with either vehicle or 1 mm SIN-1 for 20 min using anti-FLAG M2 affinity resin. 
Proteins were resolved by SDS-PAGE, transferred to PVDF membranes, and probed with 
either anti-ubiquitin or anti-CHT antibodies. Lysates prepared from SH-SY5Y cells that 
stably express the empty vector pcDNA3.1, and not CHT protein, were used as a negative 
control (“Vector” lane). Representative immunoblots show total FLAG-CHT and actin 
proteins in total cell lysates (top two panels). The bottom two panels illustrate FLAG-
CHT proteins recovered on anti-FLAG affinity resin probed first with anti-ubiquitin 
antibody (1:5000), and then with anti-CHT antibody (1:10,000) following stripping. The 
arrows show ubiquitin and CHT-positive bands that appear at ∼80 kDa. The 
immunoblots shown are representative of data obtained in three independent experiments. 
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to the addition of approximately four ubiquitin molecules to CHT, indicating that this 
could be due to multiple mono-ubiquitin or di-ubiquitin molecules or a short 
polyubiquitin chain. 
2.4 Discussion 
The mechanisms by which SIN-1 could alter CHT activity include structural modification 
of the protein by nitration of tyrosine residues or S-nitrosylation or oxidation of cysteine 
residues, changes in cell surface levels of CHT proteins due to altered subcellular 
trafficking or localization or degradation, dissipation of transmembrane electrochemical 
gradients, or loss of cell viability. I made novel findings in the present study that support 
my prediction that CHT inhibition by SIN-1 is mediated by changes to protein trafficking 
events, since the activity of a CHT mutant that does not undergo clathrin-mediated 
endocytosis is not affected by SIN-1. I also found that with SIN-1 treatment CHT 
internalizes from the cell surface by a clathrin- and dynamin-mediated process, since DN 
proteins that block either clathrin or dynamin function attenuate SIN-1-mediated 
inhibition of CHT. Moreover, I show for the first time that CHT proteins move through 
the endosomal–lysosomal pathway colocalizing with compartment markers, but that SIN-
1 does not alter this trafficking. Our studies reveal that CHT normally undergoes 
lysosomal degradation, since lysosome inhibitors enhance choline uptake activity likely 
by increasing CHT availability for recycling to the cell surface. Importantly, however, 
proteasome, but not lysosome, inhibitors attenuate SIN-1-mediated inhibition of choline 
uptake, indicating that proteasomal degradation has a role in CHT protein disposition in 
cells exposed to SIN-1. Finally, I demonstrate for the first time that CHT protein 
undergoes ubiquitination, and this is enhanced by SIN-1 treatment. 
I made the critical observation that mutant L531A-CHT is resistant to the SIN-1-
mediated inhibition that is seen with wild-type CHT. Thus, inactivation of CHT function 
by SIN-1 is not likely due to oxidative or nitrosative modification of essential amino 
acids, thereby highlighting the importance of changes in intracellular trafficking of CHT 
proteins in its response to SIN-1. These findings for CHT inhibition differ from 
mechanisms by which hDAT activity is decreased in ONOO
−
-treated cells or hSERT is 
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inhibited in cells exposed to NO and related compounds, including peroxynitrite. With 
hDAT, inhibition by ONOO
−
 is caused by modification of a cysteine residue that is 
critical for transporter function (10). It is interesting, however, that ONOO
−
 does not 
block hDAT directly, as it was shown that inhibition is caused by a highly reactive 
dopamine-quinone moiety formed by reaction of ONOO
−
with intracellular dopamine 
(25). Similarly, hSERT inhibition may involve S-nitrosylation of cysteine residues since 
inhibition was attenuated by addition of L-cysteine to the incubation buffer (11); L-
cysteine acts as a “sink” by providing excess thiol groups to interact with reactive 
compounds (26). CHT is relatively cysteine poor, having only five cysteine residues in 
human CHT (17) compared with 13 in hDAT (27) and 18 in hSERT (28), but it is not 
known whether any of these cysteines are critical for CHT function. With regard to 
nitration of tyrosine residues in CHT, we did not detect this in SIN-1-treated cells by 
immunoblot using nitrotyrosine antibodies (4). 
We reported that SIN-1 enhances CHT endocytosis from plasma membrane, thereby 
decreasing its cell surface levels and reducing choline uptake capacity (4). Now, my data 
shows that CHT proteins internalize by clathrin- and dynamin-dependent mechanisms to 
Rab5a-positive early endosomes in both control and SIN-1-treated cells. Moreover, CHT 
levels in this compartment are not altered by SIN-1, suggesting that transporters are not 
retained there and move to other endosomal compartments. In relation to the mechanism 
underlying changes in CHT endocytosis, dynamin, which carries out endocytic budding 
of vesicles and membrane scission (29, 30), undergoes S-nitrosylation at a critical 
cysteine residue in NO-treated cells. Importantly, this modification of dynamin causes 
accelerated endocytosis of plasma membrane proteins (30, 31). There are no data on the 
effects of ONOO
−
 on dynamin function, but since NO can be rapidly converted to 
ONOO
−
 and both of these highly reactive molecules can S-nitrosylate reactive cysteines, 
enhanced endocytosis associated with dynamin modification might also be mediated by 
ONOO
−
. 
In addition to CHT proteins recycling back to the cell surface following endocytosis (32, 
15), other potential destinations for CHT in the neuron include being directed into the late 
endosomal pathway and/or lysosomes for degradation. This would effectively remove 
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CHT proteins from the recycling pool that is important for supplying CHT to the cell 
surface and regulating choline uptake activity. I now show that some CHT proteins in 
both vehicle- and SIN-1-treated cells move to colocalize with late endosome pathway 
small GTPases Rab7 and Rab9 and LAMP-1-positive lysosomes. The amount of CHT 
colocalized with these markers did not differ between vehicle- and SIN-1-treated cells; 
thus, SIN-1 does not promote CHT accumulation in these compartments. My data also 
shows for the first time that the normal site for CHT degradation is the lysosome, since 
the lysosome inhibitor chloroquine enhances choline uptake activity. 
An unexpected finding is that the decreased CHT activity observed in SIN-1-treated cells 
was attenuated by proteasome blockers, suggesting that proteasomal protein degradation 
is involved in SIN-1-mediated loss of CHT function. Trafficking patterns for plasma 
membrane proteins to lysosomes or proteasomes may be altered under diverse conditions, 
including oxidative stress [glucose transporter GLUT1 (33)], single point mutations [low-
density lipoprotein receptor (34)], and loss of intramolecular disulfide bonding [ATP-
binding cassette transporter ABCG2 (35)]. While the mechanisms mediating these 
changes likely differ, there are similarities between our observations with CHT and 
effects of oxidative stress on GLUT1. Cell surface GLUT1 levels decrease during 
oxidative stress due to enhanced internalization and altered subcellular trafficking, with 
this linked to ubiquitination of GLUT1 and proteasome-dependent changes in protein 
kinase B (Akt) activation. Under these conditions, GLUT1 also undergoes mono-
ubiquitination or di-ubiquitination (33). 
Trafficking of solute transporters is also regulated by phosphorylation, and this is 
modulated by oxidative stress. Like CHT, GLUT4 glucose transporters are located 
mostly in intracellular vesicles under basal conditions and its plasma membrane levels are 
increased when solute is needed by the cell; insulin, ischemia, and hypoxia increase 
GLUT4 translocation (36). Acute exposure of cardiomyocytes to H2O2 enhances plasma 
membrane GLUT4 levels by a mechanism involving activation of AMP-activated protein 
kinase and PI3-kinase/Akt (37). However, GLUT4 is not the substrate for these kinases, 
with regulatory proteins including Rab GAP AS160 being phosphorylated and then 
modulating GLUT4 disposition (38). CHT in neurons is phosphorylated, and PKC 
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regulates its activity and cell surface levels (39, 40), although the underlying mechanisms 
are unknown. Multiple kinases are altered by ONOO
−
, including activation of p38 kinase 
and Src kinase (41, 43, 44), but there are no data on the effects of kinases that are 
modulated by ONOO
−
 on CHT disposition. 
CHT interacts with amyloid precursor protein (APP) through its C-terminal tail, and APP 
has a role in regulating CHT subcellular trafficking in cholinergic neurons (44); APP 
serves as substrate for generation of β-amyloid, a critical feature in Alzheimer's disease 
pathogenesis, which is involved in production of oxidative stress in brain. APP is 
internalized from plasma membrane by endocytosis and moves through the endosomal 
pathway to lysosomes where it is cleaved by secretases. However, APP can also enter a 
novel, rapid transport pathway to move directly from the cell surface to lysosomes (45). It 
is not known whether this trafficking is altered by oxidative–nitrosative stress or what 
effect this could have on the function of its binding partner CHT, but this raises important 
questions about the regulation of cholinergic presynaptic function by APP disposition and 
trafficking in neuropathology. 
In summary, plasma membrane CHT levels are determined by the balance between cell 
surface recruitment of CHT-containing vesicles and retrieval of CHT proteins to 
subcellular organelles. Events that alter the dynamics of either this constitutive or the 
depolarization-regulated recycling of CHT will control the amount of choline that is 
available for ACh synthesis and the ability of cholinergic neurons to communicate with 
their target cells. It is not known whether the enhanced endocytosis and loss of cell 
surface CHT proteins in SIN-1-treated cells is a mechanism to remove damaged proteins 
from the neuron or a protective measure to prevent protein damage, but our previous 
work examining transferrin receptor disposition in SIN-1-treated cells shows changes to 
that receptor that parallel effects on CHT (4), suggesting that this is a more generalized 
mechanism for the response of some cell surface proteins to cellular stress. 
 
 
 90 
 
2.5 References 
1. Yamamura, H. I., and Snyder, S. H. (1972) J Neurochem 21, 1355-1374  
2. Haga, T., and Noda, H. (1973) Biochem Biophys Acta 291, 564-575 
3. Guermonprez, L., Ducrocq, C., and Gaudry-Talarmain, Y.M. (2001) Mol 
Pharmacol 60, 838-846 
4. Pinthong, M., Black, S.A., Ribeiro, F.M., Pholpramool, C., Ferguson, S.S., and 
Rylett, R.J. (2008) Mol Pharmacol 73, 801-812 
5. Wang, X., and Michaelis, E.K. (2010) Front Aging Neurosci 2,12  
6. Smith, M.A., Richey Harris, P.G., Sayre, L.M., Beckman, J.S., and Perry, G. 
(1997) J Neurosci 17, 2653-2657 
7. Beckman, J.S. (1991) J Dev Physiol 15, 53-59 
8. Alkam, T., Nitta, A., Mizoguchi, H., Itoh, A., and Nabeshima, T. (2007) Behav 
Brain Res 180, 139-145 
9. Xu, J., Kim, G.M., Chen, S., Yan, P., Ahmed, S.H., Ku, G., Beckman, J.S., Xu, 
X.M., and Hsu, C.Y. (2001) J Neurotrauma 18, 523-532 
10. Park, S.U., Ferrer, J.V., Javitch, J.A., and Kuhn, D.M. (2002) J Neurosci 2, 4399-
4405 
11. Bryan-Lluka, L.J., Papacostas, M.H., Paczkowski, F.A., and Wanstall, J.C. (2004) 
Br J Pharmacol 143, 63-70  
12. Ferguson, S.M., Savchenko, V., Apparsundaram, S., Zwick, M., Wright, J., 
Heilman, C.J., Yi, H., Levey, A.I., and Blakely, R.D. (2003) J Neurosci 23, 9697-
9709 
 91 
 
13. Ribeiro, F.M., Alves-Silva, J., Volknandt, W., Martins-Silva, C., Mahmud, H., 
Wilhelm, A., Gomez, M.V., Rylett, R.J., Ferguson, S.S., Prado, V.F., and Prado, 
M.A. (2003) J Neurochem 87, 136-146 
14. Ribeiro, F.M., Black, S.A., Cregan, S.P., Prado, V.F., Prado, M.A., Rylett, R.J., 
and Ferguson, S.S. (2005) J Neurochem 94, 86-96 
15. Ribeiro, F.M., Black, S.A., Prado, V.F., Rylett, R.J., Ferguson, S.S., and Prado, 
M.A. (2006) J Neurochem 97, 1-12 
16. Ribeiro, F.M., Pinthong, M., Black, S.A., Gordon, A.C., Prado, V.F., Prado, 
M.A., Rylett, R.J., and Ferguson, S.S. (2007a) Eur J Neurosci 26, 3437-3448 
17. Apparsundaram, S., Ferguson, S.M., George, A.L. jr., and  Blakely, R.D. (2000) 
Biochem Biophys Res Commun 276, 862-867 
18. Okuda, T., and Haga, T. (2000) FEBS Lett 484, 92-97 
19. Okuda, T., Haga, T., Kanai, Y., Endou, H., Ishihara, T., and Katsura, I. (2000) 
Nat Neurosci 3, 120-125 
20. Ford, M.G., Pearse, B.M., Higgins, M.K., Vallis, Y., Owen, D.J., Gibson, A., 
Hopkins, C.R., Evans, P.R. and McMahon, H.T. (2001) Science 291, 1051-1055 
21. Damke, H., Binns, D.D., Ueda, H., Schmid, S.L., and Baba, T. (2001) Mol Biol 
Cell 12, 2578-2589 
22. Pacher, P., Beckman, J.S., and Liaudet, L. (2007) Physiol Rev 87, 315-424 
23. Ashki, N., Hayes, K.C., and Bao, F. (2008) Neurosci 156, 107-117 
24. Dale, L.B., Seachrist, J.L., Babwah, A.V., and Ferguson, S.S. (2004) J Biol Chem 
279, 13110-13118 
25. Whitehead, R.E., Ferrer, J.V., Javitch, J.A., and Justice, B. (2001) J Neurochem 
76, 1242-1251 
 92 
 
26. Kaye, D.M., Wiviott, S.D., Kobzik, L., Kelly, R.A., and Smith, T.W. (1997) Am J 
Physiol 272, 875-888 
27. Giros, B., el Mestikawy, S., Bertrand, L., and Caron, M.G. (1991) FEBS Lett 295, 
149-154 
28. Ramamoorthy, S., Bauman, A.L., Moore, K.R., Han, H., Yang-Feng, T., Chang, 
A.S., Ganapathy, V., and Blakely, R.D. (1993) Proc Natl Acad Sci U S A 90, 
2542-2546 
29. Conner, S.D., and Schmid, S.L. (2003) Nature 422, 37-44 
30. Dessy, C., Kelly, R.A., Balligand, J-L., and Feron, O. (2000) EMBO J 19, 4272-
4280 
31. Wang, G., Moniri, K., Ozawa, K., Stamler, J.S., and Daaka, Y. (2006) Proc Nat 
Acad Sci U S A 103, 1295-1300 
32. Ferguson, S.M., and Blakely, R.D. (2004) Mol Interv 4, 22-37 
33. Fernandes, R., Hosoya, K., and Pereira, P. (2011) Am J Physiol Cell Physiol 300, 
927-936 
34. Martín de Llano, J.J., Fuertes, G., Andreu, E.J., Puig, O., Chaves, F.J., Soutar, 
A.K., Armengod, M.E., and Knecht, E. (2006) Int J Biochem Cell Biol 38, 1340-
1351 
35. Wakabayashi, K., Nakagawa, H., Tamura, A., Koshiba, S., Hoshijima, K., 
Komada, M., and Ishikawa, T. (2007) J Biol Chem 282, 27841-27846 
36. Fischer, Y., Thomas, J., Sevilla, L., Munoz, P., Becker, C., Holman, G., Kozka, 
I.J., Palacin, M., Testar, X., Kammermeier, H., and Zorzano, A. (1997) J Biol 
Chem 272, 7085-7092 
37. Horie, T., Ono, K., Nagao, K., Nishi, H., Kinoshita, M., Kawamura, T., Wada, H., 
Shimatsu, A., Kita, T., and Hasegawa, K. (2008) J Cell Physiol 215, 733-742 
 93 
 
38. Chavez, J.A., Roach, W.G., Keller, S.R., Lane,W.S., and Lienhard, G.E. (2008) J 
Biol Chem 283, 9187-9195 
39. Gates, J., Ferguson, S.M., Blakely, R.D., and Apparsundaram, S. (2004) J 
Pharmacol Exp Ther 310, 536-545 
40. Black, S.A.G., Ribeiro, F.M., Ferguson, S.S.G., and Rylett, R.J. (2010) 
Neuroscience 167, 765-773 
41. Li, X., De Sarno, P., Song, L., Beckman, J.S., and Jope, R.S. (1998) Biochem J 
331, 599-606 
42. Di Stasi, A.M., Mallozzi, C., Macchia, G., Petrucci, T.C., and Minetti, M. (1999) 
J Neurochem 73, 727-735 
43. Oh-Hashi, K., Maruyama, W., and Isobe, K. (2001) Free Radic Biol Med 30, 213-
221 
44. Wang, B., Yang, L., Wang, A., and Zheng, H. (2007) Proc Nat Acad Sci U S A 
104, 14140-14145 
45. Lorenzen, A., Samosh, J., Vandewark, K., Anborgh, P.H., Seah, C., Magalhaes, 
A.C., Cregan, S.P., Ferguson, S.S.G., and Pasternak, S.H. (2010) Molecular Brain 
3, 11 
  
 94 
 
Chapter 3  
3 Regulation of the high-affinity choline transporter 
activity and trafficking by its association with 
cholesterol-rich lipid rafts2  
  
                                                 
2
 A version of this work has been published in the following manuscript: 
Cuddy LK, Winick-Ng W, Rylett RJ. Regulation of the high-affinity choline transporter activity and 
trafficking by its association with cholesterol-rich lipid rafts J Neurochem 4 November 2013 128 (5):725-
740 
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3.1 Introduction 
The activity and trafficking of membrane proteins can be regulated by the plasma 
membrane lipid environment. Proteins can be segregated into cholesterol and 
sphingolipid-rich microdomains in membranes termed lipid rafts (1, 2) that are involved 
in cellular events, including membrane organization, protein–protein interactions, and 
signal transduction (3, 4). Lipid rafts also have a role in trafficking of membrane proteins 
by facilitating their endocytosis in clathrin-independent caveolae (5, 6). Cholesterol can 
play a critical role in organization of membrane proteins, and influence their function or 
activity either indirectly through changes in membrane fluidity or directly by cholesterol–
protein interactions (7, 8). The disruption of lipid rafts by removal of cholesterol can 
significantly affect either the structure or function of some membrane proteins (9). In 
relation to this study, several neurotransmitter transporters are localized to lipid rafts. One 
mechanism by which this can regulate their solute uptake activity is by altering their 
endocytosis and trafficking, thereby affecting the amount of cell surface transporter 
protein (10-13). However, specific cholesterol–transporter interactions have also been 
identified that are independent of association of the protein with lipid rafts. For example, 
reconstitution of 5-HT transporter and GABA transporter activity is not observed when 
cholesterol is replaced by other sterols that have similar effects on membrane fluidity (14, 
15), and depletion of membrane cholesterol can decrease 5-HT transporter affinity for its 
substrate (14). 
CHT is active at the plasma membrane, but experimental evidence indicates that the 
majority of CHT proteins form a subcellular reserve pool within endocytic and synaptic 
vesicles (16, 17). Only a small proportion of total cellular CHT proteins are at the cell 
surface, with a constitutive cycle of endocytosis by a clathrin/dynamin-dependent 
mechanism and recycling back to the plasma membrane serving as a critical regulatory 
mechanism that controls cell surface CHT density (16, 17). Plasma membrane CHT 
levels are enhanced by depolarization-induced exocytosis of synaptic vesicles that deliver 
additional CHT proteins to the cell surface during excitation of cholinergic nerve 
terminals, thereby increasing the amount of choline transported into cholinergic nerve 
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terminals to drive ACh synthesis (18). CHT trafficking is also regulated by 
phosphorylation (19), extracellular ligand concentration (21), and by interaction with 
other proteins, such as amyloid precursor protein (22). 
To-date, there have been only limited, and conflicting, reports regarding the influence of 
cholesterol or cholesterol-rich lipid rafts on high-affinity choline uptake; one study shows 
that cholesterol reduction in isolated nerve endings (synaptosomes) decreased choline 
uptake (23), whereas another study reports that depletion of membrane cholesterol in 
synaptosomes did not significantly influence choline uptake (24). A recent study suggests 
that depleting membrane cholesterol by treating synaptosomes with high concentrations 
of methyl-β-cyclodextrin (MβC) reduced high-affinity choline uptake (25). Although 
these observations suggest that cholesterol has a role in regulation of CHT, the 
underlying mechanisms were not investigated and there has been no assessment of 
whether CHT proteins are partitioned in membrane lipid rafts. Thus, the goal of this study 
was to address these points and provide data on cholesterol-related changes to CHT 
activity. I used pharmacological approaches to modulate membrane cholesterol levels in 
neural cells, and found that treatments that reduced cholesterol caused a reduction in 
CHT activity and addition of cholesterol to cells resulted in enhanced CHT activity. I 
showed for the first time that CHT proteins are enriched in lipid rafts, and that disruption 
of lipid rafts reduces cell surface CHT. These results suggest that membrane cholesterol 
and lipid rafts serve as an important regulator of CHT trafficking and activity by retaining 
functional CHT at the cell surface. 
3.2 Materials and methods 
3.2.1 Materials 
Filipin, MβC, cholesterol–MβC complex (MβC–Chol), and cholesterol oxidase were 
from Sigma-Aldrich (St. Louis, MO, USA) and [methyl-
3
H]choline chloride 
(128 Ci/mmol) and [methyl-
3
H]hemicholinium-3 diacetate ([
3
H]HC-3) (169 Ci/mmol) 
were from Perkin-Elmer Life Sciences (Boston, MA, USA). Other chemicals were from 
Sigma-Aldrich at the highest purity available. SH-SY5Y human neuroblastoma cells 
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were from American Type Culture Collection (Manassus, VA, USA), and Invitrogen 
(Burlington, ON, Canada) supplied AlexaFluor 647 cholera toxin subunit B conjugate 
(CTB), Zenon AlexaFluor 555 rabbit IgG and Zenon AlexaFluor 488 mouse IgG labeling 
kits, Amplex Red Cholesterol Assay kit, and culture media and reagents. Enhanced 
ChemiLuminescence immunoblot reagent was from GE Healthcare Life Sciences (Baie 
d'Urfé, QC, Canada) and Biodegradable Scintillant was from Amersham Canada Ltd. 
(Oakville, ON, Canada). Purified mouse anti-EEA1 antibody was from BD Biosciences 
(Mississauga, ON, Canada) and rabbit polyclonal flotillin-1 antibody from Santa Cruz 
Biotechnology, Santa Cruz, CA, USA. Polyclonal CHT antibody was raised in rabbits to 
the antigenic peptide DVDSSPEGSGTEDNLQ that is conserved at the carboxyl terminus 
of human and rat CHT (Genemed Synthesis, San Antonio, TX, USA); this peptide was 
conjugated to keyhole limpet hemocyanin carrier protein by an amino-terminal cysteine. 
CHT-specific IgG was affinity purified in our laboratory from crude anti-serum on NHS-
Sepharose (Amersham) to which antigenic peptide was coupled as the binding element. 
Specificity of this antibody for detection of CHT was described previously (26). 
3.2.2 Selection of cell line and cell culture  
Full-length rat CHT cDNA ligated to pSPORT was a gift from Dr T. Okuda (21); a 
FLAG epitope tag was added to the amino terminus by PCR and the resulting cDNA 
ligated to pcDNA3.1 (26). SH-SY5Y cells were transfected with this FLAG-CHT 
plasmid by Lipofectamine 2000. Stable transformants were selected using 500 μg/mL 
G418 for 4 weeks, then grown in DMEM, 10% FBS U/mL penicillin, and 100 μg/mL 
each of streptomycin and G418. SH-SY5Y cell differentiation was induced by addition of 
10 μM RA for 3 days; substantial morphological and biochemical differentiation of cells 
occurred during this time (data not shown). 
3.2.3 [3H]Choline uptake assay 
Monolayers of cells were washed, then incubated at 37°C in KRH. Vehicle or drug was 
added to cells for specified times, followed by incubation for 5 min with 0.5 μM 
[
3
H]choline (0.5 μCi/mL) in the absence or presence of 1 μM HC-3. Following this 
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incubation, cells were placed on ice and washed with cold KRH, then lysed in 0.1 M 
NaOH. After 30 min lysis, aliquots of samples were analyzed for tritium content by liquid 
scintillation spectrometry and protein concentration using Bio-Rad protein dye (Bio-Rad 
Laboratories, Hercules, CA, USA). Each independent experiment consisted of triplicate 
plates of cells per treatment group, with results normalized to sample protein content and 
averaged. Specific choline uptake was the difference between total choline uptake and 
non-specific uptake in the presence of HC-3, with the resulting [
3
H]choline uptake data 
expressed as pmol/mg protein per 5 min ± SEM. 
3.2.4 [3H]HC-3 binding assay  
Monolayers of cells were washed and incubated in KRH at 37°C with addition of vehicle 
or drug for specified times, then washed with ice-cold KRH, and kept on ice for 10 min 
to stop protein trafficking activity. Cells were incubated with [
3
H]HC-3 (10 nM; 
1 Ci/mmol) in the presence or absence of 1 μM unlabeled HC-3 for 1 h on ice. For kinetic 
analysis, HC-3 binding was measured over the range of 0.5–10 nM HC-3 with the 
specific activity of [
3
H]HC-3 held constant at 1 Ci/mmol. Following incubation, cells 
were washed rapidly with cold KRH to remove unbound HC-3 and lysed in 0.1 M NaOH 
for 30 min. Aliquots of lysates were used for quantification of tritium and protein content. 
Each independent experiment had triplicate determinations with HC-3 binding 
normalized to sample protein content, then averaged. Specific HC-3 binding was 
calculated as the difference between total and non-specific HC-3 binding, and values 
were expressed as fmol/mg protein ± SEM. 
3.2.5 Lipid raft preparation and sucrose flotation gradients 
SH-SY5Y cells stably expressing CHT were grown to confluence on 100-mm dishes 
prior to the preparation of membrane fractions. Cells were placed on ice and washed 
twice with HBSS, then lysed for 30 min in sodium carbonate lysis buffer (0.5 M 
Na2CO3 with 1 mM AEBSF, 10 μg/mL each of leupeptin and aprotinin, and 25 μg/mL 
pepstatin A) or Triton X-100 lysis buffer (0.5% Triton X-100 with 1 mM AEBSF, 
10 μg/mL each of leupeptin and aprotinin, and 25 μg/mL pepstatin A). Cell lysates were 
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collected and homogenized three times for 10 s each using a Polytron tissue grinder. 
Homogenates were next sonicated three times for 20 s using a Sonic Dismembrator. 
Homogenates were adjusted to 40% sucrose, then added to ultracentrifuge tubes and 
overlaid with 30% sucrose and 5% sucrose solutions. Samples were centrifuged at 
120 000 g for 16 h at 4°C using a Beckman SW 41 (Beckman Coulter Canada LP, 
Mississauga, ON, Canada) Ti rotor. Twelve or ten (for cells lysed in sodium carbonate or 
Triton X-100, respectively) 1 mL fractions were collected from the top to bottom of each 
sucrose gradient. Protein aliquots from each fraction were incubated for 10 min at 55°C 
with Laemmli buffer (2% sodium dodecyl sulfate, 10% glycerol, 62.5 mM Tris-HCl, pH 
6.8, 2.5% β-mercaptoethanol, and 0.001% bromophenol blue), then separated on 7.5% 
SDS–PAGE gels and transferred to PVDF membranes. Membranes were blocked in 8% 
non-fat dry milk in wash buffer (phosphate-buffered saline, 0.15% Triton X-100) and 
incubated with either anti-CHT antibody, anti-EEA1 antibody or anti-flotillin antibody 
overnight at 4°C. After washing, membranes were incubated for 1 h with species-
matched secondary antibodies in wash buffer containing 8% milk, and washed again. 
Immunoreactive proteins on membranes were detected by chemiluminescence using the 
ECL kit. Immunopositive bands were quantified by densitometry using Scion Image 
software (NIH). 
3.2.6 Synaptosome preparation 
Purified nerve terminals [synaptosomes] were isolated from mouse forebrain using 
established methods (27). Young adult (3–4 months of age) C57B6 mice of either sex 
bred locally were used in these experiments in compliance with the Canadian Council on 
Animal Care (CCAC) and the ARRIVE (www.nc3rs.org.uk/ARRIVE) guidelines, and a 
protocol approved by the Animal Use Subcommittee at the University of Western 
Ontario. Briefly, tissues were homogenized in 0.32 M sucrose buffered with 5 mM 
HEPES, pH 7.4. Following differential centrifugation at 1000 g for 10 min and 
12 000 g for 20 min to recover the crude P2 fraction, pellets were resuspended in 
buffered 0.32 M sucrose and layered onto discontinuous gradients comprised of 8.5, 13, 
and 20% Ficoll in buffered 0.32 M sucrose. Following centrifugation at 27 000 g for 
45 min, fractions at the 8.5–13% and 13–20% interfaces were recovered as they 
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contained purified synaptosomes; these were diluted 5-fold with 0.32 M sucrose, then 
centrifuged at 12 000 x g for 30 min. Purified synaptosome pellets were lysed in sodium 
carbonate lysis buffer and the resulting homogenates used directly to isolate lipid rafts, as 
described above. 
3.2.7 Cellular imaging  
Digital images of fixed cells were acquired with a Zeiss LSM510-Meta laser-scanning 
confocal microscope (Carl Zeiss Canada Ltd., Toronto, ON, Canada) using a 63X oil-
immersion objective and magnified three times, unless specified otherwise. FLAG-tagged 
CHT proteins were fluorescently labeled in live cells using rabbit anti-FLAG antibody 
complexed to either Zenon 555 dye (for EEA1 staining) or Zenon 488 dye (for flotillin 
staining). The fluorescently tagged antibody was added to medium bathing the cells 
where it could bind to the FLAG epitope located on the extracellularly oriented amino 
terminus of CHT proteins at the plasma membrane. After allowing internalization of 
Zenon-labeled CHT proteins, cells were formaldehyde fixed then counter-stained with 
AlexaFluor 647 CTB (0.2 ng/μL) and either anti-flotillin (1: 200) or anti-EEA1 (1: 100) 
antibodies. Following immunostaining, images were acquired using 488-nm excitation 
and 505- to 530-nm emission wavelengths for flotillin; 543-nm excitation and 560- to 
615-nm emission for EEA1; and 647-nm excitation and 650-nm emission using a long-
pass filter for CTB. FLAG-CHT was visualized using 488-nm excitation and 505- to 530-
nm emission (for EEA1-labeled cells) or using 543-nm excitation and 560- to 615-nm 
emission (for flotillin-labeled cells). Images were processed and colocalization was 
analyzed in Imaris (version 7.0.0; Bitplane Scientific Software, South Windsor, CT, 
USA), then formatted in Adobe Illustrator and Photoshop (Adobe Systems Inc, San Jose, 
CA, USA). 
3.2.8 Cholesterol quantification 
SH-SY5Y cells expressing FLAG-tagged CHT were grown to confluence on 100-mm 
dishes, then lysed in sodium carbonate lysis buffer and lipid rafts were isolated on 
sucrose gradients, as described above. Total cholesterol levels were measured in pooled 
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raft fractions (#4–6) and non-raft fractions (#9–12) using the Amplex Red Cholesterol 
Assay, according to manufacturer's instructions. Briefly, 50 μL of cholesterol standards 
(0–20 μM per well) or sample replicates was added to 96-well black plates. Fifty μL of 
working solution (300 μM Amplex Red reagent, 2 unit/mL horseradish peroxidase, 
2 unit/mL cholesterol oxidase, and 0.2 unit/mL cholesterol esterase) was added to each 
well and plates were incubated in the dark for 30 min at 37°C. Fluorescence was 
measured (excitation 544 nm, emission 590 nm, SpectraMax M5 Molecular Devices, 
Palo Alto, CA, USA). Relative fluorescence units of samples were converted into μM 
cholesterol per μg sample protein using the standard curve, and data were expressed as a 
percentage of vehicle-treated controls 
3.2.9 Cell surface protein biotinylation assay  
Cells plated on 100-mm dishes were washed with HBSS, then treated at 37°C with either 
vehicle or drug. After treatment, cells were placed on ice under cold HBSS to stop 
protein trafficking. Plasma membrane proteins were biotinylated at 4°C by incubating 
with 1 mg/mL sulfo-NHS-SS-biotin in HBSS for 1 h (26, 28) with gentle agitation. 
Unbound biotin was quenched by washing and incubating cells in cold 100 mM glycine 
in HBSS. After two further washes with HBSS, cells were lysed on ice for 30 min in 
sodium carbonate lysis buffer and lipid rafts prepared on sucrose flotation gradients as 
described above. Twelve 1-mL gradient fractions were collected and pooled as either raft 
fractions (#4–6) or non-raft fractions (#9–12). Pooled fractions were diluted to 10 mL 
with lysis buffer (1% w/v Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, and pH 7.5) 
and pH adjusted to 7.5. Protein concentrations were measured using Bio-Rad dye and 
aliquots of cell lysates containing 30 μg protein subjected to SDS–PAGE to determine 
total CHT, flotillin, and EEA1 levels. Biotinylated proteins in sucrose density gradient 
fractions were separated from non-biotinylated proteins by Neutravidin bead pull-down 
from 500 μg total cellular protein from each sample. Beads were washed three times with 
lysis buffer to remove non-specifically bound proteins. Proteins were eluted for 10 min at 
55°C with Laemmli buffer, then separated on 7.5% SDS–PAGE gels and transferred to 
PVDF membranes. Immunoblots for CHT, flotillin, and EEA1 were carried out as 
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described above and analyzed using a Chemidoc Imaging System (Bio-Rad 
Laboratories). 
3.2.10 Internalization cell surface biotinylation assay  
Cells plated on 100-mm dishes were washed twice with cold HBSS and placed on ice 
under cold HBSS to stop protein trafficking. Plasma membrane proteins were 
biotinylated at 4°C by incubating with 1 mg/mL sulfo-NHS-SS-biotin in HBSS for 1 h 
with gentle agitation, then unbound biotin was quenched by washing and incubating cells 
in cold 100 mM glycine in HBSS. Dishes were washed with warm HBSS, then incubated 
at 37°C with either vehicle or drug to allow constitutive internalization of CHT proteins. 
CHT internalization was subsequently terminated by transferring dishes of cells to ice 
and replacing medium with cold HBSS. Residual cell surface biotin was stripped by 
incubating cells once for 15 min and twice for 30 min with freshly prepared 50 mM 
mercaptoethanesulfonic acid (MesNa) in TE buffer (150 mm NaCl, 1 mm EDTA, 0.2% 
bovine serum albumin, 20 mm Tris, and pH 8.6). Stripping efficiency was determined for 
each experiment on parallel sets of biotinylated cells that were maintained on ice and 
which did not undergo MesNa stripping to assess the amount of CHT at the plasma 
membrane. Cells were lysed in lysis buffer (1% w/v Triton X-100, 150 mM NaCl, 
50 mM Tris-HCl, pH 7.5, 1 mM AEBSF, 10 μg/mL each of leupeptin and aprotinin, 
25 μg/mL pepstatin A, and 700 U/mL DNase) and protein concentration was measured 
using Bio-Rad dye. Biotinylated proteins were separated from non-biotinylated proteins 
by Neutravidin bead pull-down from 500 μg protein from each sample. Beads were 
washed three times with lysis buffer to remove non-specifically bound proteins, then 
proteins eluted for 10 min at 55°C with Laemmli buffer, separated on 7.5% SDS–PAGE 
gels, and transferred to PVDF membranes. Immunoblots for CHT were carried out as 
described above and analyzed using a Chemidoc Imaging System. 
3.2.11 Data analysis  
Data are presented as mean ± SEM with n values representing the number of independent 
experiments performed on separate populations of cells. Each n value was obtained from 
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the average of multiple sample replicates in each experiment. Replicate experiments were 
performed on cells cultured in successive passages as much as possible to minimize 
interexperiment variability; intraexperiment variability between replicate samples was 
minimal thus facilitating comparison of treatment effects. GraphPad Prism 5 (GraphPad 
Software, San Diego, CA, USA), InStat software (GraphPad Software) and Image Lab 
4.1 (Bio-Rad Laboratories) were used for data analysis. Sigmoid and Michaelis–Menten 
equations were used to calculate kinetic parameters (Bmax and KD) of HC-3 binding. Data 
were assessed for statistically significant differences by unpaired Student's t-test, or 
between groups using repeated measures one-way ANOVA with Tukey's post 
hoc multiple comparison test as appropriate, with statistical significance defined 
as p ≤ 0.05. 
3.3 Results 
3.3.1 Membrane cholesterol manipulation modulates choline 
uptake activity  
The initial experiments were designed to determine the effect of manipulation of 
membrane cholesterol content on HC-3-sensitive, high-affinity choline uptake activity in 
SH-SY5Y cells that stably express FLAG-tagged CHT. Three separate pharmacological 
approaches having different mechanisms of action were used to lower membrane 
cholesterol levels, and one approach was used to increase the membrane cholesterol level. 
Cells were treated with either filipin which binds to and sequesters free cholesterol within 
both lipid raft and non-raft areas of membrane and disrupts lipid rafts (29), MβC which 
extracts unesterified cholesterol from plasma membrane resulting in the disruption of 
lipid rafts and direct cholesterol–protein interactions (30), or cholesterol oxidase which 
converts cholesterol to the inactive sterol cholest-4-en-3-one and does not alter 
membrane fluidity (31). Neither cell density of cultures nor cell morphology was visibly 
altered after drug treatments, and the level of total CHT protein was unchanged (data not 
shown). I predicted that if cholesterol is required for CHT function, then HC-3-sensitive 
choline uptake activity would be altered by these drugs. Figure 3-1 illustrates dose–
response relationships for [
3H]choline uptake in cells treated with filipin, MβC, and  
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Figure 3-1 Manipulation of membrane cholesterol modulates choline uptake in SH-
SY5Y cells. 
A, Cells were treated with either vehicle (methanol) or 2.5 or 5 μg/mL of filipin for 
60 min at 37°C. Hemicholinium-3 (HC-3)-sensitive [
3
H]choline uptake activity was 
assayed in cells during a 5-min incubation at 37°C. B, Cells were treated with either 
vehicle (H2O) or 0.1 or 0.3 mM methyl-β-cyclodextrin (MβC) for 30 min at 37°C, then 
[
3
H]choline uptake activity was determined. C, Cells were treated with either 0, 0.5, or 
1 U/mL cholesterol oxidase in a buffer containing 100 mM MES and 3 M NaCl in Krebs-
Ringer-HEPES (KRH) solution at 37°C for 30 min, then [
3
H]choline uptake was 
measured. D, To assess whether supplementing membranes with additional cholesterol 
influenced choline uptake, cells were treated with either vehicle (H2O), 5, or 25 μM 
cholesterol–methyl-β-cyclodextrin (MβC–Chol), then [3H]choline uptake was assayed. In 
all experiments, [
3
H]choline uptake activity was determined as the difference between 
uptake in the absence and presence of 1 μM HC-3, and expressed as pmol/mg of protein 
per 5 min and transformed to % of the respective control values. Data are expressed as 
mean ± SEM of four independent experiments. Non-transformed data were analyzed by 
one-way anova followed by Tukey's post-test. Asterisks (*) denote when drug treatment 
groups are significantly different from vehicle groups (p < 0.05). 
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cholesterol oxidase. When cells were pre-treated with vehicle or filipin for 60 min, 
[
3
H]choline uptake was significantly reduced at both doses of filipin (2.5 or 5 μg/mL) 
(Figure 3-1A). Similarly, treating cells with MβC for 30 min (0.1 or 0.3 mM) resulted in 
a statistically significant decrease in [
3
H]choline uptake at the higher concentration of the 
drug (Figure 3-1B). Finally, when cells were treated with cholesterol oxidase for 30 min, 
a statistically significant reduction in [
3
H]choline uptake activity was observed at both 
concentrations of cholesterol oxidase (0.5 and 1 U/mL) compared to vehicle-treated 
control cells (Figure 3-1C). 
In the next set of experiments, I determined if CHT activity is altered by increasing the 
level of membrane cholesterol. SH-SY5Y cells were incubated with a cholesterol-
saturated form of MβC (MβC-Chol) for 30 min (MβC-Chol complex concentration was 5 
or 25 μM, calculated by weight of cholesterol) or with vehicle, then [3H]choline uptake 
was measured. Importantly, when cholesterol was added to cells, a statistically significant 
increase in choline uptake was observed at 25 μM MβC-Chol when compared to vehicle-
treated cells (Figure 3-1D). 
3.3.2 MβC decreases both the Bmax and KD for [
3H]HC-3 binding to 
CHT  
Several studies suggest that membrane cholesterol and lipid rafts regulate 
neurotransmitter transporter activity by controlling the number of transporters at the cell 
surface (11, 32, 33). However, cholesterol can also regulate the function of 
neurotransmitter transporters by modulating their solute binding activity (34, 14, 35). To 
establish whether the observed decrease in choline uptake following cholesterol depletion 
was owing to a change in ligand binding affinity (KD) or to a change in the number of cell 
surface CHT proteins (Bmax), kinetic analysis of binding of the non-transported 
competitive inhibitor [
3
H]HC-3 to CHT was performed following treatment of cells with 
either vehicle or 0.3 mM MβC (Figure 3-2A). These data revealed that cell surface CHT 
levels were reduced by approximately 50% by MβC treatment, with Bmax for [
3
H]HC-3 
binding decreased from 470.5 ± 115 to 220.7 ± 77 fmol [
3
H]HC-3 bound/mg protein in  
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Figure 3-2 MβC modifies the binding kinetics for [3H]HC-3 to high-affinity choline 
transporters by decreasing Bmax and KD. 
Cells were treated with either vehicle (H2O) or 0.3 mM MβC for 30 min at 37°C, then 
kinetic parameters for cell surface [
3
H]HC-3 binding were estimated using 0.5–10 nM 
hemicholinium-3 (HC-3). Data were calculated as pmol [
3
H]HC-3bound/mg protein, and 
expressed as mean±SEM from five independent experiments. A, A representative 
experiment is shown for equilibrium binding of [
3
H]HC-3 to SH-SY5Y cells expressing 
CHT. Data were fit by Michaelis–Menten non-linear regression analysis of individual 
experiments. Differences between vehicle and MβC treatments were examined by 
comparison of the number of CHT sites (Bmax) B, and the apparent binding affinity for 
ligand (KD), C. When compared to control cells, the KD for HC-3 binding to CHT was 
decreased approximately 60% and Bmax was reduced by approximately 50% in MβC-
treated cells (*p < 0.05, unpaired Student's t-test). 
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control and MβC-treated cells, respectively (Figure 3-2B). This coincides with a small, 
but significant, MβC-mediated increase in binding affinity with the KD for [
3
H]HC-3 
binding reduced from 8.5 ± 1.1 to 4.0 ± 0.6 nM in control and MβC-treated cells, 
respectively (Figure 3-2C). 
3.3.3 CHT proteins are associated with lipid rafts  
The observation that choline uptake activity is modulated by changes in membrane 
cholesterol suggests that CHT proteins may be located in lipid rafts. Technically, lipid 
rafts are defined as membrane domains that are insoluble in cold non-ionic detergents, 
such as Triton X-100, and have a specific buoyant density during sucrose gradient 
centrifugation (36). However, non-ionic detergents can also solubilize proteins that are 
only weakly associated with lipid rafts, and also lipid and protein composition of rafts 
can differ between different extraction methods (37-39). Therefore, I used a second 
approach to isolate lipid rafts and validate our findings using a non-detergent procedure 
that is based on pH and carbonate resistance of lipid raft domains (40). 
Importantly, my data show for the first time that CHT proteins are highly concentrated in 
lipid rafts prepared from SH-SY5Y cells that stably express the transporter (Figure 3-3). 
Membrane lipid rafts from cells lysed in either 1 M Na2CO3 pH 11 or 0.5% Triton X-100 
were isolated using sucrose density gradient ultracentrifugation (41, 42). Solubilized 
proteins remain in the bottom fractions of the gradient (within 40% sucrose), whereas 
proteins associated with lipid rafts float to the upper layers (between 5% and 30% 
sucrose). To confirm isolation of lipid rafts, I also analyzed the distribution of flotillin-1, 
a lipid raft protein (43), and EEA1, a non-raft protein (41), in gradient fractions. Thus, 
CHT proteins are found predominantly in lipid raft fractions, and this distribution profile 
is similar in cells lysed with either Na2CO3 (Figure 3-3A and 3-3C) or Triton X-100 
(Figure 3-3B and 3-3D). Figure 3-3A and 3-3B show representative immunoblots for 
CHT protein, with blotting membranes stripped and reprobed with anti-flotillin 
antibodies and anti-EEA1 antibodies. The histograms displayed in Figure 3-3C and 3-3D 
illustrate quantification of CHT protein distribution in sucrose density gradients by  
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Figure 3-3 CHT proteins are distributed between raft and non-raft membrane 
domains.  
Cells were lysed with either 1 M sodium carbonate pH 11 (A, C) or 0.5% Triton X-100 
(B, D), then lipid rafts were isolated on sucrose gradients based on buoyant density. A, 
Representative immunoblots of gradient fractions 1–12 obtained using the sodium 
carbonate method showing CHT, non-raft marker EEA1 and raft-resident protein flotillin. 
B, Representative immunoblots of gradient fractions 1–10 obtained using the Triton X-
100 method. (C, D) Densitometric analysis of CHT in raft and non-raft fractions 
expressed as a percentage of total CHT for cells lysed in either sodium carbonate or 
Triton X-100, respectively. To determine CHT protein distribution in membrane domains 
in brain cholinergic neurons, lipid rafts were isolated from mouse forebrain 
synaptosomes. E, Representative immunoblots of gradient fractions 1–12 obtained using 
the sodium carbonate method, from data obtained in three independent experiments. F, 
Densitometric analysis for CHT in raft and non-raft fractions prepared from 
synaptosomes expressed as a percentage of total CHT. Data are mean ± SEM of three 
independent experiments. G, Free cholesterol content was determined in raft (5) and non-
raft (9–12) fractions from sucrose density gradients using the Amplex Red Cholesterol 
Assay Kit (Invitrogen) and normalized to sample protein content. Raft fraction #5 
contains the highest cholesterol content when compared to the non-raft fractions #9–12. 
Data are expressed as the mean ± SEM of three independent experiments. 
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densitometry. Enrichment of CHT proteins in lipid rafts is seen with 85 ± 10% and 
85 ± 6% of total CHT present in pooled flotillin-positive raft fractions, compared to 
15 ± 6% and 15 ± 5% of total CHT present in EEA1-positive non-raft fractions from cells 
lysed with Na2CO3 and Triton X-100, respectively. 
To confirm if CHT proteins are also present in lipid rafts in brain cholinergic nerve 
terminals, I prepared purified synaptosomes from mouse forebrain. Synaptosomes were 
lysed in 1 M Na2CO3, then membrane lipid rafts were isolated on sucrose density 
gradients and immunoblots performed for CHT, EEA1, and flotillin. Figure 3-3E shows a 
representative immunoblot of the distribution of these proteins in gradient fractions. 
Importantly, in confirmation of my findings using cultured neural cells, a substantial 
proportion of CHT protein was found in lipid raft fractions. Densitometric quantification 
of CHT protein on immunoblots revealed that 47 ± 5% is present in fraction #5 that also 
coincides with the greatest density of the lipid raft protein flotillin. This is compared to 
53 ± 15% in EEA1 positive non-raft fractions #9-12 (Figure 3-3F). Interestingly, the 
maximum CHT protein distribution in fractions #5 and 12 coincide with higher levels of 
free cholesterol content (Figure 3-3G) 
3.3.4 CHT colocalizes with the lipid raft makers flotillin and 
ganglioside GM1 
Confocal imaging experiments where cell surface CHT proteins were fluorescently 
labeled in live SH-SY5Y cells allowed further assessment of distribution of the 
transporter in raft and non-raft membrane domains. I assessed the colocalization of CHT 
with CTB, which binds to ganglioside GM1 and is found concentrated in lipid rafts (44), 
along with either flotillin (raft marker) or EEA1 (non-raft marker). To identify 
colocalized proteins, a threshold fluorescence intensity was set that filters for the 
brightest 2% of pixels of CHT (red channel) that also fall within the brightest 2% of 
pixels of GM1 (blue channel) and either flotillin (green channel) or EEA1 (green 
channel); this approach to visualize protein colocalization was validated previously (45). 
The colocalized pixels are identified in a separate colocalization channel (shown as 
‘Colocalized pixels’ images). I found that CHT colocalizes to a similar extent with both  
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Figure 3-4 CHT proteins colocalize with flotillin and cholera toxin-labeled GM1, 
and to a lesser extent with EEA1. 
Panel A, Confocal images show the distribution in SH-SY5Y cells of Zenon 488-labeled 
CHT (red), AlexaFluor 555-labeled flotillin (green), and AlexaFluor 647-labeled cholera 
toxin subunit B (CTB) binding to GM1. The Zenon 555 dye conjugated to rabbit anti-
FLAG antibody was added to medium bathing live cells for 15 min where it could bind to 
the FLAG epitope of the amino terminus of CHT located at the cell surface. This 
facilitated tracking of CHT proteins at the cell surface, and as they are internalized into 
and traffic within cells. Cells were then formalin fixed and stained for endogenous 
ganglioside GM1 and flotillin. Colocalization of CHT and flotillin is yellow in Overlay 
panels and colocalization of CHT and GM1 is white in Overlay panels. Images were 
analyzed as described in Methods. CHT and flotillin determined to be colocalized in the 
colocalization channel are shown as yellow in the ‘Colocalized pixels’ image, and CHT 
and GM1 determined to be colocalized in the colocalization channel are shown as purple 
in the ‘Colocalized pixels’ image. Panel B, Confocal images show Zenon 555-labeled 
CHT (red), AlexaFluor 488-labeled EEA1 (green), and AlexaFluor 647 CTB-labeled 
GM1 distribution. Colocalization of CHT and EEA1 is yellow and colocalization of CHT 
and GM1 is white in the Overlay panels. CHT and EEA1 determined to be colocalized in 
the colocalization channel are shown as yellow in the ‘Colocalized pixels’ image and 
CHT and GM1 determined to be colocalized in the colocalization channel are shown as 
purple in the ‘Colocalized pixels’ image. Data are representative of 10 cells from four 
independent experiments. Scale bar, 5 μm. 
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GM1 (Figure 3-4A, colocalized pixels shown in purple) and flotillin (Figure 3-4A, 
colocalized pixels shown in yellow), and that all three proteins are found together in a 
punctate distribution pattern indicative of lipid rafts (triple colocalized pixels panel not 
shown). In contrast, in cells stained for EEA1 and GM1, I found that CHT appears to be 
found more in GM1-positive compartments (Figure 3-4B, colocalized pixels shown in 
purple) than colocalized with EEA1 (Figure 3-4B, colocalized pixels shown in yellow). 
3.3.5 Effect of cholesterol manipulating drugs on cholesterol level 
in SH-SY5Y cell membranes  
I analyzed the effect of treatment of SH-SY5Y cells with either MβC or filipin on free 
and esterified cholesterol content in pooled lipid raft fractions (#4–6) and non-raft 
fractions (#9–12) obtained from sucrose gradients (Figure 3-5). As expected, total 
cholesterol levels were higher in lipid raft fractions when compared to non-raft fractions, 
with about 65% of the cholesterol contained in rafts (data not shown). Filipin, which 
functionally depletes cholesterol by forming filipin–cholesterol complexes within the 
membrane, did not significantly alter cholesterol levels. In cells treated with 5 μg/mL 
filipin, cholesterol levels were 7.2 ± 0.5 and 3.9 ± 0.5 μmol/μg protein in raft and non-raft 
fractions, respectively, compared to vehicle-treated controls where cholesterol levels 
were 7.2 ± 0.4 and 3.9 ± 0.3 μmol/μg protein in lipid raft and non-raft fractions, 
respectively (Figure 3-5A). In contrast, treatment of cells with 0.3 mM MβC, which 
extracts cholesterol from membranes, significantly reduced cholesterol content in raft 
fractions but not in non-raft fractions; in MβC-treated cells, cholesterol levels were 
6.8 ± 0.4 and 3.7 ± 0.5 μmol/μg protein in raft fractions and non-raft fractions, 
respectively, compared to 7.7 ± 0.3 and 3.8 ± 0.4 μmol/μg protein in raft and non-raft 
fractions, respectively, in vehicle-treated cells (Figure 3-5B). This corresponds to a 
cholesterol reduction of approximately 10% in lipid raft fractions, which compares with 
the findings of Foster et al. (2008) (46) who showed that treatment of cells with a much 
higher concentration of MβC (5 mM) causing a 52% reduction in cholesterol in lipid raft 
fractions.  
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Figure 3-5 The effect of treatments that manipulate membrane cholesterol on 
cholesterol levels in raft and non-raft fractions from SH-SY5Y cells.  
Cholesterol content was determined using the Amplex Red Cholesterol Assay kit and 
normalized to sample protein content. Methyl-β-cyclodextrin (MβC), but not filipin, 
significantly decreased cholesterol levels in lipid raft fractions. A, No changes in 
cholesterol content were observed in cells treated with filipin. B, MβC caused a 
significant reduction in cholesterol content in lipid raft fractions, but not non-raft 
fractions. Samples were measured from pooled raft fractions (#4–6) and non-raft 
fractions (#9–12) and data are expressed as % of control. Data were analyzed by one-
way anova followed by Tukey's post-test and are given as the mean ± SEM of four 
independent experiments. *p < 0.05, paired Student's t-test. 
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3.3.6 Lipid raft disruption decreases plasma membrane CHT 
protein levels  
Kinetic analysis of [
3
H]HC-3 binding to CHT (Figure 3-2) revealed that MβC treatment 
of cells decreases Bmax, suggesting that the number of CHT proteins at the plasma 
membrane is decreased. To confirm this and extend my studies on how lipid raft 
disruption alters CHT localization at the plasma membrane, we undertook cell surface 
protein biotinylation experiments. CHT proteins are located predominantly in subcellular 
endocytic compartments and synaptic vesicles (16) that also contain lipid rafts. Since we 
wanted to examine the relative distribution of CHT within lipid rafts only at the cell 
surface, plasma membrane proteins were biotinylated using membrane impermeable 
sulfo-NHS-biotin at 4°C to ensure that labeled CHT proteins did not undergo 
endocytosis. Prior to protein biotinylation, cells were treated at 37°C with either 5 μg/mL 
filipin, 0.3 mM MβC or vehicle. Na2CO3-insoluble lipid rafts were isolated, then 
biotinylated proteins were recovered from the pooled raft and non-raft fractions for 
analysis. 
A critical finding is that modification in membrane cholesterol by either filipin or MβC 
reduced the amount of CHT protein in plasma membrane lipid raft fractions, but not in 
non-raft fractions (Figure 3-6). Representative immunoblots show the levels of cell 
surface (biotinylated) CHT protein, and the amount of total CHT protein, flotillin-1, and 
EEA1 in raft and non-raft fractions from cells treated with either filipin (Figure 3-6A) or 
MβC (Figure 3-6B). In vehicle-treated cells, plasma membrane CHT proteins are 
concentrated in lipid rafts with a distribution similar to that seen for total cellular CHT 
protein. Cell surface CHT levels in raft fractions were significantly reduced by 
approximately 50% in both filipin- and MβC-treated cells when compared to vehicle- 
treated cells (p < 0.05) (Figure 3-6C and 3-6D). This does not reflect redistribution of 
CHT to non-raft areas of plasma membrane, as changes were not observed in CHT levels 
in non-raft fractions between vehicle- and drug-treated cells. Immunoblots for cell 
surface CHT were reprobed with anti-flotillin and anti-EEA1 antibodies to confirm the  
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Figure 3-6 
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Figure 3-6 Filipin and MβC decrease cell surface CHT proteins in lipid rafts.  
Cells were treated at 37°C for 60 min with vehicle (methanol) or 5 μg/mL filipin (A, C, 
E), or for 30 min with vehicle (H2O) or 0.3 mM MβC (B, D, F). Cells were washed and 
placed on ice, then plasma membrane proteins were biotinylated. Sodium carbonate-
resistant lipid rafts were prepared and biotinylated proteins were isolated from the pooled 
raft (#4–6) and non-raft (#9–12) fractions. (A and B) Representative immunoblots for 
CHT dimer, cell surface (biotinylated) CHT, total CHT, lipid raft-resident protein flotillin 
and non-raft marker EEA1. (C and D) Densitometric analysis of cell surface CHT in raft 
and non-raft fractions from cells treated with vehicle or drug shows a statistically 
significant reduction in cell surface CHT in lipid rafts in drug-treated cells compared with 
control. Data were analyzed by repeated measures one-way ANOVA followed by 
Tukey's post hoc test, and are expressed as mean ± SEM of four independent experiments 
*p < 0.05. (E and F) Increased exposures of cell surface CHT immunoblots shown in (A 
and B) reveal CHT-immunopositive bands that likely represent CHT dimers in lipid raft 
fractions. Densitometric analysis of CHT dimers shows a statistically significant 
reduction in lipid rafts from drug-treated cells compared with control. Data are expressed 
as mean ± SEM of four independent experiments. (*p < 0.05, paired Student's t-test). 
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isolation of lipid rafts. As predicted, flotillin-1 levels in raft fractions were reduced in 
drug-treated cells confirming disruption of lipid rafts. No changes in EEA1 levels or 
distribution were observed between samples from vehicle- and drug-treated cells. Taken 
together, these results suggest that total cellular and cell surface CHT proteins are 
partitioned similarly between lipid raft and non-raft membrane domains in SH-SY5Y 
cells, with lipid raft disruption resulting in reduced cell surface CHT in lipid rafts. 
It is important to note the presence of CHT-immunopositive bands with an apparent 
molecular mass of about 100 kDa in lipid raft fractions at higher exposures of the 
immunoblots for cell surface CHT proteins (Figure 3-6A and 3-6B). These bands, which 
are not present in the non-raft fractions, likely represent CHT protein dimers. In both 
filipin- and MβC-treated cells, levels of the putative CHT dimers at the cell surface are 
significantly reduced by about 50% (p < 0.05) (Figure 3-6E and 3-6F) 
3.3.7 Lipid raft disruption does not alter CHT internalization from 
the cell surface  
CHT proteins at the cell surface undergo constitutive internalization by a clathrin-
mediated mechanism into early endosomes, and these proteins can recycle back to the 
cell surface (17). I tested the hypothesis that the decrease in plasma membrane CHT 
protein in filipin- and MβC-treated cells is because of an increase in internalization of 
CHT. SH-SY5Y cell plasma membrane proteins were biotinylated on ice, and then cells 
were incubated at 37°C with either vehicle, 0.3 mM MβC or 5 μg/mL filipin to allow 
endocytosis of proteins from the cell surface to subcellular organelles. Only internalized 
biotinylated proteins were measured as, following drug treatments, cells were returned to 
ice to terminate endocytosis and residual biotin remaining on cell surface proteins was 
stripped by membrane-impermeant MesNa. Figure 3-7 illustrates that neither filipin nor 
MβC significantly alters CHT internalization from the cell surface to subcellular 
organelles. The amount of internalized biotinylated CHT protein was normalized to total 
cell surface CHT levels from cells that were incubated on ice in the absence of either 
filipin or MβC (Figure 3-7A and 3-7C, lane 2). A separate set of cells was incubated on 
ice throughout the procedure to ensure that MesNa efficiently stripped biotin from cell  
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Figure 3-7 Lipid raft disruption does not alter CHT internalization.  
Cell surface proteins were biotinylated for 1 h at 4°C, then cells were warmed to 37°C 
and CHT proteins allowed to internalize in the presence of vehicle or drug. A, 
Representative immunoblots for total and surface CHT showing no change in CHT 
internalization at 15, 30, and 60 min in cells treated with 5 μg/mL filipin compared with 
control. C, Representative immunoblots for total and surface CHT showing no change in 
CHT internalization at 15 and 30 min in cells treated with 0.3 mM methyl-β-cyclodextrin 
(MβC) compared with control. (B and D) Histograms show quantification of 
immunoblots for CHT internalization, with internalized CHT normalized to total cell 
surface CHT in each experiment. Data were analyzed by repeated measures one-
way ANOVA followed by Tukey's post hoc test and expressed as mean ± SEM of five 
independent experiments. (* measurement at 60 min is statistically different from 
15 min, p < 0.05). 
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surface proteins (Figure 3-7A and 3-7C, lane 1). Immunoblots of cell lysates (Figure 3-
7A and 3-7B, lower panels) show that there were no changes in total CHT levels in cells 
as a consequence of the treatments. A statistically significant time-related increase in 
internalized CHT was observed in cells treated with either vehicle or filipin at 60 min 
when compared to 15 min, but no other statistically significant changes between groups 
were found (Figure 3-7B and 3-7D). 
3.3.8 Identification of putative cholesterol-binding motifs in CHT 
protein 
Transmembrane proteins may bind cholesterol molecules, with the two most common 
sites for this interaction on the protein being the Cholesterol Recognition/interaction 
Amino acid Consensus sequence (CRAC domain) and the CARC domain that comprised 
an inverted CRAC domain sequence (47, 48). The definition of both of these motifs is 
based on a triad of basic (K or R), aromatic (Y or F), and aliphatic (L or V) residues. The 
CRAC domain sequence is defined as L/V-(X)1-5-Y-(X)1-5-R/K, where X can be one to 
five residues of any amino acid. The CARC domain is the reverse sequence and the 
residue Y may be substituted by F. Analysis of the primary sequence of rat CHT reveals 
putative cholesterol-binding motifs, with these being conserved between rodent and 
human proteins. As illustrated in Figure 3-8, candidate sequences for putative CRAC and 
CARC domains are found in TMD 4, 11, 12, and 13 of CHT. TMD 4 contains the CARC 
sequence R-X5-F-X3-L that could bind cholesterol in the plasma membrane cytoplasmic 
leaflet. TM 13 contains a CRAC sequence V-X1-Y-X2-K, also on the bilayer cytoplasmic 
side. CRAC-like motifs, bearing close similarity to CRAC sequences, that could 
potentially bind cholesterol on the cytoplasmic leaflet are in TM 11 and 12 [TM 11, L-
X3-F-X1-K or L-X4-F-X1-K; TM 12, V-X2-Y-X6-R]. In addition to cholesterol binding to 
CRAC and CARC motifs, transmembrane domains containing G-XXX-G motifs may 
also be engaged in binding cholesterol molecules (48, 49). Importantly, as shown in 
Figure 3-8, TMD 12 of CHT has a conserved G-XXX-G-XXX-G motif (G-AVA-G-
YVS-G) that could potentially serve as both a cholesterol-binding motif and as a  
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Figure 3-8 Schematic representation of transmembrane topology of rat high-affinity 
choline transporters showing putative cholesterol-binding motifs.  
The positions of putative CRAC-like and CARC sequence motifs are shown in 
transmembrane domains 4, 11, 12, and 13. The positioning of transmembrane domains 
shown is based on data for human CHT [Q9GZV3] submitted recently to 
UniProtKB/Swiss-Prot athttp://www.uniprot.org/uniprot/Q9GZV3 [Last modified July 
24, 2013]; rat and human CHT share 93% sequence identity. 
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dimerization motif. This sequence of the protein also coincides with a CRAC-like 
domain.  
3.4 Discussion 
I made several novel findings in this study that indicate that partitioning of CHT proteins 
into cholesterol-rich lipid rafts, and potentially direct interaction of CHT with cholesterol, 
may play a critical role in CHT localization at the cell surface and activity. I showed for 
the first time in both SH-SY5Y cells and mouse brain cholinergic nerve terminals that 
CHT proteins are partitioned between membrane lipid raft and non-raft microdomains, 
and tend to be concentrated in lipid rafts. Microscopically, CHT proteins colocalize with 
the lipid raft-resident protein flotillin and the lipid raft marker ganglioside GM1, and to a 
lesser extent with the non-raft protein EEA1. Second, I found that choline uptake activity 
shows a dependence on membrane cholesterol levels. Thus, treatment of neural cells with 
the cholesterol interfering drugs filipin, cholesterol oxidase, or MβC causes a significant 
decrease in HC-3-sensitive choline uptake. Moreover, choline uptake is significantly 
increased by adding exogenous cholesterol to cells. Third, I determined that reducing cell 
membrane cholesterol levels and disrupting lipid rafts by extracting cholesterol with 
MβC decreased the number of cell surface CHT proteins when measured by [3H]HC-3 
binding to CHT (decreased Bmax) and enhanced ligand binding affinity (decreased KD). 
Fourth, I observed that treatment of cells with filipin and MβC results in a decrease in 
plasma membrane CHT protein levels from lipid rafts, but not non-raft areas, measured 
by cell surface protein biotinylation. This is not related to an accelerated rate of CHT 
protein internalization. Finally, I identified putative cholesterol-binding motifs in CHT 
protein that are conserved between rodent and human. 
I used four separate pharmacological approaches that alter membrane cholesterol by 
different mechanisms to assess how cholesterol may regulate CHT function and activity. 
Treatment of cells with cholesterol oxidase results in conversion of membrane cholesterol 
to its functionally inactive analogue steroid 4-cholesten-3-one, but does not alter the 
physical state of plasma membranes (31). This allowed me to test if the change in choline 
uptake activity in choline oxidase-treated cells is owing to altered membrane fluidity, 
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rather than a change in membrane cholesterol levels. Based on my findings, it is unlikely 
that the decrease in choline uptake observed in these cells is because of an alteration of 
membrane fluidity. In other experiments, I treated cells with MβC which extracts cellular 
cholesterol and can disrupt lipid rafts and cholesterol–protein interactions in both raft and 
non-raft areas (30). Low concentrations of MβC (0.3 mM) significantly decreased 
cholesterol content measured in membrane lipid raft fractions and resulted in decreased 
choline uptake activity. However, it is not possible to determine from these experiments 
if the loss of CHT activity is caused by a direct or indirect effect of lowering cholesterol. 
Filipin, which binds to and chelates free cholesterol within the membrane resulting in 
disruption of lipid rafts, was not expected to lower cholesterol levels and our results are 
in agreement with previous reports with filipin and the polyene antifungal agent nystatin 
(29, 35). Filipin treatment did, however, reduce choline uptake activity, suggesting that 
disruption of lipid rafts does impact CHT function. Finally, I incubated cells with MβC–
Chol to increase membrane cholesterol levels and this significantly enhanced choline 
uptake. Based on these experimental manipulations, it appears that CHT function requires 
the presence of membrane lipid rafts and may also be modulated by changes in 
cholesterol levels, indicating a potential role for direct interaction between cholesterol 
and CHT proteins. 
Decreased choline uptake in cells treated with agents that reduce membrane cholesterol 
could be because of a loss of functional transporters at the cell surface, or be the result of 
conformational changes in CHT protein that alter solute binding affinity or impair solute 
translocation subsequent to binding. Kinetic analysis of binding of the inhibitor [
3
H]HC-3 
to CHT in MβC-treated cells and quantification of cell surface protein biotinylation 
assays in cells treated with either filipin or MβC indicate that there is a reduction in CHT 
levels at the plasma membrane. Interestingly, the decrease in CHT protein is seen in lipid 
raft fractions prepared from either filipin- or MβC-treated cells and is not accompanied 
by an increase in CHT levels in non-raft fractions, indicating that down-regulation of 
choline uptake activity is not a result of CHT movement between these compartments. 
Indeed, some proteins display redistribution between these membrane compartments in 
response to lipid raft disrupting treatments, whereas other proteins do not (36). My results 
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are in agreement with those found for the dopamine transporter (DAT) by Foster et al. 
(2008) who showed that while MβC treatment reduced DAT cell surface levels, it did not 
affect partitioning of DAT proteins between lipid raft and non-raft fractions. My finding 
of increased binding affinity (KD) of CHT for HC-3 in MβC-treated SH-SY5Y cells is in 
agreement with a report of increased HC-3 binding affinity to CHT observed in MβC-
treated synaptosomes (25), and is similar to reports of increased ligand binding affinity 
found for other neurotransmitter transporters, such as DAT in MβC-treated cells (29, 35). 
The change in binding properties of CHT in MβC-treated cells could indicate that the 
conformational state of CHT required for solute binding is modulated by either lipid raft 
association or by cholesterol binding. Previous studies show that CHT proteins may exist 
in more than one state or conformation and that binding sites in some states may be 
occluded under some conditions (50, 51). Alternatively, changes to the physical 
properties of lipid rafts may disrupt cholesterol-sensitive protein–protein interactions 
involving CHT or affect the ability of CHT to undergo post-translational modifications 
such as phosphorylation, both of which could affect solute binding or translocation (36, 
45). 
Membrane cholesterol and/or lipid rafts could have a role in regulating the amount of 
CHT protein at the cell surface by altering its rate of internalization into endosomes 
and/or its recycling back to the cell surface. Several reports suggest that proteins can 
traffic to the plasma membrane and be selectively recruited to lipid raft microdomains 
(52-54). We showed previously that alterations in CHT internalization critically affect 
transporter function, while CHT recycling is required to maintain the level of transporter 
at the cell surface thereby regulating CHT activity to deliver sufficient choline to 
maintain ACh synthesis. CHT undergoes endocytosis by a clathrin- and dynamin-
dependent mechanism, but there is no evidence that CHT internalizes by a clathrin-
independent, caveolin-dependent process from lipid raft domains. In this study, we found 
that CHT protein internalization was not significantly altered by disruption of membrane 
cholesterol or rafts by either filipin or MβC, suggesting that the decrease in plasma 
membrane CHT levels was not owing to increased endocytosis; while not measured in 
my studies, reduced recycling of transporters to the cell surface could result in decreased 
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cell surface levels of the protein. These experiments also reinforce that CHT proteins do 
not likely undergo internalization by caveolae since, as lipid rafts were disrupted, an 
increase in plasma membrane CHT protein would have been predicted. In the current 
studies, cells were treated with a relatively low concentration of MβC (0.3 mM) since we 
observed that higher concentrations of the drug (2 or 5 mM) used in other studies led to 
accumulation of CHT proteins at the cell surface (data not shown). MβC can inhibit 
clathrin-mediated endocytosis (55) and as CHT undergoes rapid constitutive endocytosis, 
conditions that disrupt this process can result in substantial accumulation of the protein at 
the cell surface. Thus, I chose to use an MβC concentration that significantly decreased 
cholesterol levels in lipid rafts, and was less likely to perturb endocytosis. 
Interestingly, we observed a CHT-immunopositive band with an apparent molecular mass 
of about 100 kDa in lipid raft fractions. These bands could represent homo-oligomers of 
CHT proteins, with recent work by Okuda et al. (2012) showing that CHT expressed in 
cultured cells can form homo-oligomers at the cell surface. Here, my studies provide 
evidence that these homo-dimers are located within lipid rafts, and that these are reduced 
by lipid raft disrupting treatments. This suggests that oligomerization may result in 
stabilization of CHT into the raft domain and be required for cell surface localization of 
CHT. Detection of CHT in cell lysates often reveals multiple protein species and it has 
been suggested that these represent varying glycosylated forms of CHT (57). CHT may 
undergo differential post-translational modifications, such as phosphorylation, between 
raft and non-raft areas of membrane, but it remains to be established if these impact either 
CHT activity or plasma membrane trafficking. For example, activation of PKC enhances 
internalization of the noradrenaline transporter through a dynamin- and clathrin-
independent lipid raft-mediated process (32). In comparison, PKC-induced internalization 
of DAT is dynamin and clathrin dependent, and is independent of lipid rafts (46). 
Several lines of evidence support a connection between alterations in cholesterol levels 
and its disposition in aging (58) and AD (59) and the organization of lipid rafts is 
disrupted in AD brains (60). Here, my studies provide the first evidence that association 
of CHT proteins with cholesterol-rich lipid rafts is critical for transporter function and 
localization. These data are important for understanding the normal function of widely 
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distributed cholinergic neurons, and how they are altered in disorders that involve 
cognitive dysfunction owing to reduced cholinergic transmission. These studies will 
allow us to analyze responses to changes in the cholinergic nerve endings and to assess 
alterations in pathology to aide in the design of new therapies. Therapeutic strategies 
directed at CHT function may be useful for enhancing cholinergic transmission, for 
example, early in AD when ACh release is reduced but cholinergic neurons remain 
viable. Given the projected increases in our aging population and the prevalence of 
neurodegenerative disorders, these studies are both timely and critical. 
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Chapter 4  
4 Differential regulation of the high-affinity choline 
transporter CHT by wild-type and Swedish mutant 
amyloid precursor protein 
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4.1 Introduction 
Pathologically, two major features of AD are the processing of APP to Aβ, which are the 
principal component of Aβ plaques, and the dysfunction and eventual loss of cholinergic 
neurons. While these two features of AD pathology are well established, the connection 
between them is not fully understood. APP is a type 1 transmembrane protein that exists 
in three different isoforms (APP695, APP751 and APP770) as a result of differential 
splicing of exons 7 and 8 (1), with APP695 being the main isoform expressed in neurons 
(2). APPwt is trafficked to the cell surface where it undergoes two distinct pathways of 
proteolytic processing. Amyloidogenic processing of APPwt is thought to occur within the 
endosomal pathway, where it is cleaved first by BACE1, followed by the γ-secretase 
complex, resulting in Aβ production (3). Non-amyloidogenic processing occurs mainly at 
the cell surface, where APPwt is cleaved by α-secretases within the Aβ domain (4). 
Inheritable mutations in the genes encoding APP can alter subcellular trafficking and 
proteolytic processing of APP. For example, APP695 containing the Swedish mutation 
(K595N/M596L) (APPSwe), which causes early-onset familial AD by increasing Aβ 
production by 6- to 8-fold, undergoes high-efficiency BACE1 cleavage primarily within 
the TGN and secretory pathway (5, 6), and exhibits differences in its trafficking from the 
cell surface through the endosomal pathway compared to APPwt (7).   
The relationship between APP and cholinergic dysfunction is not well understood. 
Evidence suggests that cholinergic neurotransmission promotes α-cleavage of APP 
through ACh stimulation of specific muscarinic AChR subtypes (8), while in turn Aβ 
oligomers inhibit ACh synthesis and release (9-11). Importantly, high-affinity choline 
uptake in rat brain hippocampal synaptosomes is impaired by exposure to picomolar-
nanomlar concentrations of Aβ (11, 12). An important link between APPwt and the 
cholinergic system identified recently shows a direct physiological role for APP within 
cholinergic neurons by demonstrating that APPwt interacts with CHT, mediating its 
presynaptic localization and increasing its rate of internalization from the cell surface 
(13).  
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Altering CHT trafficking has a direct impact on choline uptake activity and cholinergic 
neurotransmission (16). The purpose of this study was to further investigate how APPwt 
regulates CHT trafficking and activity, and to determine whether this interaction is 
altered by the Swedish mutation. Here, I observed that CHT protein interacts significantly 
less with APPSwe than with APPwt. Interestingly however, the expression of either APPwt 
or APPSwe decreased CHT cell surface levels and CHT activity, and increased CHT 
colocalization to early endosomes, to the same extent. In these experiments, neural cells 
expressing APPSwe secreted significantly more Aβ than did cells expressing APPwt. 
Importantly, lowering the production of Aβ through BACE1 inhibition significantly 
increased CHT cell surface level in cells expressing APPSwe, but not in cells expressing 
APPwt compared to vehicle-treated control cells. I confirm here that APPwt interacts 
directly with CHT and make the novel observation that the interaction of CHT with APP 
is disrupted by the Swedish mutation. Furthermore, I propose that CHT function is 
inhibited by both APPwt and APPSwe, but the underlying mechanisms by which this 
occurs differ. My data reveal that APPwt facilitates CHT endocytosis, while APPSwe-
mediated inhibition of CHT function could be caused by the susceptibility of the 
transporter to Aβ found in the extracellular environment. 
4.2 Materials and methods 
4.2.1 Materials  
BACE1 inhibitor IV was obtained from Calbiochem, anti-FLAG M2 affinity gel, mouse 
IgG-agarose, Duolink in situ orange starter kit mouse/rabbit, protease inhibitor cocktail 
and polyclonal rabbit anti-APP c-terminal antibody were from Sigma-Aldrich, β-amyloid 
1-16 (6E10) mouse monoclonal antibody was from Covance, rabbit polyclonal anti-actin 
antibody was from Santa Cruz Biotechnology, anti-amyloid precursor protein A4 (clone 
22C11) was from Millipore and [methyl-
3
H]choline chloride (88.5 Ci/mmol) was 
from PerkinElmer Life Sciences. Other chemicals were purchased from Sigma-Aldrich at 
the highest purity available. SH-SY5Y human neuroblastoma cells were from the 
American Type Culture Collection, and Invitrogen supplied FBS, Lipofectamine 2000, 
OptiMEM, and culture media and reagents. AlexaFluor 555 donkey anti-mouse IgG and 
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AlexaFluor 647 goat anti-rabbit IgG antibodies were from Invitrogen. ECL was from GE 
Healthcare Life Sciences and Biodegradable Scintillant was from GE Healthcare. 
Polyclonal CHT antibody was raised in rabbits to the antigenic peptide 
DVDSSPEGSGTEDNLQ, which is conserved at the carboxyl-terminus of human and rat 
CHT (Genemed Synthesis); this peptide was conjugated to KLH carrier protein by an N-
terminal cysteine residue. CHT-specific IgG was affinity-purified in our laboratory from 
the crude antiserum on NHS-Sepharose (GE Healthcare) to which antigenic peptide had 
been coupled as the binding element. Peroxidase-conjugated goat anti-rabbit IgG was 
from Jackson ImmunoResearch Laboratories. 
4.2.2 Cell transfection and selection of cell lines  
Full-length rat CHT cDNA ligated to pSPORT was a gift from Dr. T. Okuda (14); a 
FLAG epitope tag (DYKDDDDK) was added to the amino-terminus by PCR and the 
resulting cDNA ligated to pcDNA3.1 or pcDNA5. SH-SY5Y cells were transfected with 
FLAG-CHT cDNA ligated to pcDNA3.1 by Lipofectamine 2000. Stable transformants 
(SY5Y-CHT) were selected using 500 μg/ml G418 for 4 weeks, and then grown in 
DMEM containing 10% FBS, 100 U/ml penicillin, and 100 μg/ml each of streptomycin 
and 100 μg/ml G418. SH-SY5Y cell differentiation was induced by the addition of 10 
μM RA for 3 d; substantial morphological and biochemical differentiation of cells 
occurred during this time frame. 
For transient transfection, cells were plated and treated with retinoic acid for 3 d before 
transfection, and immediately before transfection the culture medium was changed to 
complete medium that did not contain antibiotics. At the time of transfection, 1 μg of 
plasmid DNA in 100 μl of OptiMEM was added to 100 μl of OptiMEM containing 2.5 μl 
of Lipofectamine 2000, and then incubated for 20 min at room temperature. This mixture 
was added to monolayers of cells in antibiotic-free medium and incubated for 4-6 h. At 
the end of the incubation with transfection reagents, culture medium was replaced with 
complete medium containing RA and grown for an additional 24 h.  
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4.2.3 DNA constructs  
Full-length human wild-type APP695 (APPwt) and APP695 containing the Swedish 
mutation K595N/M596L (APPSwe) cDNA plasmids were generated by Dr. Dennis Selkoe 
(15) and obtained from Addgene (Addgene plasmid 30137 and Addgene plasmid 30145, 
respectively). SY5Y-CHT cells were transiently transfected with a ratio of 1 μg APPwt 
plasmid DNA : 1.5 μg APPSwe plasmid DNA in all experiments to obtain equal levels of 
expression of these two proteins. Control cells were transiently transfected with the 
empty vector pcDNA3.1. In some confocal imaging experiments, cells were transiently 
transfected with plasmids encoding cDNA for either full-length human HA-labeled 
APP750-YFP (APPwt-YFP) or HA-labeled APP750-YFP containing the Swedish 
mutation (APPSwe-YFP) to mediate expression of these fusion proteins.  
4.2.4 Co-immunoprecipitation of FLAG-CHT and wild-type or 
Swedish mutant APP  
Either SY5Y-CHT cells or SH-SY5Y cells stably-expressing pcDNA3.1 empty vector 
were plated on 100 mm dishes, then transiently transfected with either 6 μg APPwt 
plasmid DNA or 9 μg APPSwe plasmid DNA using Lipofectamine 2000, according to 
manufacturer’s instructions. For a control, cells were transfected with 9 μg pcDNA3.1. In 
experiments where BACE1 activity was to be inhibited, cells were incubated in complete 
medium containing either vehicle (DMSO) or 25 µM BACE1 inhibitor IV immediately 
following transfection. Twenty-four hours after transfection, cells were lysed with 1% 
Triton X-100 lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 
700 Units/ml DNase I and 10µL/mL protease inhibitor cocktail), then sample protein 
concentration was measured using a BioRad protein assay reagent. Aliquots of cell 
lysates containing 500 μg lysate protein were pre-cleared for 60 min with 50 μl mouse 
IgG-agarose, then incubated overnight with 100 μl of washed anti-FLAG M2 affinity 
resin. Alternatively, following pre-clearing, lysates were incubated on ice for 30 min with 
2µL of anti-APP A4 (22C11) antibody and then incubated overnight with 50 µL of 
washed Protein-G Sepharose. Anti-FLAG affinity resin with bound proteins and Protein-
G Sepharose with bound proteins were collected by centrifugation and washed 3 times 
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with lysis buffer to remove non-specifically bound proteins. Proteins were eluted by 
incubation for 10 min at 55°C with Laemmli sample buffer (0.125 M Tris-HCl, pH 6.8, 
4% SDS, 20% glycerol, 0.01% bromophenol blue, 5% 2-mercaptoethanol), then 
separated on 7.5% SDS-PAGE gels and transferred to PVDF membranes. Membranes 
were blocked in 8% non-fat dry milk in wash buffer (PBS with 0.15% Triton X-100) for 
1 h, then incubated overnight at 4°C with anti-CHT (1:1000) antibody or anti-APP -
terminal antibody (1:1000). After washing, membranes were incubated for 1 h in wash 
buffer containing 8% milk and peroxidase-conjugated goat anti-rabbit IgG secondary 
antibody. Immunoreactive proteins on membranes were detected by chemiluminescence 
using a Chemidoc Imaging System (BioRad).  
4.2.5 Proximity ligation assay  
To evaluate the interaction between CHT and either APPwt or APPSwe in situ, we used a 
proximity ligation assay (PLA) method using Duolink technology (Sigma). In these 
experiments, SY5Y-CHT cells grown on 35 mm confocal dishes were transiently 
transfected with 1 µg APPwt plasmid DNA or 1.5 µg APPSwe plasmid DNA and allowed 
to express for 24 h. Cells were then washed twice with warm HBSS, formalin-fixed for 
15 min at room temperature and then blocked for 30 min at room temperature in blocking 
solution (HBSS containing 3% goat serum). Cells were then labeled with primary 
antibodies against either CHT (anti-CHT 1:500) or APP (anti-APP 6E10 1:100) in 
blocking solution. Cells were then washed twice in HBSS and incubated with Duolink 
secondary antibodies (Duolink in situ PLA probe anti-rabbit PLUS and Duolink in situ 
PLA probe anti-mouse MINUS). Following binding of probes to target CHT and either 
APPwt or CHT and APPSwe, protein complexes cells were washed twice in Duolink Wash 
Buffer A and then incubated in ligation solution (1 U/µL DNA ligase) for 30 min at 
37°C. Cells were then washed twice in Duolink Wash Buffer A and the hybridized DNA 
molecule was amplified by rolling-circle amplification by incubation of the cells in 
amplification solution (10 U/µL DNA polymerase) containing fluorescently-labeled 
oligonucleotides for 100 min in the dark at 37°C. Cells were then washed twice with 
Duolink Wash Buffer B and allowed to dry. Dishes were then mounted with coverslips 
using Duolink in situ mounting media containing DAPI, and images were acquired using 
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a Zeiss LSM510-Meta laser scanning confocal microscope using a 63X magnification 
oil-immersion objective. Imaris software version 7.7.0 was used to count the number of 
spots per cell signifying an interaction between either APPwt and CHT or APPSwe and 
CHT protein complexes. As a control, background spots per cell were counted in cells 
that had not been transfected. Statistical analysis was performed using GraphPad Prism 
using one-way ANOVA with Tukey’s post-hoc test.  
4.2.6 Cell surface protein biotinylation assay  
SY5Y-CHT cells plated on 100 mm dishes were transiently-transfected with either 6 μg 
APPwt plasmid DNA or 9 μg APPSwe plasmid DNA using Lipofectamine 2000 and 
allowed to express for 24 h. For a control, cells were transfected with 9 μg empty vector. 
In experiments where BACE1 activity was to be inhibited, cells were incubated in 
complete medium containing either vehicle (DMSO) or 25 µM BACE1 inhibitor IV 
immediately following transfection. Cells were then washed twice with cold HBSS and 
placed on ice under cold HBSS to stop protein trafficking. Plasma membrane proteins 
were biotinylated on ice by incubating with 1 mg/ml sulfo-NHS-SS-biotin in HBSS for 1 
h. Unbound biotin was quenched by washing and incubating cells in cold 100 
mM glycine in HBSS. After two further washes with HBSS, cells were lysed on ice for 
30 min in 1% Triton X-100 lysis buffer. Neutravidin beads were incubated with cell 
lysates for 1 h at 4°C with gentle mixing to bind biotin-labeled proteins to allow their 
separation from the non-biotinylated proteins. Beads were then washed with lysis buffer 
3 times and bound proteins were eluted by incubation for 10 min at 55°C with Laemmli 
sample buffer. Aliquots of biotinylated proteins and total cell lysates were separated on 
7.5% SDS-PAGE gels and transferred to PVDF membranes. Membranes were blocked in 
8% nonfat dry milk in wash buffer for 1 h, and then incubated overnight with either anti-
CHT antibody (1:1000) or anti-APP c-terminal antibody (1:1000) in wash buffer with 8% 
non-fat milk. After washing, membranes were incubated for 1 h with peroxidase-
conjugated goat anti-rabbit IgG secondary antibody (1:10,000) in wash buffer containing 
8% milk, and washed again. Immunoreactive proteins were detected by 
chemiluminescence using a Chemidoc Imaging System (BioRad). Immunopositive bands 
(at ∼50-kDa for CHT protein and at ~100-kDa for APP) were quantified by 
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densitometry. Bands for cell surface CHT were compared to vector-transfected control 
cells in each experiment, which represented the basal cell surface CHT levels. 
4.2.7 [3H]Choline uptake assay 
Choline uptake activity was evaluated in SY5Y-CHT cells transiently transfected with 1, 
2 or 4 µg APPwt plasmid DNA or 1, 2 or 4 µg of APPSwe plasmid DNA. Control cells 
were transfected with 4 µg pcDNA3.1 DNA. Monolayers of cells were rinsed with warm 
KRH, then incubated in KRH at 37
o
C for 15 min. Medium was then aspirated from cells 
and choline uptake initiated by addition of KRH buffer containing 0.5 µM [
3
H]choline 
(0.5 Ci/mmol) either with or without 1 µM HC-3. Uptake was stopped after 5 min by 
placing cells on ice and washing with ice-cold KRH buffer. Cells were solubilized in 0.1 
M NaOH, then aliquots taken for tritium quantification by liquid scintillation counting 
and protein measurement.  
4.2.8 Confocal imaging  
Digital images of fixed cells were acquired with a Zeiss LSM510-Meta laser-scanning 
confocal microscope using a 63x magnification oil-immersion objective and magnified 3 
times. SY5Y-CHT cells plated on 35 mm confocal dishes were transfected with either 
wild-type HA-tagged APP 750-YFP or HA-tagged APP 750-YFP containing the Swedish 
mutation. Cells were allowed to express for 24 h. Cells were then washed twice in warm 
HBSS and formaldehyde-fixed. Fixed cells were incubated first with anti-CHT (1:1000) 
or anti-EEA1 (1:100) primary antibodies, then incubated with secondary antibodies rabbit 
AlexaFluor 647 (1:1000), to label CHT, and mouse AlexaFluor 555 (1:1000), to label 
EEA1. Images were then acquired using 488 nm excitation and 505-530 nm emission 
wavelengths for APP; 543 nm excitation and 560-615 nm emission for EEA1; and 647 
nm excitation and 650 nm emission using a long pass filter for CHT. Colocalization 
analysis was performed on confocal images using Imaris software version 7.7.0 with the 
Imaris Colocalization module (bit-plane) to examine the colocalization of the brightest 
2% of pixels in each channel, as described previously (16). Graphing and statistical 
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analysis of the data were performed with GraphPad Prism using one-way ANOVA with 
Tukey's post-hoc test. 
4.2.9 Aβ1-42 ELISA assay 
SY5Y-CHT cells plated on 100 mm dishes were transiently-transfected with either 6 μg 
APPwt or 9 μg APPSwe plasmid DNA using Lipofectamine 2000 and allowed to express 
for 24 h. As controls,, cells were transfected with 9 μg vector DNA.  The human Aβ1-42 
released by cells was measured in culture media at 24 h following transfection using the 
human Aβ1-42 ELISA kit (Invitrogen), according to the manufacturer’s protocols.  
4.2.10 Data analysis  
Data are presented as the mean ± SEM with n values representing the number of 
independent experiments performed on separate populations of cells; each n value was 
obtained from the average of multiple sample replicates in each experiment. Replicate 
experiments were performed on cells cultured in successive passages as much as possible 
to minimize inter-experiment variability, and intra-experiment variability between 
replicate samples was minimal. GraphPad Prism 5 was used for data analysis. Statistical 
significance was determined by unpaired Student’s t-test, or between groups using 
repeated measures one-way ANOVA with Tukey’s post-hoc multiple comparison test, as 
appropriate. 
4.3 Results  
4.3.1 CHT interacts more with APPwt than with APPSwe in a neural 
cell line  
My initial experiments were designed to confirm the interaction between CHT and APPwt 
in a neural cell line, and to determine if CHT interacts with APPSwe and how this 
compares to its interaction with APPwt. I used SY5Y-CHT cells stably-expressing FLAG-
tagged CHT protein as a model, with SH-SY5Y cells stably-expressing the empty vector 
DNA without CHT serving as a negative control. Cells were transiently transfected with 
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either empty vector or APPwt or APPSwe plasmid DNA and allowed to express for 24 h, 
then either FLAG-CHT or APP and interacting proteins were recovered from cell lysates 
using anti-FLAG affinity resin or anti-APP antibody and Protein-G Sepharose, 
respectively. Figures 4-1A and B show representative immunoblots that were probed for 
CHT protein using anti-CHT antibody or APP using anti-APP c-terminal antibody. 
Importantly, the anti-APP immunoblot for APP proteins interacting with FLAG-CHT 
shown in Figure 4-1A (top panel) reveals strong APPwt-positive protein bands (at ~100-
kDa) in SY5Y-CHT cells transfected to express APPwt, but only weak APPSwe-positive 
protein bands (at ~100-kDa) in SY5Y-CHT cells transfected to express APPSwe. No 
interacting APP-positive bands were present in co-IPs of lysates from SH-SY5Y cells not 
expressing FLAG-CHT (vector), suggesting that the interaction is specific to CHT. These 
data were verified in a reverse protocol using anti-APP antibody to recover APP and 
interacting proteins. Thus, Figure 4-1B (top panel) shows the anti-CHT immunoblot for 
CHT proteins interacting with APP revealing strong CHT-positive protein bands (at ~50 
kDa) from lysates of SY5Y-CHT cells transfected to express APPwt, but only faint CHT-
positive protein bands (at ~50 kDa) from lysates of SY5Y-CHT cells transfected to 
express APPSwe. Again, no interacting CHT-positive bands were present from lysates of 
SH-SY5Y cells not expressing FLAG-CHT (vector).  
Quantification of the interacting APP and CHT protein bands (Figures 4-1A and B, top 
panels) by densitometry reveals 3-fold less APPSwe-positive protein interacting with 
FLAG-CHT in SY5Y-CHT cells expressing APPSwe, when compared to APPwt-positive 
protein interacting with FLAG-CHT in SY5Y-CHT cells expressing APPwt (Figure 4-1C) 
(p < 0.05). The APP-positive protein bands were normalised to the amount of FLAG-
CHT recovered on the anti-FLAG affinity resin. In agreement with these findings, 
significantly less CHT-positive protein was found interacting with APP in SY5Y-CHT 
cells expressing APPSwe, when compared to CHT-positive proteins interacting with APP 
in SY5Y-CHT cells expressing APPwt (Figure 4-1D) (p < 0.05). The CHT-positive 
protein bands were normalised to the amount of APP recovered on Protein-G Sepharose. 
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Figure 4-1  
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Figure 4-1 CHT interacts to a greater extent with APPwt than with APPSwe in SY5Y-
CHT cells and cultured cortical neurons.  
A, FLAG-tagged CHT was isolated from SY5Y-CHT or SH-SY5Y cells stably 
expressing empty vector that had been transiently transfected with either the APPwt or 
APPSwe plasmids using anti-FLAG M2 affinity resin. Proteins were solubilized, separated 
by SDS-PAGE and transferred to PVDF membranes. Membranes were probed with anti-
APP c-terminal and anti-CHT antibodies (top 2 panels). Representative immunoblots 
show total APP, FLAG-CHT and actin proteins in total cell lysates (bottom 3 panels). 
Lysates prepared from SH-SY5Y cells not expressing CHT protein (vector) were used as 
a negative control (left 3 lanes). The immunoblots shown are representative of data 
obtained from 5 independent experiments. B, APP was isolated from SY5Y-CHT or SH-
SY5Y cells stably expressing empty vector that had been transiently transfected with 
either the APPwt or APPSwe plasmids using Protein-G Sepharose. Representative 
immunoblots show total APP, FLAG-CHT and actin proteins in total cell lysates (bottom 
3 panels). The top two panels illustrate APP proteins recovered on protein G Sepharose 
probed with anti-CHT antibody and anti-APP antibody. The immunoblots shown are 
representative of data obtained from 3 independent experiments. C, Analysis of the 
interacting APP immunobands in A by densitometry revealed that significantly less 
APPSwe interacts with CHT than does APPwt (*p < 0.05). Data were analysed by unpaired 
Student’s t-test and are expressed as the mean ± SEM of 5 independent experiments. D, 
Analysis of the interacting CHT immunobands in this Figure B by densitometry revealed 
that significantly less CHT interacts with APPSwe than does APPwt (*p < 0.05). Data were 
analysed by unpaired Student’s t-test and are expressed as the mean ± SEM of 3 
independent experiments.   
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4.3.2 In-situ proximity ligation assay (PLA) detection of the 
interaction of CHT with APPwt and APPSwe 
The FLAG pull-down assay and co-immunoprecipitation experiments shown in Figure 4-
1 allowed me to observe stable protein interactions between either CHT and APPwt or 
CHT and APPSwe, but they do not reveal more transient interactions or the distribution of 
the interacting proteins within individual cells. To address this, and to confirm my 
findings above, I used in situ PLA to examine protein-protein proximity between either 
CHT and APPwt or CHT and APPSwe in formalin-fixed SY5Y-CHT cells.  
Figure 4-2A shows representative confocal images of SY5Y-CHT cells transiently 
expressing either APPwt (top panel) or APPSwe (lower panel). The interacting protein 
complexes are visualized as bright fluorescent red spots and the cell nuclei are visualized 
in blue. The numbers of discrete spots per cell were quantified and enumerated using 
Imaris Software version 7.7.0, and are shown in white in Figure 4-2A, far right panels. 
Interestingly, as shown in Figure 4-2A, I found that interacting CHT and APPwt protein 
complexes appear to be distributed throughout both the cell body and neuritic projections, 
whereas CHT and APPSwe appear to interact primarily within the cell body. Furthermore, 
and consistent with the results of my anti-FLAG affinity pull-down assay and co-
immunoprecipitation experiments, quantification of the number of spots per cell revealed 
a significantly lower number of interacting CHT and APPSwe protein complexes in cells 
expressing APPSwe (69 ± 5 puncta per cell) compared to interacting CHT and APPwt 
protein complexes in cells expressing APPwt (108 ± 8 puncta per cell) (p<0.05) (Figure 
2B). In some images, a small number of interacting endogenous APP and CHT punctate 
spots were present in surrounding untransfected cells and these were subtracted from the 
final number of spots counted per image. No bright fluorescent red spots were found to 
be present in negative control cells where primary antibodies were omitted, and cells 
labeled with secondary probes alone (data not shown). To confirm that this observation 
was not related to differences in primary antibody immunostaining due to differences in 
APP or CHT protein expression, SY5Y-CHT cells transiently-expressing  
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Figure 4-2 
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Figure 4-2 In-situ proximity ligation assay demonstrating the greater interaction of 
CHT with APPwt than with APPSwe.  
A, Confocal microscopy was used to image the interaction of APPwt (top panel) or 
APPSwe (lower panel) with CHT proteins. SH-SY5Y cells stably expressing CHT were 
transiently transfected with either APPwt or APPSwe, then labeled with primary antibodies 
directed against CHT (rabbit anti-CHT) or APP (mouse anti-APP 6E10). The binding of 
the probes (oligonucleotide-linked secondary antibodies) to CHT and APP proteins in 
close proximity (~30-40 nm) allowed the hybridization of the DNA strands and ligation 
into a circular DNA molecule. This DNA circle was then amplified using rolling circle 
amplification and detected by the hybridization of fluorescently-labeled oligonucleotides.  
The signal was imaged using confocal microscopy and Imaris Software was used to 
quantify the number of interacting proteins shown as white spots (far right panels). The 
interacting protein complexes are visualized as bright fluorescent red spots and the cell 
nuclei are visualized in blue. Confocal images are representative of 3 independent 
experiments. B, This histogram reports the quantification of the interacting protein 
complexes (white spots) per cell. Significantly fewer white spots per cell were present in 
cells expressing APPSwe than in cells expressing APPwt. Data are expressed as the mean ± 
SEM for a minimum of 25 cells per transfection group from 3 independent experiments, 
and were analysed using a repeated-measures one-way ANOVA with Tukey’s post hoc 
multiple comparisons test (*p < 0.05). C, Confocal images show the distribution of 
AlexaFluor 555-labeled APP (red) and AlexaFluor 488-labeled CHT (green) in SY5Y-
CHT cells transiently transfected with either APPwt (top panel) or APPSwe (bottom panel). 
The colocalization of CHT and APP can be seen as yellow in the Overlay panels.  
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either APPwt or APPSwe were formalin-fixed and labeled with primary antibodies 
recognizing either APP or CHT following the PLA experimental protocol, and then 
incubated with AlexaFluor-labeled secondary antibodies. Representative confocal images 
of SY5Y-CHT cells show similar immunostaining for APP (red) and CHT (green) 
between cells expressing either APPwt or APPSwe (Figure 4-2C). 
4.3.3 BACE1 inhibition does not alter the preferential interaction 
between CHT and APPwt versus to APPSwe 
The Swedish mutation dramatically accelerates the β-cleavage of APP by BACE1 and 
thus increases the generation of Aβ (17, 18). To determine if my observation that CHT 
interacts less with APPSwe than it does with APPwt is related to differences in the β-
cleavage rate of APPwt and APPSwe, I evaluated the interaction of either CHT with APPwt, 
or CHT with APPSwe in the presence or absence of BACE1 inhibitor IV. 
To test this, I used SY5Y-CHT cells stably expressing FLAG-tagged CHT protein. Cells 
were transiently transfected with either empty vector or APPwt or APPSwe plasmid DNA. 
Immediately following transfection, cells were treated with vehicle or BACE1 inhibitor 
IV and allowed to express for 24 h. FLAG-CHT and interacting proteins were recovered 
from cell lysates using anti-FLAG affinity resin. Figure 4-3A shows a representative 
immunoblot that was probed for CHT using anti-CHT antibody or for interacting APP 
proteins using anti-APP C-terminal antibody. These experiments showed that BACE1 
inhibition did not alter the relative difference between the interaction of CHT with APPwt 
compared to that with APPSwe. Thus, quantification of the intensity of the interacting APP 
protein bands (Figure 4-3A, top panel) by densitometry reveals a greater level of 
interaction of APPwt with FLAG-CHT when compared to that of APPSwe with FLAG-
CHT in SY5Y-CHT cells, regardless of whether the cells were treated with vehicle or 
BACE1 inhibitor IV (Figure 4-3B). The APP protein bands were normalised to the 
amount of FLAG-CHT recovered on the anti-FLAG affinity resin. Inhibition of BACE1 
activity was confirmed by the observation that the steady-state levels of both total and 
interacting full-length APP protein were greater, and the level of the βCTF was lower in 
cells treated with BACE1 inhibitor IV compared to vehicle-treated control cells (Figure  
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Figure 4-3 The proportion of CHT protein interacting with APPwt versus CHT 
interacting with APPSwe is the same in cells treated with vehicle or BACE1 inhibitor 
IV.  
A, FLAG-tagged CHT was isolated from SY5Y-CHT or SY5Y cells stably expressing 
empty vector that had been transiently transfected with either the APPwt  or APPSwe 
plasmids. Cells that were treated with vehicle (DMSO) were used as a negative control 
(left 3 lanes) for comparison with cells that were treated for 24 h with 25 µM BACE 
inhibitor IV (right 3 lanes). Representative immunoblots show total full-length APP, 
FLAG-CHT and c-terminal APP protein fragments in total cell lysates (bottom 3 panels). 
The top two panels illustrate FLAG-CHT proteins recovered on anti-FLAG affinity resin 
probed with anti-APP antibody and anti-CHT antibody. The immunoblots shown are 
representative of data obtained from 6 independent experiments. B, Analysis of the 
interacting APP immunobands (top panel) by densitometry revealed that less APPSwe 
interacts with CHT than does APPwt, regardless of whether cells were treated with vehicle 
or BACE1 inhibitor IV. Data are expressed as the mean ± SEM of 6 independent 
experiments, and were analysed using a repeated-measures one-way ANOVA with 
Tukey’s post hoc multiple comparisons test (*p < 0.05). 
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4-3A, lower panels). The expression of CHT was comparable in cells treated with either 
vehicle or BACE1 inhibitor IV.  
4.3.4 CHT cell surface levels and choline uptake activity are 
decreased by expression of APPwt or APPSwe 
To compare the effect of the interaction of CHT with either APPwt or APPSwe on CHT 
function in SY5Y-CHT cells, I assessed high-affinity choline uptake activity and CHT 
cell surface levels in SY5Y-CHT cells transiently expressing either APPwt or APPSwe by 
performing 
3
[H]choline uptake assay and cell surface protein biotinylation experiments, 
respectively. In the biotinylation experiments, SY5Y-CHT cells were transiently 
transfected with either vector or the APPwt or APPSwe plasmid and allowed to express for 
24 h. Plasma membrane proteins were then biotinylated using membrane impermeable 
sulfo-NHS-biotin at 4°C to ensure that labeled CHT proteins did not undergo 
endocytosis. Representative immunoblots in Figure 4-4A show the levels of cell surface 
(biotinylated) CHT protein and APP protein, and the amount of total CHT and APP 
protein. Total CHT protein levels are equal between cells expressing either vector, or 
APPwt or APPSwe, and total APP levels are equal between cells expressing APPwt or 
APPSwe, and greater than cells expressing vector. Analysis of cell surface (biotinylated) 
CHT and APP protein immunoblots reveals that CHT cell surface levels were 
significantly reduced by approximately 30% in SY5Y-CHT cells expressing either APPwt 
or APPSwe when compared to vector-expressing control cells (Figure 4-4B) (p < 0.05). 
Moreover, the APPSwe protein cell surface levels are approximately 50% lower in SY5Y-
CHT cells expressing APPSwe when compared to the APPwt protein cell surface levels in 
cells expressing APPwt (Figure 4-4C) (p < 0.05).    
CHT proteins are active at the cell surface, where they mediate the transport of choline 
into cholinergic nerve terminals. Since the expression of APPwt or APPSwe significantly 
reduced the number of CHT proteins at the cell surface, I predicted that the expression of 
either APPwt or APPSwe would inhibit the high-affinity choline uptake activity of CHT. To 
test this prediction, we measured 
3
[H]-choline uptake activity in SY5Y-CHT cells 
expressing different amounts of either empty vector, or APPwt or APPSwe plasmid DNA.  
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Figure 4-4 
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Figure 4-4 Both [
3
H]-choline uptake activity and CHT plasma membrane levels are 
reduced in SY5Y-CHT cells transfected with either APPwt or APPSwe.  
A, Cells were washed and placed on ice, and then plasma membrane proteins were 
biotinylated. Biotinylated proteins were captured using NeutrAvidin agarose, then 
proteins were solubilized and separated by SDS-PAGE. PVDF membranes were 
processed by immunoblotting with antibodies recognizing APP and CHT. Representative 
immunoblots show steady-state APP and FLAG-CHT protein levels in total cell lysates 
(2 lower panels). The top two panels illustrate cell surface (biotinylated) FLAG-CHT and 
APP proteins. The immunoblots shown are representative of data obtained from 4 
independent experiments. B, Analysis of cell surface CHT protein bands by densitometry 
reveals that the level of CHT protein at the cell surface is significantly reduced in cells 
expressing either APPwt or APPSwe when compared to vector-expressing control cells. 
Data are expressed as the mean ± SEM of 5 independent experiments, and were analysed 
using a repeated-measures one-way ANOVA with Tukey’s post hoc multiple 
comparisons test (*p < 0.05). C, Analysis of cell surface APP protein bands by 
densitometry reveals that the level of APP at the cell surface is significantly less in cells 
expressing APPSwe when compared to APPwt. Data were analysed using a paired 
Student’s t-test with Tukey’s and are expressed as the mean ± SEM of 5 independent 
experiments (*p < 0.05) D, Choline uptake was assayed in SY5Y-CHT cells transfected 
with varying amounts of either vector, or APPwt or APPSwe plasmid DNA. CHT activity 
was significantly reduced in cells transfected with either 4 µg of APPwt or 4 µg of APPSwe 
plasmid DNA when compared to vector-transfected control cells. Data are expressed as 
the mean ± SEM of 5 independent experiments, and were analysed using a repeated-
measures one-way ANOVA with Tukey’s post hoc multiple comparisons test (*p < 0.05). 
E, Representative immunoblots show steady-state total APP, βCTF and FLAG-CHT 
protein levels in total cell lysates from a representative choline uptake experiment. 
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Figure 4-4D shows that high-affinity choline uptake was significantly reduced in cells 
expressing higher amounts of either the APPwt plasmid or the APPSwe plasmid, compared 
to vector-expressing control cells (p < 0.05). As shown in Figure 4-4E, the steady-state 
levels of full-length APPwt protein increased, corresponding to the increasing amount of 
APPwt plasmid DNA transfected. In contrast, the steady-state levels of full-length APPSwe 
protein did not show a corresponding increase related to the increasing amount of APPSwe 
plasmid DNA transfected. Importantly, however, in the APPSwe transected cells, there 
was an increase in the amount of the βCTF that corresponded to the increasing amount of 
APPSwe plasmid DNA transfected. The steady-state levels of total CHT protein were 
equal between all transfection groups. Thus, in cells expressing APPwt, CHT activity 
appears to be inhibited in a manner that parallels the increase in full-length APPwt protein 
levels, whereas in cells expressing APPSwe, the inhibition of CHT activity corresponds 
more to the appearance and levels of βCTF than to the levels of full-length APPSwe 
protein. 
4.3.5 CHT colocalizes with EEA1-positive early endosomes to a 
similar extent in APPwt or APPSwe expressing cells  
Both CHT and APPwt colocalize with early endosome marker Rab5, and co-expression of 
CHT and APPwt increases the rate at which CHT proteins undergo endocytosis (13). This 
could potentially account for the observation of a significant reduction of CHT proteins at 
the plasma membrane in cells expressing either APPwt or APPSwe when compared to 
vector-expressing control cells (Figure 4-4B). To evaluate whether the interaction of 
CHT with either APPwt, or APPSwe affects CHT colocalization with early endosomes, I 
used confocal microscopy to evaluate the subcellular distributions of CHT in conjunction 
with the early endosome marker EEA1 and either APPwt-YFP or APPSwe-YFP in SY5Y-
CHT cells. Images illustrating the distribution of CHT and EEA1 are provided for SY5Y-
CHT cells transiently expressing either APPwt-YFP or APPSwe-YFP in Figures 4-5A and 
4-5B, respectively. To assess the extent of colocalization between either APPwt-YFP or 
APPSwe-YFP, and CHT and EEA1, I used a quantitative approach where a threshold 
fluorescence intensity is set that filters the brightest 2% of pixels of CHT (blue channel) 
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that also fall within the brightest 2% of pixels of either APPwt-YFP or APPSwe-YFP 
(green channel) or EEA1 (red channel). In separate analyses, I also evaluated the 
brightest 2% pixels of either APPwt-YFP or APPSwe-YFP that fall within the brightest 2% 
of pixels of EEA1, and the brightest 2% of pixels of EEA1 with the colocalized pixels of 
either APPwt-YFP and CHT or APPSwe-YFP and CHT. The colocalized pixels are 
identified in a separate colocalization channel and shown as white in the lower overlay 
panels of Figures 4-5A and 4-5B.  
As documented in Figure 4-5C, analysis of the quantified pixels revealed that 45±1.6% of 
CHT colocalized with APPwt-YFP and 40±1.6% of CHT colocalized with APPwt-YFP. 
The percentage colocalization of APPwt-YFP with EEA1 was significantly greater than 
the percentage colocalization of APPSwe-YFP with EEA1 (48±2.1% and 36±1.8% 
colocalization, respectively), which is consistent with the model that rapid cleavage of 
APPSwe-YFP within the secretory pathway results in a smaller population available at the 
cell surface for endocytosis to early endosomes. Also in these experiments, the 
percentage of colocalized pixels of APPwt-YFP and CHT with EEA1 was significantly 
greater than the percentage colocalization of APPSwe-YFP and CHT with EEA1 
(60±1.9% and 48±2.1% colocalization, respectively) (Figure 4-5C) (p < 0.05). Finally, I 
determined the effect of transiently expressing either APPwt-YFP or APPSwe-YFP in 
SY5Y-CHT cells on the localization of CHT to early endosomes. To accomplish this, I 
compared the colocalization of CHT with EEA1 in cells transiently-expressing either 
APPwt-YFP or APPSwe-YFP to cells that were untransfected in the same culture dish. 
Importantly, there were no statistically significant differences in the percentage of 
colocalization of CHT with EEA1 found in cells expressing either APPwt-YFP or APPSwe-
YFP (34±1.3% and 33±1.2% colocalization, respectively). However, both of these values 
were significantly greater than the percentage colocalization found for CHT with EEA1 
in untransfected cells in culture plates that were transfected with either APPwt-YFP or 
APPSwe-YFP (24±1.7% and 24±1.3% colocalization, respectively) (p < 0.05) (Figure 4-
5D).  
 
 155 
 
 
 
 
Figure 4-5 
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Figure 4-5 Colocalization of CHT with EEA1 is increased in SY5Y-CHT cells 
expressing either APPwt or APPSwe.  
Panel A, Confocal images show the distribution of AlexaFluor 647-labeled CHT (blue), 
AlexaFluor 555-labeled EEA1 (red) and APPwt-YFP (green). Colocalized pixels were 
identified in the colocalization channel and are shown as white in the lower overlay 
panels. Scale bar, 5 µM. Panel B. Confocal images show the distribution of AlexaFluor 
647-labeled CHT (blue), AlexaFluor 555-labeled EEA1 (red) and APPSwe-YFP (green). 
Colocalized pixels were identified in the colocalization channel and are shown as white 
in the lower overlay panels. Scale bar, 5 µM.  C, CHT and APPwt-YFP, CHT and 
APPSwe-YFP, APPwt-YFP and EEA1, and APPSwe-YFP and EEA1 pixels that were 
determined to be colocalized in the colocalization channel were quantified using Imaris 
software. Data are expressed as the mean ± SEM for a minimum of 25 cells per 
transfection group from 4 independent experiments, and were analysed by one-way 
ANOVA followed by Tukey’s post-test (*p < 0.05). D, CHT and EEA1 pixels that were 
determined to be colocalized in cells expressing either APPwt-YFP or APPSwe-YFP or 
in untransfected control cells were quantified using Imaris software. Data are expressed 
as the mean ± SEM for a minimum of 25 cells per transfection group from 4 independent 
experiments, and were analysed by one-way ANOVA followed by Tukey’s post-test and 
(*p < 0.05). 
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4.3.6 BACE1 inhibition reduces Aβ generation and increases CHT 
protein cell surface levels in SY5Y-CHT cells expressing 
APPSwe 
A critical finding in the present study indicates that CHT proteins interact significantly 
less with APPSwe than with APPwt. Importantly, however, the expression of either APPwt 
or APPSwe in SY5Y-CHT cells increases CHT colocalization to early endosomes to a 
similar extent, and significantly decreases both CHT cell surface levels and CHT activity. 
Since APPSwe interacts much less with CHT than does APPwt, I next investigated the 
mechanism by which APPSwe mediates changes to CHT function. Our findings above 
show that CHT activity is inhibited in a manner that is dependent on the level of full-
length APPwt protein, whereas in cells expressing APPSwe, inhibition of CHT activity 
corresponds more to the processing of APP as shown by the increased production of the 
βCTF. Thus, I hypothesized that decreases in the activity and cell surface levels of CHT 
in SY5Y-CHT cells expressing APPSwe are related to the increased generation of βCTF or 
Aβ in these cells as a result of enhanced BACE1 processing of APPSwe compared to 
APPwt. 
To test this hypothesis, I measured CHT protein cell surface levels in SY5Y-CHT cells 
that transiently transfected to express either vector, APPwt or APPSwe and treated with 
either vehicle or BACE1 inhibitor IV for 24 h. Plasma membrane proteins were then 
biotinylated using membrane impermeable sulfo-NHS-biotin at 4°C. Representative 
immunoblots in Figure 4-6A show the levels of cell surface (biotinylated) CHT and APP 
proteins (top two panels), and the steady-state amount of total CHT, full-length APP, 
αCTF and βCTF proteins (bottom three panels). Similar to findings above (Figure 4-
4A,B), analysis of the cell surface (biotinylated) CHT and APP protein immunoblots 
reveals that in vehicle-treated cells, CHT cell surface levels are reduced by approximately 
30% in SY5Y-CHT cells expressing either APPwt or APPSwe when compared to vector-
expressing control cells (Figure 4-6A top panel, 4-6B white bars). Moreover, the cell 
surface levels of APPSwe are approximately 50% lower when compared to that of APPwt 
(Figure 4-6A second panel, 4-6C white bars). I next compared the effects of vehicle or 
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BACE1 inhibitor IV treatment on CHT cell surface levels in groups of cells expressing 
either vector, APPwt or APPSwe. No significant differences in CHT cell surface expression 
are found between the vehicle or BACE1 inhibitor IV treated groups of cells expressing 
either vector or APPwt. Interestingly however, CHT cell surface expression is 
significantly greater in APPSwe-expressing cells that were treated with BACE1 inhibitor 
IV when compared to the APPSwe-expressing cells treated with vehicle (Figure 4-6A top 
panel, Figure 4-6B, p < 0.05). Moreover, the APPSwe protein cell surface levels are 
significantly higher in BACE1 inhibitor IV-treated SY5Y-CHT cells expressing APPSwe 
compared to that observed in vehicle-treated SY5Y-CHT cells expressing APPSwe (Figure 
4-6A second panel, Figure 4-6C, p < 0.05). No significant differences in APPwt cell 
surface protein expression level are observed between vehicle or BACE1 inhibitor IV-
treated SY5Y-CHT cells expressing APPwt. Finally, I measured the amount of Aβ1-42 
secreted into the culture medium by ELISA of SY5Y-CHT cells treated with vehicle or 
BACE1 inhibitor IV transiently expressing either empty vector, APPwt or APPSwe plasmid 
DNA for 24 h. As predicted, culture medium collected from vehicle-treated SY5Y-CHT 
cells expressing APPSwe contains a significantly greater amount of Aβ1-42 than that 
collected from vehicle-treated SY5Y-CHT cells expressing either APPwt or empty vector 
(Figure 4-6D white bars, p < 0.01). Importantly, BACE1 inhibition significantly lowers 
the amount of Aβ1-42 in culture medium collected from cells expressing APPSwe when 
compared to that collected from vehicle-treated APPSwe-expressing cells (p < 0.01)  
(Figure 4-6D). 
Also shown in Figure 4-6A (middle panel), the total CHT protein levels are equal 
between the vehicle and BACE1 inhibitor IV-treated cells expressing either empty vector, 
APPwt or APPSwe. As anticipated, the steady-state levels of total full-length APP protein 
are increased and the level of the βCTF is lower in cells treated with BACE1 inhibitor IV 
when compared to vehicle-treated cells (Figure 4-6A, lower panels).     
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Figure 4-6 BACE1 inhibition reduces Aβ secretion and increases CHT cell surface 
levels in SY5Y-CHT cells expressing APPSwe.  
A, Cells were washed and placed on ice, and then plasma membrane proteins were 
biotinylated. Biotinylated proteins were captured using NeutrAvidin agarose, then 
proteins were solubilized and separated by SDS-PAGE. PVDF membranes were 
processed by immunoblotting with antibodies recognizing APP and CHT. This 
representative immunoblot shows cell surface (biotinylated) FLAG-CHT and APP 
proteins (top two panels). Steady-state CHT, APP and βCTF protein levels in total cell 
lysates are illustrated in the lower 3 panels. The immunoblots shown are representative of 
data obtained from 6 independent experiments. B, Analysis of cell surface CHT protein 
bands by densitometry reveals that the level of CHT protein at the cell surface is 
significantly increased in cells expressing APPSwe when compared to vehicle-treated 
APPSwe-expressing control cells. Data are expressed as the mean ± SEM of 5 independent 
experiments, and were analysed using a repeated-measures one-way ANOVA with 
Tukey’s post hoc multiple comparisons test (*p < 0.05). C, Analysis of cell surface APP 
protein bands by densitometry reveals that the level of APPSwe at the cell surface is 
significantly greater than that found in vehicle-treated APPSwe expressing control cells. 
Data were analysed using a two-way ANOVA with Bonferonnis’s post-test and are 
expressed as the mean ± SEM of 5 independent experiments (*p < 0.05). D, Conditioned 
medium was collected from these cell groups, then the Aβ1-42 levels were measured by 
ELISA and quantified. Vehicle-treated APPSwe-expressing cells produced significantly 
higher levels of Aβ1-42 than did BACE1 inhibitor IV –treated APPSwe-expressing cells. 
Data are expressed as the mean ± SEM of 5 independent experiments, and were analysed 
using a repeated measures two-way ANOVA with Bonferonni’s post hoc multiple 
comparisons test (*p < 0.01) 
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4.3.7 Choline uptake activity is reduced by conditioned medium 
from APPSwe-expressing SY5Y-CHT cells  
My previous experiment shows that inhibition of BACE1 activity significantly reduces 
the amount of Aβ present in the culture medium of APPSwe-expressing cells, and 
significantly increases CHT cell surface levels in these cells when compared to that found 
in vehicle-treated APPSwe-expressing SY5Y-CHT cells. Since Aβ can inhibit high-affinity 
choline uptake (4), I next examined whether the decrease in CHT activity in SY5Y-CHT 
cells expressing APPSwe is related to the increased amount Aβ released into the culture 
medium of these cells. To accomplish this, I collected culture medium conditioned for 24 
h by SY5Y-CHT cells transiently expressing empty vector, APPwt or APPSwe plasmid 
DNA. Using an Aβ1-42 ELISA, I found that the amount of Aβ1-42 secreted into the 
medium by APPSwe-expressing cells is significantly greater than that from cells 
expressing either APPwt or empty vector (p < 0.05) (Figure 4-7A). The conditioned 
medium was added to SY5Y-CHT cells stably-expressing CHT but not transfected with 
other plasmids for 30 min, 4 h or 24 h, then [
3
H]choline uptake activity was measured. As 
shown in Figure 4-7B, cells treated with conditioned culture medium collected from 
APPSwe-expressing SY5Y-CHT cells for 24 h have a statistically-significant (32%) 
decrease in choline uptake activity when compared to cells treated with conditioned 
culture medium collected from either vector or APPwt -expressing cells. It is interesting to 
note that this corresponds to the 35% decrease in choline uptake activity that I observed 
in SY5Y-CHT cells at 24 h after transient transfection with APPSwe (Figure 4-4D). 
4.4 Discussion 
The subcellular trafficking of CHT maintains a steady level of this solute transporter at 
the cell surface, thereby regulating choline uptake activity and maintaining cholinergic 
neurotransmission. Thus, any protein-protein interaction that regulates CHT trafficking 
will have a direct impact on choline uptake activity and ACh synthesis. Previous studies  
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Figure 4-7 Treatment of SY5Y-CHT cells with conditioned medium containing Aβ 
from cells expressing APPSwe inhibits choline uptake activity.  
A, SY5Y-CHT cells were transfected with either vector, or APPwt or APPSwe plasmid 
DNA and allowed to express for 24 h. APPSwe-expressing cells produced significantly 
higher levels of Aβ1-42 than did either vector or APPwt-expressing cells. Data are 
expressed as the mean ± SEM of 5 independent experiments, and were analysed using a 
repeated-measures one-way ANOVA with Tukey’s post hoc multiple comparisons test 
(*p < 0.05). B, SY5Y-CHT cells were treated with conditioned medium collected from 
SY5Y-CHT cells transiently expressing either empty vector, or APPwt or APPSwe, 24 h, 
then added to untransfected SY5Y-CHT for either 30 min, 4 h or 24 h prior to 
[
3
H]choline uptake assays being performed. CHT activity was significantly reduced only 
in cells treated for 24 h with conditioned medium collected from SY5Y-CHT cells 
expressing APPSwe. Data are expressed as the mean ± SEM of 5 independent experiments, 
and were analysed using a repeated-measures one-way ANOVA with Tukey’s post hoc 
multiple comparisons test (*p < 0.05). 
 163 
 
identified APP as a binding partner for CHT involved in regulating CHT endocytosis and 
subcellular localization (13). Because APP containing the Swedish mutation is cleaved 
within the secretory pathway (19, 20) and is trafficked differently from the cell surface 
through the endosomal pathway as compared to APPwt, (7) the purpose of my study was 
to investigate further how APP regulates CHT trafficking and activity and whether this is 
altered by the Swedish mutation. 
Through experiments that used co-immunoprecipitation and proximity ligation assays, I 
made the novel observation that CHT associates significantly less with APPSwe than with 
APPwt in SY5Y-CHT cells and in cultured mouse brain cortical neurons, and that this was 
not related to the enhanced BACE1-mediated cleavage of APPSwe. Interestingly, the 
expression of either APPwt or APPSwe decreased CHT cell surface levels and choline 
uptake activity to the same extent. Moreover, the proportion of total cellular CHT 
proteins that colocalize with the early endosomal marker EEA1 was increased to a similar 
level in cells expressing either APPwt-YFP or APPSwe-YFP when compared to 
untransfected control cells. In these experiments, SY5Y-CHT cells expressing APPSwe 
secreted significantly more Aβ1-42 into the culture medium than did cells expressing 
APPwt, and lowering the production of Aβ by BACE1 inhibition significantly increased 
CHT cell surface level in cells expressing APPSwe, but not in cells expressing either 
vector or APPwt, when compared to vehicle-treated cells. Finally, I found that treating 
untransfected SY5Y-CHT cells with the culture medium collected from SY5Y-CHT cells 
transiently expressing APPSwe significantly inhibited choline uptake activity.  
My co-immunoprecipitation data reveal that CHT interacts significantly less with APPSwe 
than it does with APPwt in both SH-SY5Y cells and cultured cortical neurons from mouse 
brain. One explanation for this finding is that the subcellular trafficking pathway and 
processing location of APPSwe (in the TGN), compared to APPwt (in endosomes), 
substantially reduces the potential for APPSwe to interact with CHT. Differences in the 
regulation of APPwt and APPSwe as a result of their subcellular processing locations have 
been observed. For example, the interaction of the cellular prion protein with BACE1 
retains BACE1 in the TGN and therefore inhibits its activity towards APPwt, but not 
towards APPSwe, which is explained by the differential subcellular sites of action of 
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BACE1 on APPwt, compared with APPSwe (21). Therefore, it is possible that APPSwe and 
APPwt in turn can regulate other cellular proteins differently as a result of their distinct 
subcellular processing locations. APPwt is proposed to interact with CHT and facilitate its 
endocytosis into Rab5-positive early endosomes (13). Retention and processing of 
APPSwe within the TGN could result in a smaller pool of APPSwe present at the cell 
surface and in endosomal compartments available to interact with CHT. My PLA 
experiments provide support for this hypothesis showing that interacting CHT and APPwt 
protein complexes were distributed throughout both the cell body and neuritic 
projections, whereas CHT and APPSwe appeared to interact primarily within the cell body. 
A second explanation for the reduced interaction of CHT with APPSwe compared to 
APPwt is that the APP and CHT association involves the amino acid residues K595 or 
M596 that are mutated in APPSwe. While previous studies showed that the carboxyl-
terminal domain of APP is sufficient to immunoprecipitate CHT (13), protein-protein 
interactions depend both on the protein sequence and conformation, so this possibility 
cannot be completely ruled out. Lastly, the differential interaction between CHT and 
APPSwe compared to APPwt appears to be unique to CHT, as the Swedish mutation does 
not appear to alter the ability of APP to mediate protein trafficking in a general manner. 
For example, APPwt interacts with assembled NMDA receptors and enhances their cell 
surface trafficking (22, 23) and this is not altered by either the London or Swedish APP 
mutations (23).  
Because CHT associates significantly less with APPSwe than with APPwt, I predicted that 
APPSwe and APPwt over-expression would have different effects on CHT function and 
localization. Unexpectedly, CHT cell surface levels were significantly reduced to similar 
extents in SY5Y-CHT cells expressing either APPwt or APPSwe when compared to vector-
expressing control cells, and this corresponds to a significant reduction in high-affinity 
choline uptake in cells expressing APPwt as well as in cells expressing APPSwe. Consistent 
with the findings of Yamakawa et al. (2010), I found significantly less APPSwe than 
APPwt proteins at the cell surface, which could be explained by the greater level of 
processing of APPSwe within the secretory pathway. Interestingly, in cells expressing 
APPwt, there was a reciprocal relationship between CHT activity and APPwt levels with 
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the reduction in CHT activity being greater as the APPwt protein level increased. In 
contrast, the reduction of CHT activity in cells expressing APPSwe was related more to the 
increased production and level of βCTF. Finally, CHT localization to early endosomes 
was significantly increased in cells expressing either APPwt-YFP or APPSwe-YFP when 
compared to untransfected control cells, suggesting that the internalization rate of CHT is 
increased similarly in cells expressing either APPwt or APPSwe. The increased movement 
of CHT from the plasma membrane to early endosomes could represent the mechanism 
by which CHT activity and cell surface expression was reduced in cells expressing either 
APPwt or APPSwe. My results indicate that APPwt regulates CHT cell surface expression 
and activity through a direct interaction with the transporter. Since APPSwe interacts much 
less with CHT than it does with APPwt, but expression of either APPwt or APPSwe causes a 
similar inhibition of CHT function, I investigated the hypothesis that the decrease in CHT 
activity and cell surface expression in SY5Y-CHT cells expressing APPSwe is related to 
the increased release of Aβ from these cells. Support for this hypothesis comes from 
previous observations that Aβ can interact directly with CHT (26) and impairs high-
affinity choline uptake (11), and from my finding that SY5Y-CHT cells expressing 
APPSwe secrete significantly more Aβ1-42 into culture media than do cells expressing 
APPwt. Furthermore, BACE1 inhibition significantly reduced the amount of Aβ in culture 
medium of cells expressing APPSwe and significantly increased CHT cell surface level in 
these cells, but not in cells expressing either vector or APPwt, compared to vehicle-treated 
cells. Finally, my data show that treating untransfected SY5Y-CHT cells with the culture 
medium collected from SY5Y-CHT cells transiently expressing APPSwe significantly 
inhibited choline uptake activity. Therefore, I propose that the inhibition to CHT function 
observed in APPSwe expressing cells is due to the increased generation of Aβ in these 
cells, and not a result of the interaction between CHT and APPSwe itself. In addition to 
APP itself, APP metabolites including Aβ, βCTF, sAPPβ and AICD also been shown to 
exert physiological effects. Since BACE1 inhibition not only blocks the production of 
Aβ, but also inhibits the generation of sAPPβ and βCTF, we cannot rule out the 
possibility that these fragments may be mediating some of the CHT impairment in 
APPSwe-expressing SY5Y-CHT cells.  
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Several previous studies report cognitive impairment beginning in the early stages before 
Aβ plaque development in the Tg2576 mouse model over-expressing human APP695 with 
the Swedish mutation compared to non-transgenic controls (27-29). These early studies 
were not able to determine that the high concentrations of Aβ were responsible for the 
memory and learning deficits, and not the over-expression of APP (30); however, this 
was clarified by a study showing that reduction of Aβ levels through genetic inactivation 
of BACE1 in Tg2576 mice prevented memory deficits and hippocampal neuronal 
abnormalities (31). My data regarding APPSwe regulation of CHT activity offer a 
mechanistic explanation for this observation and highlight the importance of future 
studies comparing mice over-expressing wild-type human APP695 with Tg2576 mice. In 
conclusion, my results support the idea that APPwt plays a physiological role in regulating 
the trafficking and activity of CHT through a direct protein-protein interaction. The 
Swedish mutation disrupts this interaction and appears to cause changes to CHT function 
through increased β-cleavage of APPSwe and subsequent Aβ production, as opposed to an 
association between CHT and APPSwe itself.   
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Chapter 5  
5 Summary of major findings, discussion of results and 
future directions3 
  
                                                 
3
 Parts of this work have been published and submitted in the following manuscripts: 
Cuddy LK, Winick-Ng W, Rylett RJ. Regulation of the high-affinity choline transporter activity and 
trafficking by its association with cholesterol-rich lipid rafts J Neurochem 4 November 2013 128 (5):725-
740 
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5.1 Summary of major findings  
5.1.1 Summary of major findings from experiments regarding the 
effect of reactive oxygen species ONOO- donor SIN-1 on 
CHT activity and subcellular trafficking (Chapter 2) 
1. The mutant L531A-CHT transporter, but not wild-type CHT, is resistant to 
SIN-1 effects. 
2. Expression of the DN proteins AP180C and dynamin-K44A expression 
block CHT endocytosis and attenuate CHT inhibition by SIN-1. 
3. In both vehicle and SIN-1-treated cells, CHT colocalizes with Rab5-
positive early endosomes, Rab7 and Rab9-positive late endosomes and 
Lamp1-positive lysosomes to a similar extent. 
4. Inhibition of the proteasome by lactacystin and MG-132 treatment 
attenuate SIN-1-mediated inhibition of choline uptake. 
5. SIN-1 treatment enhances CHT ubiquitination. 
5.1.2 Summary of major findings from experiments regarding the 
effect of cholesterol and lipid raft association on CHT activity 
and substrate binding (Chapter 3) 
1. CHT is partitioned between lipid raft and non-raft membrane 
compartments and tends to be concentrated in lipid rafts. 
2. CHT colocalizes with flotillin and cholera toxin, and to a lesser extent 
with EEA1. 
3. Choline uptake activity depends on membrane cholesterol levels. 
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4. Filipin and MβC cause a decrease in plasma membrane CHT protein 
levels from lipid rafts, but not non-raft areas, which is not related to an 
accelerated rate of CHT protein internalization. 
5. CHT contains putative cholesterol binding motifs in CHT that are 
conserved between rodent and human. 
5.1.3 Summary of major findings from experiments 
investigating whether CHT differentially interacts with 
APPwt versus APPSwe and how this affects CHT surface 
expression and activity (Chapter 4) 
1. CHT interacts significantly less with APPSwe than with APPwt in SH-SY5Y 
cells stably expressing the transporter and in primary cortical neurons. 
2. BACE1 inhibition increases the expression levels of both APPwt and 
APPSwe, and enhances both the interaction between CHT and APPwt and 
between CHT and APPSwe. 
3. APPwt or APPSwe expression significantly reduced both CHT cell surface 
levels and choline uptake activity. 
4. CHT colocalization with EEA1-positive early endosomes is increased in 
cells expressing either APPSwe-YFP or APPwt-YFP when compared to 
untransfected control cells.  
5. BACE1 inhibition significantly increases CHT cell surface levels in cells 
expressing APPSwe when compared to vehicle-treated control cells.  
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5.2 Discussion of results and future studies  
A wide range of neuron models were used in the experiments described in this thesis to 
investigate and validate the mechanisms by which CHT protein function is regulated. The 
majority of the studies carried out in this thesis were performed in monolayers of intact 
SH-SY5Y human neuroblastoma cells that stably-express FLAG-tagged rat CHT proteins 
as an experimental model. These cells were differentiated with all-trans retinoic acid to 
cause neurite outgrowth and enhance the cholinergic and neuronal phenotype of the cells. 
In several confocal imaging experiments, the FLAG-tagged amino terminus of CHT was 
labeled using Zenon Alexafluor-conjugated FLAG antibodies, which allowed us to track 
the internalization of CHT from the plasma membrane. Since cell type-dependent 
differences in the regulation of CHT trafficking have been observed (1), some studies 
performed in this thesis were repeated using different experimental models. In the 
investigations described in Chapter 4, transiently transfected cortical neurons cultured 
from embryonic mouse brain were used as an experimental model to verify the results 
from co-immunoprecipitation experiments carried out in the SH-SY5Y neuronal cell line. 
In the studies performed in Chapter 3, mouse brain synaptosomes were utilized as an 
experimental model to confirm the plasma membrane distribution of CHT between raft 
and non-raft membrane. While these models more closely replicate the endogenous 
environment of CHT proteins, mouse cortical neuron cultures have a low percentage of 
cholinergic neurons and a low transfection efficiency, which prevented the examination 
of either the trafficking or activity of the endogenous or transiently transfected CHT 
proteins. Synaptosomes are re-sealed synaptic nerve terminals that are created during the 
homogenization of brain tissue and isolated by centrifugation. These likely contain a 
higher density of CHT proteins than do cultures of primary cortical neurons since CHT 
proteins are found to be concentrated within axon terminals and neuronal processes (2-7). 
However, a potential caveat with the use of synaptosomes is that the synaptosomal 
membranes may not reseal properly during their isolation. Consequently, they may not be 
an ideal model for some experiments performed in the studies outlined in this thesis, and 
in this case cultured cells with intact plasma membranes were used in assays to measure 
the levels and internalization of cell surface proteins by biotinylation.  
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The experiments in Chapter 2 were designed to characterize the effect of the ONOO
-
 
donor SIN-1 on CHT activity and trafficking. The first observation that CHT is sensitive 
to ONOO
-
 was made by Guermonprez et al. (2001). These authors found that CHT 
activity was inhibited by ONOO
-
, but not H2O2, indicating that CHT displays selective 
sensitivity to ONOO
-
. Further work by Pinthong et al. (2008) found that ONOO
-
 inhibited 
choline uptake by reducing the level of cell surface CHT expression. Moreover, these 
authors found that ONOO
- 
increased the rate of CHT internalization from the plasma 
membrane, and that CHT inhibition occurred at concentrations of SIN-1 that did not 
disrupt cell membrane integrity or cause cell death. Taken together, the results of this 
previous work suggested that inhibition of CHT activity by SIN-1 is due to a change in 
CHT protein localization, as opposed to a change in the conformation of the protein due 
to nitration or oxidation. The goal of Chapter 2 of this thesis was to determine the route 
of CHT subcellular trafficking under SIN-1 treatment. The results of the initial 
experiments in Chapter 2, which examined [
3
H]HC-3 binding kinetics of CHT under 
SIN-1 treatment, and compared high-affinity choline uptake kinetics between cells stably 
expressing wild-type CHT or L531A-CHT, which is unable to undergo endocytosis, 
confirmed that SIN-1 inhibition is not due to a direct nitrosative or oxidative modification 
of CHT protein itself. To assess the route of CHT subcellular trafficking under SIN-1 
treatment, I used various different experimental approaches and found that SIN-1 did not 
alter CHT endocytosis through a clathrin and dynamin-dependent pathway, or the 
movement of CHT through early and late endosomes to lysosomes. Importantly, 
exposure of cells to SIN-1 resulted in CHT ubiquitination and blocking the proteasome 
restored choline uptake activity in SIN-1 treated cells. Figure 5-1 shows a general 
schematic of the results found in Chapter 2 in regard to CHT trafficking in a cholinergic 
nerve terminal under ONOO
-
 stress.  
The nitration of tyrosine residues is a well-characterized consequence of ONOO
-
 
treatment and increased 3-nitrotyrosine (3-NT) immunoreactivity is found in necropsy 
AD brain (10). Early studies found that inhibitors of protein nitration did not protect CHT 
activity from ONOO
-
 (8) and experiments carried out in our laboratory found no evidence 
of nitration of tyrosines in CHT (9). While increased 3-NT levels are the signature 
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Figure 5-1 Pathways of CHT subcellular trafficking in cells treated with ONOO
-
 
donor SIN-1. 
In vehicle and SIN-1 treated cells, CHT is internalized from the plasma membrane 
through a clathrin-dependent mechanism. Once internalized, CHT colocalizes with Rab-
5-positive early endosomes, and can be transported through Rab-7 and Rab-9 positive 
late endosomes to lysosomes for degradation. This subcellular trafficking pathway does 
not appear to be altered by SIN-1 treatment. My studies suggest that CHT undergoes 
polyubiquitination following SIN-1 treatment, and that this then can result in the 
subcellular trafficking of the transporter to the proteasome for degradation.  
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marker of ONOO
- 
-mediated damage in post-mortem AD brain, it can be expected that 
other direct modifications to proteins, including oxidation, or nitrosylation of amino acids 
(11), or indirect changes to protein function, for example, through the activation of 
phosphorylation pathways by ONOO
-
 (12-14) are occurring in the brain under 
pathological conditions. The production of ONOO
-
 depends on the availability of its 
precursors, O2 and NO, which are not normally produced in large quantities in the brain. 
However, under certain conditions associated with AD, such as tissue injury and 
inflammation, or a reduced antioxidant capacity, ONOO
-
 becomes a significant 
pathological risk. The ONOO
-
 treatment used in this study parallels physiological levels 
of ONOO
-
 produced in the brain under multiple disease conditions including AD, thus the 
observed alteration in CHT trafficking could occur in the cholinergic nerve terminal 
microenvironment in the brain.  
The results of experiments in Chapter 2 reveal that the loss of CHT activity in cells 
treated with ONOO
-
 is mediated by proteasomal degradation of the protein. ONOO
-
-
treatment also results in enhanced CHT ubiquitination. Although not tested, the 
internalization of modified or damaged CHT proteins into ONOO
-
-treated cells may 
result in either polyubiquitination, which promotes protein degradation, or 
monoubiquitination, which alters protein trafficking, as a measure of quality control 
within the cell. My results show the addition of approximately four ubiquitin molecules 
to CHT, which could indicate the presence of a short polyubiquitin chain. A very recent 
study by Hartnett et al. (2014) confirmed my observation that CHT undergoes 
polyubiquitination using tandem ubiquitin binding entities technology. These authors also 
found that CHT interacts with ubiquitin carboxyl-terminal hydrolase L1 (UCHL1), a 
deubiquitinating enzyme involved in the ubiquitin-proteasome system, and showed that 
UCHL1 knockdown increases CHT polyubiquitination and decreases CHT protein 
expression level. Interestingly, UCHL1 activity is altered (16, 17) and down-regulated 
(18) by its oxidation in the brains of patients with AD. Another recent study found that 
CHT interacts with the exogenous ubiquitin ligase Nedd4-2 causing a reduction its cell 
surface levels (19). Nedd4-2 has also been shown to cause the internalization of other 
membrane proteins, including the neurotransmitter transporter hDAT and the voltage-
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gated potassium channel (20, 21). ONOO
-
 inhibits hDAT function (22), suggesting the 
possibility that during pathological conditions ONOO
-
 regulates the production or activity 
of Nedd4-2, which in turn mediates the ubiquitination of membrane proteins altering 
protein degradation or subcellular trafficking. It is clear that the ubiquitin-proteasome 
system is disrupted in AD based on the observation that hallmark features of AD, for 
example the deposition of amyloid fibrils and the formation of tau helices, are the product 
of ubiquitin-mediated protein defects (23). It is not understood how CHT is regulated by 
the ubiquitin-proteosome system, and how this is altered by pathological conditions 
associated with AD. Future studies investigating an association between CHT and 
Nedd4-2 or UCHL1 could provide interesting and novel information regarding the 
mechanisms involved in CHT regulation during AD, in particular under conditions of 
oxidative stress.  
In addition to oxidative stress, a second important modifiable risk factor for AD is high 
serum cholesterol level at midlife. Cholinergic neurons rely on cholesterol for synapse 
formation and membrane integrity, thus changes in cholesterol homeostasis in the brain 
could potentially lead to changes in the microenvironment of the cholinergic nerve 
terminal, leading to alterations in the function of CHT. Early reports regarding CHT 
regulation by cholesterol are limited and contradictory. One report shows that lowering 
cholesterol in rat brain synaptosomes reduced choline uptake activity (24), whereas 
another study found that membrane cholesterol depletion did alter choline uptake (25). 
The experiments proposed in Chapter 3 were focused on defining the mechanistic 
changes occurring to CHT in response to changes in membrane cholesterol levels. Here, I 
found that membrane cholesterol and lipid rafts serve as an important regulator of CHT 
trafficking and activity by retaining functional CHT proteins at the cell surface. 
In these experiments, I used a variety of drug treatments to manipulate membrane 
cholesterol levels with the goal of disrupting lipid rafts and specific cholesterol-protein 
interactions. While many studies have looked at the effect of statin drugs on the 
development and pathology of AD, I did not use statins to manipulate membrane 
cholesterol levels in the experiments performed in Chapter 3 due to their pleiotropic 
effects. The majority of cholesterol-independent, pleiotropic effects of statins come from 
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their ability to block the synthesis of critical isoprenoid intermediates. Isoprenylation is 
an important post-translational modification of the Ras superfamily of G-proteins, 
including Rab proteins (26). The inhibition of Rab GTPase isoprenylation by statin 
treatment causes these proteins to lose their normal function and leads to dysfunction in 
protein trafficking and cellular signalling (27). Importantly, Rab proteins facilitate the 
movement of CHT through endosomal and lysosomal compartments, and therefore statin 
treatment could have a compounding influence on CHT function through inhibition of 
both cholesterol and isoprenoid synthesis. Future studies assessing the individual effects 
of cholesterol and isoprenoids on CHT trafficking and activity could provide vital 
information about the underlying mechanisms involved in statin-mediated AD risk 
reduction.    
The results of experiments in Chapter 3 revealed that CHT association with lipid rafts is 
critical for its function. As depicted in Figure 5-2, lipid rafts could play a role in 
regulating the amount of CHT at the cell surface by altering its internalization rate and/or 
its recycling back to the cell surface. In this study, I found that CHT internalization was 
not altered by raft disruption, suggesting that decreased recycling of transporters to the 
cell surface could be responsible for the reduction in CHT plasma membrane levels and 
choline uptake activity following lipid raft disruption. Thus, the mechanism by which 
CHT is targeted to rafts is of particular importance. My results show that CHT has a 
conserved motif within TMD12 that could serve both as a cholesterol-binding motif and 
as a protein dimerization motif these data reveal the presence of a homo-oligomer of 
CHT protein within lipid raft fractions. However, it cannot be ruled out that other 
modifications to CHT protein may be responsible for its inclusion into lipid rafts. For 
example, protein-protein interactions or post-translational modifications of CHT, such as 
phosphorylation, could be involved in the targeting of CHT to raft areas of the plasma 
membrane. Previous work done in our lab found treatment of cells with the PKC 
activator PMA increases choline uptake activity by diminishing CHT endocytosis and 
increasing CHT recycling to the cell surface (28). A potential mechanism underlying this 
observation may be that specific residues, when phosphorylated, promote the retention of 
CHT at the plasma membrane. It is also possible that there is differential phosphorylation  
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Figure 5-2 CHT trafficking is regulated by its association with lipid rafts.   
The results of my experiments in Chapter 3 show that CHT association with lipid rafts is 
critical for its function. Lipid rafts could play a role in regulating the amount of CHT at 
the cell surface by altering its lateral movement at the plasma membrane, altering the 
transporters internalization either through clathrin-mediated endocytosis, or through 
clathrin-independent caveola. Lipid rafts found in endosomal or synaptic vesicle plasma 
membrane could alter the subcellular trafficking pathway of CHT. Lipid rafts may also 
play a role in altering the rate of CHT internalization and/or its recycling back to the cell 
surface. CHT internalization was not altered by raft disruption, suggesting that decreased 
recycling of transporters to the cell surface could be responsible for the reduction in CHT 
plasma membrane levels and choline uptake activity following lipid raft disruption.  
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of CHT proteins in raft and non-raft areas of the plasma membrane, with this potentially 
modulating its membrane retention and trafficking. This is the case for PKC-induced 
internalization of the DAT that, like CHT, is dynamin- and clathrin-dependent, but is 
independent of lipid rafts. DAT in rafts has a lower constitutive level of phosphorylation, 
but a higher level of PMA-induced phosphorylation when compared to non-raft DAT, 
indicating that rafts are preferential sites for PKC-mediated phosphorylation (29). 
The movement of CHT to lipid rafts could also be influenced by protein-protein 
interactions. One protein of interest is APP, which binds to CHT and plays a role in 
regulating its subcellular trafficking, as demonstrated by the results of experiments 
described in Chapter 4 of this thesis. APP is found in lipid rafts; however, it is not known 
whether APP and CHT interact in raft or non-raft membrane and what affect this has on 
the function of CHT. Amyloidogenic processing of APP by BACE1 occurs in lipid rafts 
(30), thus modulating the properties of rafts to reduce the association of APP or BACE1 
with these microdomains could reduce the production of Aβ and slow the progression of 
AD. In contrast to this, my observations suggest that altering raft properties to exclude 
CHT would reduce choline available for ACh synthesis and diminish cholinergic 
neurotransmission. Several lines of evidence suggest that the organization of lipid rafts is 
disrupted in AD brains (31) and a strong link between cholesterol and AD comes from 
the identification of the ε4 allele of APOE as the strongest genetic risk factor for the 
development of late-onset AD (32). Alterations in cholesterol homeostasis in the brain, as 
a result of hypercholesterolemia or the APOE genotype, could result in reduced 
membrane cholesterol levels in cholinergic neurons and cause the disruption of lipid 
rafts. Alternatively, increased cholesterol levels in the brain could result in the formation 
of lipid rafts, or reduce the fluidity of the plasma membrane, causing raft disruption 
and/or inhibition of lateral protein movement. It is unknown how altered cholesterol 
homeostasis, and lipid raft disorganization, affects the plasma membrane distribution and 
function of raft-associated proteins, such as CHT and APP, in the AD brain. Future 
studies should investigate whether APP and CHT interact in raft or non-raft membrane, 
how this is altered by cholesterol manipulation and the impact on CHT function and APP 
processing.  
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The goal of the experiments carried out in Chapter 4 was to further investigate how APP 
regulates CHT trafficking and activity, and to determine whether this interaction is 
altered by the Swedish mutation. In this study, several experiments were carried out in 
neural cells treated with either vehicle or a BACE1 inhibitor. BACE1 inhibition 
represents an important therapeutic strategy for lowering Aβ generation, and several 
BACE1 inhibitors are currently being tested in clinical trials for their efficacy and safety 
for use in individuals with AD. The experiments performed in Chapter 4 provide 
important mechanistic data regarding CHT and APP that suggest BACE1 inhibition may 
have beneficial effects that are not directly related to lowering Aβ generation in patients 
with AD. First, I found that BACE1 inhibition increased the cell surface levels of both 
APPwt and APPSwe. This could potentially increase the movement of APP through the 
non-amyloidogenic pathway and increase production of the sAPPα, which is thought to 
have neuroprotective properties. Second, I made the critical observation that, unlike the 
APPwt/Swe-mediated reduction in cell surface CHT levels observed in vehicle-treated cells, 
treatment of cells expressing either APPwt or APPSwe with a BACE1 inhibitor restores the 
cell surface levels of CHT protein either to (APPwt) or above (APPSwe) that found in 
vector-expressing cells. The mechanism underlying this observation was not investigated 
further in this study. BACE1 inhibition blocks the production of both Aβ and βCTF. I 
hypothesized that lowering Aβ concentration in the culture medium of cells expressing 
APPwt or APPSwe by BACE1 inhibition could be responsible for the preservation of CHT 
cell surface levels, particularly in cells expressing APPSwe that produce much more Aβ. 
However, it is possible my observations are due to the reduction of βCTF generation by 
inhibiting BACE1. While my study examined the interaction of CHT with full-length 
APP, the carboxyl-terminal domain of APP is sufficient to immunoprecipitate CHT (33). 
It is possible that the interaction of CHT with the βCTF alone, rather than with full-length 
APP, is required for the internalization of CHT. BACE1 inhibition would result in less 
βCTF available for interaction with CHT, thus reducing its endocytosis. Therefore, 
BACE1 inhibition could preserve the levels of CHT at the cell surface, thereby 
maintaining CHT activity and ACh production, and have a positive effect on cholinergic 
neurotransmission in patients with AD.  
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In these studies, I observed important differences in the regulation of CHT by APPwt and 
APPSwe. I found that CHT interacted significantly less with APPSwe than with APPwt, but 
caused a similar level of decrease in CHT activity and cell surface expression. The results 
of my study, and those of the study done by Wang et al. (2007), support the hypothesis 
that APPwt plays a physiological role in cholinergic neurons by facilitating CHT 
presynaptic localization and endocytosis through a direct interaction with the transporter, 
while APPSwe-mediated inhibition of CHT function could be caused by the susceptibility 
of the transporter to Aβ that is found in the extracellular environment. This suggests that 
independent therapeutic strategies for maintaining cholinergic neurotransmission could 
be designed for AD patients depending on whether they have sporadic AD or familial AD 
caused by the Swedish mutation. In the case of a patient in the early stages of sporadic 
AD, a therapeutic strategy targeted towards promoting the interaction between CHT and 
APPwt could maintain the normal trafficking and activity of CHT in cholinergic neurons. 
As the disease progresses and Aβ accumulates, lowering Aβ generation through BACE1 
inhibition may be more relevant to maintain CHT cell surface levels, choline uptake 
activity and ACh production. In the case of a patient in the early stages of familial AD 
caused by the Swedish mutation, my results suggest that the normal physiological 
interaction between CHT and APP is disrupted, with much higher levels of Aβ produced. 
Thus, in individuals with AD caused by the Swedish mutation, targeting BACE1 early on 
in the course of the disease may be the most effective strategy to promote cholinergic 
neurotransmission.  
The Swedish mutation of APP is quite rare, found in less than 1 percent of the general 
population. However, there are more than 50 different mutations in the APP gene that can 
cause early-onset AD and these account for up 10 percent of all early-onset cases of the 
disorder (34). It is possible that other mutations of APP could also alter the interaction of 
APP with CHT. The underlying reason for the reduced interaction of CHT with APPSwe 
compared to APPwt was not investigated in my study. However, I hypothesize that it is 
likely related to differences in subcellular location and trafficking of APPSwe compared to 
APPwt.  A recent study examining APP trafficking found distinct intracellular trafficking 
pathways of APPSwe, as well as APP containing the London mutation, when compared to 
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APPwt (35). If less APPSwe than APPwt interacts with CHT proteins as a result of 
differences in their subcellular trafficking pathways, and various other APP mutations 
also alter the trafficking of APP, it is reasonable to conclude that other mutations of APP 
could also alter the interaction of APP with CHT. To test this, the experiments outlined in 
Chapter 4 could be repeated using different APP constructs expressing various other 
familial APP mutations, such as the London mutation or the Arctic mutation. Despite the 
fact that the Swedish mutation affects only 1% of the general population, the human 
mutant APP mouse Tg2576, which overexpresses the Swedish mutant form of APP695, 
is the most commonly used AD mouse model (36). This is because these mice display an 
AD phenotype, exhibiting five times the level of endogenous murine APP in the brain 
and develop plaque-like deposits of Aβ in the brain at an early age. However, 
experiments carried out in Chapter 4 reveal important differences in protein regulation, 
subcellular trafficking and subcellular processing between APPwt and APPSwe. Therefore, 
depending on the type of study to be performed, a mouse model overexpressing wild-type 
APP could be a more appropriate choice.     
5.2.1 Significance  
Several reports have suggested that the cognitive deficits seen in AD are related to the 
loss and dysfunction of cholinergic neuron signalling. However, the specific changes that 
occur in the aging brain that result in cholinergic dysfunction, and the extent to which 
they can be prevented or reversed, is still unclear. Understanding the mechanisms 
involved in CHT protein trafficking is critical since this regulates CHT activity, thereby 
sustaining ACh production and maintaining cholinergic neurotransmission. Three 
important risk factors for AD include high serum cholesterol level at midlife, mutations 
in genes encoding APP and increased generation of ROS and RNS in the brain. Gaining a 
greater understanding of the molecular events occurring in the cholinergic presynaptic 
nerve terminal that could alter CHT activity in these pathological situations is essential 
for developing new treatment methods for AD and was the overall goal of this thesis.  
Within the cholinergic nerve terminal microenvironment, changes in APP processing and 
Aβ generation, ONOO- production, or plasma membrane cholesterol levels, could cause a 
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decrease in CHT activity, thereby reducing high-affinity choline uptake and diminishing 
ACh production. The binding of ACh to certain mAChR subtypes is thought to promote 
the non-amyloidogenic cleavage of APP (37), while Aβ inhibits various steps involved in 
both ACh synthesis and release (38-41). As a result of a decrease in CHT activity, less 
ACh would be available to bind to mAChR, which could potentially reduce the 
movement of APP through the non-amyloidogenic pathway and result in more APP 
available to undergo amyloidogenic processing and generate Aβ. The results of 
experiments reported in Chapter 4 of this thesis, as well as those of other groups, show 
that Aβ can inhibit high-affinity choline uptake (42, 43), which could potentially be 
through a direct interaction with CHT (44). Interestingly, Aβ can indirectly impair CHT 
activity by causing the activation of microglia and the production of ONOO
-
 (45). 
Aggregated forms of Aβ can also bind to cholesterol and interfere with the plasma 
membrane lipid bilayer (46), which could cause a disruption of lipid raft organization and 
a decrease in CHT activity. Since the uptake of choline by CHT is the rate-limiting step 
to ACh production, a decrease in CHT activity would critically impair ACh synthesis and 
release, potentially causing more Aβ to be produced, which could result in a further 
reduction in CHT activity. This reciprocal relationship is shown schematically in Figure 
5-3. Therefore, promoting CHT activity and ACh production may not only be important 
for supporting cognition and memory, but could also critically affect the progression of 
AD pathology by preventing the generation of Aβ. The studies reported in this thesis 
reveal important mechanistic information regarding the regulation of CHT trafficking and 
activity under pathological conditions where cholinergic signalling is compromised. This 
information may aid the design of therapeutic strategies to protect against pathological 
situations in the cholinergic nerve terminal, which could play an important role early on 
in the course of the disease by maintaining CHT activity and ACh signalling, which is 
critical to many diverse biological processes. 
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Figure 5-3 The relationship between APP and the cholinergic system.  
Following the release of ACh into the synaptic cleft, the binding of ACh to certain post-
synaptic mAChR subtypes promotes the non-amyloidogenic cleavage of APP, resulting 
in the production of non-pathogenic peptides. Alternatively, Aβ, produced as a result of 
amyloidogenic processing, can inhibit various steps involved in both ACh synthesis and 
release. Aβ can potentially inhibit CHT activity directly or indirectly by activating 
microglia and causing ONOO- production or through effects on lipids at the plasma 
membrane. Inhibition of CHT activity would impair ACh synthesis. Less ACh would be 
available to bind to mAChR, which could potentially reduce the movement of APP 
through the non-amyloidogenic pathway and result in more APP available to undergo 
amyloidogenic processing and the generation of toxic Aβ peptides. 
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